Untersuchungen zur Substratspezifität von Squalen-Hopen Zyklasen (SHCs) by Seitz, Miriam
   
Characterization of the substrate specificity of squalene-
hopene cyclases (SHCs) 
 
Untersuchungen zur Substratspezifität von Squalen-Hopen 
Zyklasen (SHCs) 
 
Von der Fakultät 3: Chemie der Universität Stuttgart zur Erlangung der Würde 
eines Doktors der Naturwissenschaften (Dr. rer. nat.) genehmigte Abhandlung 
 
Vorgelegt von Miriam Seitz 
aus Rastatt 
 
Hauptberichter: Prof. Dr. Bernhard Hauer 
Mitberichter: Prof. Dr. Bernd Plietker 
Vorsitzende: Prof. Dr. Cosima Stubenrauch 
 
Tag der mündlichen Prüfung: 6. Februar 2013 
 
Institut für Technische Biochemie der Universität Stuttgart 
2012 
 
   
Die vorliegende Arbeit entstand auf Anregung und unter Anleitung von Herrn Prof. Dr. 
Bernhard Hauer in der Zeit von Oktober 2009 bis Dezember 2012 am Institut für technische 
Biochemie an der Universität Stuttgart. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Im Rahmen dieser Dissertation wurden folgende Publikationen vorab veröffentlicht: 
· “Substrate specificity of a novel squalene-hopene cyclase from Zymomonas 
mobilis”; M. Seitz, J. Klebensberger, S. Siebenhaller, M. Breuer, G. Siedenburg, D. 
Jendrossek, B. Hauer; J. Mol. Cat. B: Enzymatic 2012 (84) 72–77. 
· “Activation-Independent Cyclization of Monoterpenoids”; G. Siedenburg, D. 
Jendrossek, M. Breuer, B. Juhl, J. Pleiss, M. Seitz, J. Klebensberger, B. Hauer; Appl. 
Environ. Microbiol. 2012 (78) 1055–1062. 
· “Synthesis of Heterocyclic Terpenoids by Promiscuous Squalene-Hopene Cyclases”; 
M. Seitz, P.-O. Syrén, L. Steiner, J.Klebensberger, B. M. Nestl, B. Hauer; ChemBioChem 
2013 (14) 436-439. 
· “Squalene hopene cyclases: highly promiscuous and evolvable catalysts for 
stereoselective C-C and C-X bond formation”, S. C. Hammer, P.-O. Syrén, M. Seitz, B. 
M. Nestl, B. Hauer; Curr. Opin. Chem. Biol. 2013 (17) DOI: 
10.1016/j.cbpa.2013.01.016. 
  
   
Erklärung über die Eigenständigkeit der Dissertation 
 
Ich versichere, dass ich die vorliegende Arbeit mit dem Titel „Untersuchungen zur 
Substratspezifität von Squalen-Hopen Zyklasen (SHCs)“ selbständig verfasst und keine 
anderen als die angegebenen Quellen und Hilfsmittel benutzt habe; aus fremden Quellen 
entnommene Passagen und Gedanken sind als solche kenntlich gemacht. 
 
 
Declaration of Authorship 
 
I hereby certify that the dissertation entitled “Characterization of the substrate specificity of 
squalene-hopene cyclases (SHCs)” is entirely my own work except where otherwise 
indicated. Passages and ideas from other sources have been clearly indicated.  
 
 
 
 
 
Name/Name:  Miriam Seitz 
 
 
Unterschrift/Signed: ________________________________ 
 
 
Datum/Date:  ________________________________ 
 
   
 
Danksagungen 
Mein erster und größter Dank gilt Prof. Dr. Bernhard Hauer, der mir ein sehr spannendes 
Thema zugetraut und es mir ermöglicht hat, meine Promotion innerhalb der letzten drei 
Jahre durchzuführen. Für die ausgezeichnete Betreuung möchte ich mich sehr bedanken. 
Des Weiteren möchte ich besonders Dr. Bettina Nestl und Dr. Per-Olof Syrén danken, die 
mich durch ihre gute Betreuung sehr unterstützt, diese Arbeit sorgfältig korrigiert, mir viele 
wertvolle Ratschläge gegeben haben und mir immer sowohl fachlich als auch emotional zur 
Seite standen, sowie bei Dr. Janosch Klebensberger und Dr. Katja Koschorrek für ihre 
Betreuung. Auch dem „Team Zyklase“, bestehend aus Jörg Dominicus, Stephan Hammer, 
Per-Olof Syrén und Silvia Racolta sowie Sascha Siebenhaller, Michael Pohl und Lisa Steiner, 
die das Projekt mit gestaltet und vorangebracht haben, gilt ein herzlicher Dank für die tolle 
Zusammenarbeit, interessante Diskussionen und den stetigen Ideenaustausch. Des Weiteren 
möchte ich Dr. Gabi Siedenburg, Dr. Michael Breuer und Dr. Dieter Jendrossek für gute 
Zusammenarbeit danken. Jessica, Eric, Bernhard und Peter danke ich für das Korrekturlesen 
von meiner Arbeit. 
Dem Bundesministerium für Bildung und Forschung (BMBF) und „KYROBIO: Developing 
biocatalysts for industrial chiral compounds“ gilt ein besonderer Dank für die Finanzierung 
des Projekts. 
Meine letzten drei Jahre am ITB haben mich nicht nur auf fachlicher Seite, sondern auch 
persönlich sehr bereichert. Deswegen ist es mir wichtig, einige Leute, die mich auf meinem 
Weg begleitet haben, besonders zu erwähnen. Zuerst würde ich gerne Bettina und Bernd 
danken, die immer ein offenes Ohr für meine Sorgen hatten und auf deren Unterstützung ich 
mich stets verlassen konnte. Daniel, Sumire, Björn, Marko und Christian waren meine 
stetigen Wegbegleiter und haben mir so manches Mal sehr zur Seite gestanden. Stephan, 
Dennis, Sumire und Bettina möchte ich danken für die unvergessliche Biotrans-Konferenz, 
die ein absolutes Highlight meiner Zeit am ITB darstellt. Meine beiden Labor-Kollegen 
Christine und Jörg haben mich vor allem in der Endphase meiner Doktorarbeit stets 
motiviert, meine Sorgen angehört und mir immer geholfen. Hierfür möchte ich besonders 
danken. Die Liste mit lieben Leuten am ITB könnte an dieser Stelle noch eine Weile 
fortgesetzt werden. Aber statt alle einzeln aufzuzählen, möchte ich hier einfach allen 
   
 
Kollegen danken, die täglich für gute Stimmung gesorgt und mir meine Arbeit damit sehr 
erleichtert haben. Danke für gute fachliche Diskussionen und Hilfsbereitschaft, für die 
Freundlichkeit und Freundschaft sowie für zahlreiche schöne Erlebnisse im und außerhalb 
des Instituts. 
Auf persönlicher Seite möchte ich zuerst meinen Eltern danken für ihre liebevolle Erziehung 
und dafür, dass sie mich immer unterstützt und mir meine Ausbildung ermöglicht haben, die 
ich nun mit der Anfertigung meiner Doktorarbeit abschließe. Meinen Brüdern Niklas und 
Fabian und meiner Schwägerin Anita danke ich für unseren guten Zusammenhalt, für viele 
wichtige und lustige Gespräche und für ihre große Hilfsbereitschaft. Peters Familie, 
besonders Doris, möchte ich danken für ihre Herzlichkeit und für die jahrelange 
Unterstützung in allen Lebenslagen. Meiner kleinen Nichte Carolina und meinem kleinen 
Neffen Linus danke ich dafür, dass sie uns so viel Freude bereiten. 
Den Rastatter Freunden möchte ich für viele schöne Erlebnisse danken, und dafür, dass sie 
so lustig sind wie eh und je, und dass wir es geschafft haben, uns nicht aus den Augen zu 
verlieren. Besonders meinen lieben Freundinnen Anja, Carolin und Virginia möchte ich für 
beinahe 20 Jahre Freundschaft danken, in denen sie immer ein offenes Ohr für meine Sorgen 
hatten. 
Allen meinen Mitbewohnern, die ich in acht Jahren WG-Leben in Stuttgart hatte, und vor 
allem meinen derzeitigen Mitbewohnern Simon, Dennis und Peter danke ich für die 
Freundschaft und Fröhlichkeit, für aufmunternde und ernste Gespräche und den 
unermüdlichen Zusammenhalt während all der Jahre. Ein besonderer Dank gilt meiner 
Dienstagsgruppe und vor allem Tanja für unzählige tolle gemeinsame Erlebnisse. 
Meinem Lacrosse-Team Neckarnixen und allen von Stuttgart Lacrosse e.V., mit denen ich 
einen großen Teil meiner Freizeit verbringe, danke ich für tolle Trainings, Spiele, Team-
Events, Turniere, wichtige Unterhaltungen auf langen Autofahrten und vor für allem die 
Freundschaft, die wir teilen. 
Zuletzt und am allermeisten danke ich meinem Freund Peter, mit dem ich seit dem ersten 
Semester gemeinsam durchs Leben gehe. Er hat mich stets in meinen Eigenschaften 
gestärkt, mich in schwereren Zeiten aufgemuntert und unterstützt, und schöne Tage zu 
etwas besonderem gemacht.  
Miriam Seitz 
   
 
Table of content 
1 Zusammenfassung ............................................................................................................ 1 
2 Abstract ................................................................................................................................ 4 
3 Theoretical Background ................................................................................................. 7 
3.1 Occurrence and biosynthesis of terpenoids ............................................................ 7 
3.2 Monoterpenoids ............................................................................................................. 12 
3.3 Sesquiterpenoids ........................................................................................................... 15 
3.4 Diterpenoids .................................................................................................................... 18 
3.5 Sesterpenoids .................................................................................................................. 20 
3.6 Triterpenoids .................................................................................................................. 22 
3.6.1 Functions and occurrences ...................................................................................................... 22 
3.6.2 Biosynthesis of triterpenoids, reaction mechanisms and approaches for the 
evolution of the triterpene cyclases ..................................................................................... 23 
3.6.3 Squalene-hopene cyclases ........................................................................................................ 27 
3.6.4 Substrate specificity of SHCs ................................................................................................... 36 
3.7 Organic syntheses of cyclic terpenoids .................................................................. 38 
3.7.1 Ambroxan and sclareolide ....................................................................................................... 39 
3.7.2 Caparrapioxide ............................................................................................................................. 44 
3.7.3 Sclareoloxide and hexahydrochromene ............................................................................. 46 
3.7.4 Ambraoxide, ambreinolide and unsaturated ambraoxide .......................................... 47 
3.7.5 Isopulegol and menthol ............................................................................................................. 48 
4 Aim of the project ........................................................................................................... 52 
5 Results ................................................................................................................................ 53 
5.1 Squalene-hopene cyclases: Cloning, expression, enzyme preparation 
and biotransformations ............................................................................................... 53 
5.1.1 Cloning, expression and partial purification ..................................................................... 53 
5.1.2 Biotransformations – Elaboration of a reliable standard protocol .......................... 56 
5.2 Substrate specificity of SHCs ...................................................................................... 68 
5.2.1 Alcohols ........................................................................................................................................... 69 
5.2.2 Ketones ............................................................................................................................................ 71 
5.2.3 Carboxylic acids............................................................................................................................ 72 
   
 
5.2.4 Aldehydes ....................................................................................................................................... 73 
5.3 Comparison of the substrate specificities of ZmoSHC1, ZmoSHC2 and 
AacSHC ............................................................................................................................... 75 
5.3.1 Enhanced conversions ............................................................................................................... 78 
5.3.2 Limits of substrate specificity ................................................................................................. 79 
5.4 Directed mutagenesis ................................................................................................... 80 
5.4.1 Selection of spots for single mutants and screening ...................................................... 80 
5.4.2 Creation and screening of the loop deletion mutant ..................................................... 81 
6 Discussion ......................................................................................................................... 82 
6.1 Squalene-hopene cyclases: cloning, expression, enzyme preparation 
and biotransformations ............................................................................................... 82 
6.1.1 Biotransformations with whole cells ................................................................................... 82 
6.1.2 Biotransformations with partially purified SHCs ........................................................... 84 
6.1.3 Stability experiments ................................................................................................................. 85 
6.1.4 Substrate and product inhibition .......................................................................................... 87 
6.1.5 Internal standard experiments .............................................................................................. 89 
6.1.6 pH Studies ....................................................................................................................................... 90 
6.2 Substrate specificity of SHCs ...................................................................................... 90 
6.3 Comparison of the substrate specificity of ZmoSHC1, ZmoSHC2 and 
AacSHC ............................................................................................................................... 92 
6.3.1 Enhanced conversions ............................................................................................................... 98 
6.3.2 Limits of substrate specificity ................................................................................................. 99 
6.4 Directed mutagenesis ................................................................................................. 100 
6.4.1 Selection of spots for single mutants and screening .................................................... 100 
6.4.2 Creation and screening of the loop deletion mutant ................................................... 102 
7 Conclusion ...................................................................................................................... 105 
8 Outlook ............................................................................................................................ 106 
9 Materials and methods ............................................................................................... 108 
9.1 Instruments .................................................................................................................... 108 
9.2 Software ........................................................................................................................... 109 
9.3 Consumables .................................................................................................................. 110 
9.4 Chemicals ........................................................................................................................ 110 
9.5 Media, buffers and Kits .............................................................................................. 112 
   
 
9.6 Molecular biological devices .................................................................................... 113 
9.7 Cell culture and enzyme expression ...................................................................... 114 
9.8 Protein biochemical methods .................................................................................. 115 
9.8.1 Partial purification of the membrane bound protein fraction ................................. 115 
9.8.2 Protein determination ............................................................................................................. 116 
9.9 Biotransformations ..................................................................................................... 116 
9.9.1 Biotransformations with whole cells ................................................................................. 116 
9.9.2 Biotransformations with partially purified SHC............................................................ 117 
9.9.3 Sample preparation .................................................................................................................. 118 
9.9.4 Preparative biotransformations and product isolation.............................................. 119 
9.10 Analysis and evaluation ............................................................................................. 121 
9.10.1 GC-FID ............................................................................................................................................ 121 
9.10.2 GC-MS ............................................................................................................................................. 123 
9.10.3 New products – characterization with NMR ................................................................... 125 
9.10.4 IR and HREIMS analyses ......................................................................................................... 131 
9.10.5 Determination of log P values ............................................................................................... 132 
9.10.6 Quantification .............................................................................................................................. 133 
10 Literature ........................................................................................................................ 135 
11 Supplementary data .................................................................................................... 157 
11.1 Abbrevations ................................................................................................................. 157 
11.2 Sequences and other informations about the SHCs ......................................... 161 
11.2.1 Wildtype SHCs ............................................................................................................................ 162 
11.2.2 Mutants .......................................................................................................................................... 163 
11.3 Multiple sequence alignments ................................................................................. 165 
11.3.1 SHCs from strains containing two SHCs ........................................................................... 165 
12 Curriculum vitae ........................................................................................................... 168 
  Zusammenfassung 
 - 1 -  
1 Zusammenfassung 
Die zyklischen Terpenoide stellen eine große Gruppe von Naturstoffen mit verschiedensten 
biologischen Funktionen dar. Bis heute konnten etwa 60.000 verschiedene zyklische 
Terpenoide, die aus Gerüsten von zehn bis über 30 Kohlenstoffatomen aufgebaut sind, 
identifiziert werden.1,2 Unter dieser großen Anzahl von zyklischen Stoffen finden sich viele 
bekannte Duft- und Aromastoffe, wie zum Beispiel Menthol oder Limonen, Verbindungen, 
die als pharmazeutisch wirksame Inhaltsstoffe in Medikamenten Anwendung finden, wie 
etwa der gegen Tumor wirksame Stoff Taxol oder das gegen Malaria angewendete 
Artemisinin oder auch die als Membranbestandteile und Hormone bekannten Steroide.3–6 All 
diese interessanten Naturstoffe werden durch Zyklisierung von wenigen linearen 
Vorläufermolekülen gebildet. Diese Zyklisierungsreaktionen werden von Terpenoid Zyklasen 
katalysiert.1,7 
Der Schwerpunkt der vorliegenden Arbeit liegt auf einer Unterfamilie dieser Enzymgruppe 
der Terpenoid Zyklasen, den Squalen-Hopen Zyklasen (SHCs).8–10 Unter den über 300 
annotierten SHCs wurde die SHC vom thermophilen Bakterium Alicyclobacillus 
acidocaldarius (AacSHC) am besten untersucht. Neben der Kristallstruktur wurde auch der 
komplexe Mechanismus aufgeklärt, nach dem das lineare C30 Substrat Squalen zu den 
pentazyklischen Produkten Hopen und Hopanol zyklisiert wird.11–13 Der Mechanismus dieser 
Reaktion, bei der neun Stereozentren und 13 kovalente C-C Bindungen spezifisch entstehen, 
gilt als einer der komplexesten, die man in der Chemie der Naturstoffe bislang entdecken 
konnte.13 Neben AacSHC wurden in vorangehenden Arbeiten auch einige andere SHCs 
teilweise charakterisiert.14,15 Von besonderem Interesse ist hierbei der gegen hohe Alkohol- 
und Zuckerkonzentrationen tolerante Stamm Zymomonas mobilis, der als einer der besten 
Hopanoid-produzierenden Bakterienstämme bekannt ist und zwei Gene enthält, die für SHCs 
codieren: ZmoSHC1 und die in vorherigen Arbeiten partiell charakterisierte ZmoSHC2.14,15 
Es war gezeigt worden, dass SHCs neben dem natürlichen Substrat Squalen auch einige 
andere lineare Terpenoide als Substrate akzeptieren und diese zyklisieren. Zum Beispiel 
konnten verkürzte Squalen-Analoga von AacSHC zyklisiert werden und auch der C16-Alkohol 
Homofarnesol wurde in den entsprechenden zyklischen Ether Ambroxan umgesetzt.16–19 
Diese Ergebnisse ließen darauf schließen, dass die SHCs eine vielversprechende 
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Enzymfamilie zur Katalyse von sehr verschiedenen, komplexen Zyklisierungsreaktionen 
darstellen könnten und deswegen entschieden wir uns dazu, die Substratbreite der SHCs 
näher zu untersuchen. 
Um die Squalen-Hopen Zyklasen ZmoSHC1 und ZmoSHC2 zu charakterisieren und ihre 
biokatalytischen Aktivitäten mit der von AacSHC vergleichen zu können, wurden die für diese 
Enzyme codierenden Gene kloniert und heterolog in Escherichia coli exprimiert. Die 
Expression funktioneller Enzyme wurde durch Umsetzung des natürlichen Substrates 
Squalen bestätigt. Um die Enzyme direkt miteinander vergleichen zu können, wurde ein 
Protokoll für die partielle Aufreinigung der membrangebundenen SHCs ausgearbeitet und 
optimiert. Für diese Aufreinigung sowie für die Umsetzung der hydrophoben Substrate in 
wässrigem Milieu musste ein geeignetes Detergenz verwendet werden. ZmoSHC1 wurde des 
Weiteren näher charakterisiert, wobei die pH- und Temperaturabhängigkeit der 
katalytischen Aktivität, die biokatalytische Stabilität des Enzyms über eine längere Zeitdauer 
sowie Inhibierungseffekte untersucht wurden. Die drei Enzyme wurden auf Aktivität 
gegenüber unnatürlichen Substraten mit C-Kettenlängen von C10-C18 getestet. Ein 
besonderer Fokus wurde hierbei auf Substrate gelegt, die funktionelle Gruppen enthalten, 
wie zum Beispiel Hydroxyl-, Carboxy- oder Ketogruppen, die, wie für die Hydroxylgruppe von 
Homofarnesol gezeigt, an der Zyklisierungsreaktion teilnehmen könnten. Interessanterweise 
wurden diese funktionellen Gruppen in den finalen Ring der polyzyklischen Produkte 
integriert, wodurch Produkte mit neuen, attraktiven Eigenschaften entstanden.20–27 
Homofarnesol konnte in den zyklischen Ether und bekannten Duftstoff Ambroxan umgesetzt 
werden.16,20 Die entsprechende Carbonsäure Homofarnesolsäure wurde ebenfalls als 
Substrat akzeptiert und es wurde das zyklische Lakton Sclareolid erhalten. Der tertiäre C15 
Alkohol Nerolidol wurde zum bizyklischen Caparrapioxid umgesetzt. Des Weiteren wurden 
auch zwei Ketone als Substrate akzeptiert und in zyklische Enolether umgesetzt.  
Im Rahmen der vorliegenden Arbeit wurden die neuen Produkte nach präparativer 
Biotransformation und Aufreinigung charakterisiert. Nicht nur die Tatsache, dass diese 
Substrate sehr viel kürzere Kohlenstoff-Ketten als das „natürliche“ Substrat Squalen besitzen 
und über verschiedene funktionelle Gruppen verfügen, die an den Zyklisierungsreaktionen 
teilhaben und zu interessanten Produkten umgesetzt werden, sondern auch die 
unterschiedlichen Aktivitäten der SHCs gegenüber dieser Substrate sind bemerkenswert. Es 
konnte gezeigt werden, dass ZmoSHC1 über besondere Eigenschaften verfügt, da 
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unerwartete Umsetzungsraten bei der Katalyse mit diesem Enzym bestimmt wurden. 
Während die Zyklisierung von Squalen von ZmoSHC1 nur sehr gering katalysiert wurde, 
wurde eine gute Aktivität gegenüber der Reaktion von Homofarnesol zu Ambroxan ermittelt. 
Alle anderen beschriebenen Substrate wurden in geringen, aber signifikanten Raten 
umgesetzt. Ein vollkommen anderes Aktivitäts-Muster wurde bei Umsetzungen mit AacSHC 
erhalten. Hier wurde neben sehr guter Umsetzung von Squalen eine viel geringere Aktivität 
gegenüber allen anderen Substraten bestimmt. Vom Enzym ZmoSHC2 wurden nur Squalen 
und Farnesylaceton mit sehr geringer Aktivität als Substrate akzeptiert, alle anderen 
Substrate wurden nicht umgesetzt. 
Anhand dieser Ergebnisse kann gefolgert werden, dass SHCs als vielseitige Biokatalysatoren 
für komplexe Zyklisierungsreaktionen verwendet werden können, da diese Enzyme eine 
unerwartete Substrataktivität mit anderen Substraten als Squalen zeigen. In der 
vorliegenden Arbeit werden diese und weitere Ergebnisse im Detail beschrieben. Neben der 
erwähnten Untersuchung der Aktivität der verschiedenen SHCs gegenüber unterschiedlichen 
Substraten wurden auch Mutanten hergestellt und untersucht, die zu einer Erklärung der 
Aktivitätsunterschiede zwischen den verschiedenen Squalen-Hopen Zyklasen verhelfen 
sollten. Diese Charakterisierung der Triterpen Zyklasen und die Diskussion ihrer besonderen 
Eigenschaften führen zu neuen Schlussfolgerungen über das Potenzial von SHCs, als fähige 
Biokatalysatoren für noch nie gezeigte Reaktionen eingesetzt werden zu können. 
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2 Abstract 
Cyclic terpenoids form a large group of natural products with various biological functions. 
About 60,000 different cyclic terpenoids have been identified by now, containing scaffolds of 
ten to more than 30 carbon atoms.1,2 Among this huge amount of different cyclic 
compounds, there are many well-known flavors and fragrances, such as menthol or 
limonene, compounds which are widely used for pharmaceutical purposes like the antitumor 
compound Taxol and the anti-malaria agent artemisinin, or common membrane constituents 
and hormones such as the sterols.3–6 All of these natural products are derived from 
cyclization reactions of few linear precursor molecules catalyzed by terpenoid cyclases.1,7 
The main focus of the present work rests on one very interesting family of the terpenoid 
cyclases, the squalene-hopene cyclases (SHCs).8–10 Among the over 300 annotated SHCs, 
most extensive studies had been carried out characterizing the SHC from the thermophilic 
bacterium Alicyclobacillus acidocaldarius (AacSHC), solving the crystal structure and the 
complex cyclization mechanism of the C30 precursor squalene into the pentacyclic products 
hopene and hopanol.11–13 This reaction constitutes one of the most complex reaction 
mechanisms found in nature, including the stereospecific formation of nine stereocenters 
and 13 covalent bonds.13 Besides AacSHC, several SHCs were partially characterized in 
previous works.14,15 Our interest was triggered by the ethanol and sugar tolerant strain 
Zymomonas mobilis which is known as one of the most potent hopanoid producers. 
Zymomonas mobilis contains two genes encoding for SHCs: ZmoSHC1 and the formerly 
partially characterized ZmoSHC2.14,15 
It could be shown that the SHCs are also capable of cyclizing other linear terpenoids. For 
example, it was found that truncated squalene analogs were accepted as substrates by 
AacSHC and also the alcohol homofarnesol could be converted into the corresponding cyclic 
ether ambroxan.16–19 These results indicate that SHCs represent a promising family for 
catalysis of very different and complex cyclization reactions. Thus, we decided to investigate 
the SHCs’ potentials regarding their substrate specificities. 
In order to characterize the squalene-hopene cyclases ZmoSHC1 and ZmoSHC2 and compare 
them with AacSHC especially regarding their biocatalytic activities towards unnatural 
substrates, the SHCs were cloned and heterologously expressed in Escherichia coli. 
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Functional expression was confirmed by conversion of the natural substrate squalene. For 
the direct comparison, a protocol for partial purification of the membrane-anchored SHCs 
was elaborated and optimized. For this partial purification as well as for the conversion of 
the hydrophobic substrates in aqueous milieu a suitable detergent had to be selected. 
ZmoSHC1 was characterized in more detail, retrieving information about pH- and 
temperature-dependence of the activity and the biocatalytic stability over a long period of 
time as well as inhibitory effects. 
All of the three enzymes were tested with unnatural substrates of C10-C18 carbon chain 
lengths. A special focus was laid on substrates containing functional groups such as 
hydroxyl-, carboxy- or keto-groups expected to participate in the cyclization reaction, as 
shown for the hydroxyl-group of homofarnesol. Several of the substrates were accepted and 
cyclic products were generated. Interestingly, the functional groups were integrated in the 
final ring closure and to products with new properties were obtained.20–27 Homofarnesol 
conversion yielding the cyclic ether ambroxan, which is known as a expensive and rare flavor 
compound, was observed as reported in the literature.16,20 Also the corresponding carboxylic 
acid, homofarnesoic acid, could be converted into the cyclic lactone sclareolide. The C15 
tertiary alcohol nerolidol was accepted as substrate and the bicyclic ether caparrapioxide 
was formed. Lastly, two ketones were accepted as substrates leading to cyclic enol ether 
products. 
Within the present work, all of these new products were characterized after preparative 
biotransformation and product isolation. Not only the facts that these substrates are much 
shorter than the natural substrate squalene and possess different functional groups which 
take part in the cyclization reaction and that useful products containing new properties are 
formed, but also the different activities of the SHCs towards these substrates are 
remarkable. Thus, it could be shown that ZmoSHC1 exhibits special biocatalytic properties, 
as the substrate activity pattern was unexpected. While squalene was converted very poorly, 
good activity was found towards the reaction of homofarnesol to ambroxan. All of the other 
substrates were converted in low but significant rates into the corresponding cyclic 
products. A completely different substrate activity pattern was observed using AacSHC as 
biocatalyst. Besides very good squalene conversion, much lower activities towards all of the 
other substrates were found. Using ZmoSHC2, only very low conversion rates were found for 
squalene and farnesylacetone and no conversion of any of the other substrates. 
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Based on these observations, it can be concluded that ZmoSHC1 represents a versatile 
biocatalyst for complex cyclization reactions, as it shows unexpected substrate activity 
towards other substrates than squalene. In the present work, these and further detailed 
results are described. Besides the examination of the SHCs’ activities towards different 
substrates there were also several mutants created in order to find explanations for the 
differences between the SHCs regarding their substrate activities. This characterization of 
the triterpenoid cyclase ZmoSHC1 and discussion of their special properties leads to new 
conclusions about the potential of SHCs to serve as potent biocatalysts for new reactions. 
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3 Theoretical Background 
The family of terpenoids represents one of the largest groups of natural products with 
various biological functions. For many years, scientists have been fascinated by these 
compounds. A lot of research focuses on them, trying to identify and understand their 
occurrence, formation, significance, functionalities and their possible benefits for us. 
Pioneering research on terpenoids started almost one century ago.28–31 What is special 
about this class of compounds? Why do they draw the attention of chemists, biochemists, 
physicists and biologists? 
In 1990, Guy Ourisson, a famous chemist in the field of natural products, in particular related 
to terpenoids, published an assay with the following introduction.32,33 
“Terpenoids are a ravishment and a nightmare. A nightmare for the 
student trying to memorize hardly different structures and crazy trivial 
names, and a ravishment when he discovers that a few basic rules are 
enough to "understand" thousands of structures and to exclude from 
serious consideration many, that would otherwise apparently fit the 
available structural data. A ravishment also, when we see the white of 
betulin in the bark of birches, the orange, yellow, crimson or red of 
carotenoids in a basket of peppers or in a flight of flamingoes; a 
ravishment when used in the proper combination in a spice or a perfume, 
to lure a beetle (or ourselves) to a prospective mate, but a nightmare, 
when one is confronted with the nagging question: "Why such a 
diversity? Would nature not have worked, had it been simpler?” 
In this short paragraph Guy Ourisson describes scientists’ fascination and respect towards 
the terpenoids with few words. This present thesis about this exciting field of natural 
products will maybe not answer but advance the discussion triggered by Ourisson’s 
questions and describe the current state of knowledge on terpenoids. 
3.1 Occurrence and biosynthesis of terpenoids 
Terpenoids, also called isoprenoids, are present in all organisms. They are very abundant and 
offer a great structural diversity, acting as primary or secondary metabolites in bacteria, 
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plants and higher organisms. It is not easy to set a clear borderline between primary and 
secondary metabolites, as they cannot be differentiated clearly on the basis of precursor 
molecules, chemical structures or biosynthetic origin. Thus, the classification is made by the 
role they play in the organisms they are coming from. Primary metabolites are mostly small 
size molecules playing a role in essential metabolic processes within an organism, such as 
growth regulation, respiration or photosynthesis. The compounds called natural products 
are secondary metabolites, compounds which are influencing ecological interactions 
between an organism and its environment. To give an example, plant secondary metabolites 
can be compounds with functions against herbivores or pathogens, defending the plant or 
attracting pollinators and seed-dispersing animals. 
Many of these natural products are utilized as flavors, pigments, polymers, fibers, glues, 
waxes, drugs or agrochemicals. Plant natural products can mainly be divided into three 
groups of compounds: terpenoids, alkaloids and phenylpropanoids. Just to give one famous 
representative from each group, Fig. 3.1 shows three compounds: the sesquiterpenoid 
artemisinin, which is one of the most potent anti-malarian drugs, the alkaloid caffeine and 
the flavoring phenylpropanoid vanillin.3,34–36 
 
Fig. 3.1: Common representatives of the three groups of important natural products: the terpenoid 
artemisinin, the alkaloid caffeine and the phenylpropanoid vanillin. 
Each of these three groups of natural products possesses a great amount of different 
derivatives. Besides the 30,000 alkaloids37 and 8,000 phenylpropanoids34, the largest and 
most diverse group of natural compounds is formed by the terpenoids with about 60,000 
identified compounds.32,37–40 One of the most special facts of this large group of natural 
products is that they all originate from two very small and very simple precursors: The C5 
units isopentenyl diphosphate (IPP) and dimethylallyl diphosphate (DMAPP), as shown in Fig. 
3.2.2 
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Fig. 3.2: The terpenoid precursors: isopentenyl diphosphate (IPP) and dimethylallyl diphosphate 
(DMAPP). 
These two C5 precursors can be formed via two different biosynthesis pathways, the 
mevalonate-dependent (MAD)41 or the mevalonate-independent (MAI)34,42–45 route. 
Investigations unveiled that in most organisms just one of both pathways is occurring for 
biosynthesis of the isoprenoid precursors. The MAI pathway is found especially in lower 
organisms like bacteria and is also common in plants. In contrast to this, archaea, fungi and 
animals are just operating via MAD.34,35,44 
It is hardly believable that from these two molecules many thousands of different products 
can be created bearing very different properties and sizes. The first reactions on the 
biosynthetic routes to these important natural compounds are head-to-tail condensation 
reactions of IPP and DMAPP catalyzed by prenyltransferases (Fig. 3.3). These reactions yield 
geranyl diphosphate (GPP). Subsequent reactions elongate the chains step by step, leading 
to linear molecules of increasing chain lengths, ending up as monoterpenoids (C10), 
sesquiterpenoids (C15) and diterpenoids (C20). Longer chains are derived by head-to-head 
condensation reactions of two FPP or GPP units leading to tri- (C30), tetra- (C40) or 
polyterpenoids (Cn).
1,7,46–48 
Pioneering work on the terpenoid chemistry started in the 19th century with first 
publications of O. Wallach in the 1880s, leading to the “isoprene rule” which was defined 
later by Ruzicka and coworkers.49–51 Besides the “empirical isoprene rule” revealing that “the 
carbon skeleton of the terpenes is composed of isoprene units linked in regular or irregular 
arrangement”, the “biogenetic isoprene rule” was defined including that “the carbon 
skeleton of the biological end product is not necessarily identical to the carbon skeleton of 
the precursor”.
51 This means that in general all isoprenoids are derived from isoprene. 
However, there are also natural products persisting of a chemical structure that cannot be 
traced back to isoprene directly, since they were modified during the formation of the final 
product.51 Later, the isoprene rules, especially the biogenetic isoprene rules, were discussed 
in more detail. Explanations for the stereochemistry of the formed products were defined 
suggesting how cyclization could occur, especially regarding the triterpenes.29,52 Over the 
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following years, a lot of work was done on mechanistical studies, especially for ring forming 
reactions as it became more and more obvious that the large diversity of the family of 
terpenoids is not only due to the formation of the growing linear carbon chains.28 Besides 
the mentioned publications of Ruzicka et al., more pioneering work in the field of the 
biosynthesis of terpenoids was performed by Elias J. Corey and coworkers.53–55 In these 
works, which were started in the 1960s and resumed in the 1990s, special focus was laid on 
the complex cyclization of the C30 2,3-oxidosqualene.
56–59 
 
Fig. 3.3: Terpenoid chains are elongated by prenyltransferases creating geranyl diphosphate 
(GPP), farnesyl diphosphate (FPP), geranylgeranyl diphosphate (GGPP) and geranylfarnesyl 
diphosphate (GFPP) by head-to-tail condensation reactions of isopentenyl diphosphate (IPP) and 
dimethylallyl diphosphate (DMAPP); the triterpene squalene is formed by head-to-head 
condensation of two FPP molecules and the tetraterpene phytoene from two GGPP units, 
respectively. 
The linear terpenoids represent the precursors for manifold subsequent reactions leading to 
cyclic products with innumerable different properties and biological functions. In nature, the 
cyclization reactions are carried out by a large variety of enzymes accepting linear molecules 
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as precursors: the terpenoid cyclases. These enzymes are able to increase the number of 
products extensively and implement the biological functionalities and special properties of 
the terpenoids. 
The cyclization of linear terpenoids can occur via two different mechanisms. Thus, the 
terpenoid cyclases are divided into two classes of enzymes regarding the mechanism of the 
catalyzed cyclization reaction (Fig. 3.4). For the first group of these enzymes, class I cyclases, 
the substrate has to be diphosphate-activated and a reactive carbocation is created by Lewis 
acid (e.g. Mg2+) triggered cleavage of the diphosphate group. The respective class I 
substrates are mainly the “smaller” substrates, such as mono-, sesqui- and diterpenes. 
Class II cyclases also generate a first, highly reactive carbocation. However, the substrate is 
not diphosphate-activated but the carbocation is formed by Brønsted acid-catalyzed 
protonation of a C=C double bond or an epoxide group of the substrate. The substrates 
which are cyclized via class II reaction mechanism are the longer terpenes, such as di-, ses- 
and triterpenes.1,2,46 
 
Fig. 3.4: Differences between class I and class II cyclase-catalyzed initiation of the cyclization 
reaction. 
In order to distinguish between class I and class II-catalyzed cyclization, the type of the 
substrate and the first step of the reaction creating the first, highly reactive carbocation are 
the decisive factors to take into account, because the following steps are similar for both 
class I and class II cyclizations. During the cyclization procedure, the positive charge is passed 
through the molecule stabilized by π-electrons of aromatic residues in the active site of the 
cyclase. The stereochemically defined scaffold of the end product is formed and the final 
carbocation is either deprotonated forming a C=C-double bond or the positive charge is 
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quenched by nucleophilic attack of a water molecule or another nucleophile.60,61 As one 
example, the class II cyclization of the C30 precursor squalene to the pentacyclic products 
hopene and hopanol is shown in Fig. 3.5. The initiation of the cyclization reaction is 
performed by protonation of a terminal C=C double bond by an aspartate residue in the 
active site of the cyclase creating the initial, highly reactive carbocation. Subsequently, the 
product scaffold is formed and the terminal carbocation (C22-hopanyl cation; shown in 
square brackets), is deprotonated (blue arrows), or quenched by nucleophilic attack of a 
water molecule (red arrows) resulting in two different products.  
 
Fig. 3.5: Cyclization of squalene to the pentacyclic products hopene and hopanol. 
In the following section, the focus of the introduction will be laid on the different cyclic 
terpenoids and the enzymes able to cyclize linear terpenoids. Their occurrences, properties 
and their catalyzed reactions will be discussed in detail. They will be explained step by step, 
sorted by increasing size of their natural substrates. 
3.2 Monoterpenoids 
As most of the monoterpenoids occurring in nature are cyclic, a lot of investigation was done 
in the field of these C10 compounds. Although they can be traced to few skeletons, they 
possess a large diversity due to the occurrence of many derivatives resulting from creation 
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of positional isomers and stereochemical variants.62 Originating from geranyl diphosphate 
(GPP), the monoterpenoids are formed by the monoterpene synthases. This family of 
enzymes is known to be able to catalyze the synthesis of acyclic monoterpenes, such as 
myrcene and ocimene, as well as cyclic monoterpenoids like limonene.4 Most of the 
knowledge of the functionalism of the monoterpene synthases was derived by studying the 
(+)- and (-)-bornyl diphosphate synthases, (+)- and (-)-pinene synthases, limonene synthase, 
and (-)-endo-fenchol synthase.7,62 All of the studied monoterpenoid synthases display the 
ability to generate multiple products at the same active site. One explanation for this finding 
is that the stabilization of the reactive carbocations in the active site can occur in more than 
one way and, thus, the enzymes are able to generate a variety of products.4 
 
Fig. 3.6: Cyclization of geranyl diphosphate leading to the α-terpinyl cation as basic scaffold for 
cyclic monoterpenoids.1,4 
The monoterpene cyclization starts with stereoselective binding of GPP in the active site, 
followed by ionization by metal-dependent migration of the diphosphate leaving group and 
binding of the resulting linalyl diphosphate (Fig. 3.6, Fig. 3.7). Prior to cyclization, linalyl 
diphosphate is isomerized into its cisoid form and the cyclization is carried out after a second 
ionization of the linalyl diphosphate forming the α-terpinyl cation as universal intermediate 
for formation of cyclic monoterpenes.1,4,7  
The cyclization of GPP leading to limonene is exemplary for monoterpenoid cyclization. 
Although this reaction does not seem complex, the limonene synthase is one of the most-
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studied monoterpene synthases and has become the “prototype” for these enzymes.63 It is 
found in peppermint and spearmint and the native enzyme’s main product is limonene 
accompanied by formation of side products like myrcene, (-)-α-pinene and (-)-β-pinene. 
Limonene represents the precursor of menthol and carvone.7 Especially (-)-menthol is 
characteristic for the flavor of the essential oil of peppermint (Mentha piperita) as it 
constitutes about 40 % of the major compound of the essential oil.35 
 
Fig. 3.7: Cyclic monoterpenoids derived from the α-terpinyl cation.7 
Although the physiological functions of monoterpenoids in nature remain mostly unknown, 
some functionalities were found, such as pollinator attraction, competitive phytotoxicity and 
defense against phytophagous insects and microbial pathogens.62 Several studies suggest 
medicinal use of essential oils that contain many monoterpenoid constituents. One example 
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is caraway oil with the main constituents carvone and limonene which exhibit repellent 
properties.64 Regarding our interest in these groups of natural products cyclic 
monoterpenoids are attractive as they are often volatile and common fragrances and 
flavors.7,46,62 
Concerning the structure and amino acid sequences of the monoterpenoid synthases, it has 
been observed that there is one motif common for both prenyltransferases, monoterpene 
synthases and sesquiterpene synthases: the so called DDxxD motif represents the crucial 
position for the creation of the first reactive carbocation.7,65 This highly conserved and 
aspartate-rich motif is the best-known structural motif and is found in almost all of the 
characterized terpene synthases. It was discovered that this region is participating in the 
binding of the metal ions responsible for catalysis of the diphosphate cleavage. Profound 
mutational and biochemical characterization of the (+)-bornyl diphosphate synthase and 
other monoterpenoid synthases bargained a lot of information about the mechanism, the 
functions and evolution of the residues in the active site, reviewed in detail by several 
groups.1 
3.3 Sesquiterpenoids 
Cyclic sesquiterpenoids are formed by metal-directed cyclization of farnesyl diphosphate 
(FPP) catalyzed by sesquiterpene cyclases.1 The formation of linear FPP as a common 
precursor for all cyclic sesquiterpenoids proceeds via head-to-tail condensation of DMAPP 
with two IPP units catalyzed by farnesyldiphosphate synthases.66 The sesquiterpene cyclases 
show a similar reaction mechanism as observed for the monoterpene synthases. However, 
the structural diversity of the generated products is greatly increased. Due to the fact that 
FPP contains three C=C double bonds, in comparison to the two C=C double bonds of the 
monoterpenoid precursor GPP, and that its carbon chain offers a higher flexibility, there are 
more possibilities for reactions.4,7 
The initiation of the cyclization reaction occurs by cleavage of the diphosphate leaving 
group, and the reactive farnesyl cation is created. The following steps vary according to the 
product that will be formed. They include different ring closures forming up to ten- or 
eleven-membered rings, as shown for formation of (E,E)-gammacradienyl or (E)-humulyl 
cation (Fig. 3.8).67 Also cyclic products containing carbon rings of smaller sizes can be 
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formed, as demonstrated for the formation of the bisabolyl cation which contains a six-
membered ring, or the cycloheptenyl cation, where a seven-membered ring is formed by the 
sesquiterpenoid cyclases (Fig. 3.8).67 
 
Fig. 3.8: Intermediates in the cyclization of sesquiterpenoids. 
Most of the studied sesquiterpene cyclases generate multiple products while just some of 
them lead to one principal product. These observations are explained as follows: The highly 
reactive carbocations generated in the first steps of the cyclization reactions are very 
unstable and quenched at an early stage of the reaction cascade. Either several different or 
one single product can be formed depending on structural differences of the enzymes. In 
case of multiple product formation incomplete evolution of the active site is suggested as a 
reason. Another explanation could be the simplification for the evolution of new 
functions.1,4,7 
Both microbial and plant sesquiterpene cyclases have been investigated deeply. Whereas 
the primary structures differ, many similarities are described regarding the tertiary 
structures and the electrophilic reaction cascade mechanisms. One of the best described 
sesquiterpene cyclases is the trichodiene synthase from Fusarium sporotrichioides with 
solved reaction mechanism as well as structure-function relationships which enables the 
comparison with the monoterpene synthases.4,7,68–70 Besides this, also a large number of 
other sesquiterpene synthases has been characterized, expanding the knowledge of 
structural and mechanistic characteristics of this class of enzymes.4,7,71 
Many cyclic sesquiterpenes were shown to exhibit useful properties. Examples for 
industrially used monocyclic sesquiterpenes are damascones and ionones which belong to 
the family of rose ketones and are fragrances occurring in essential oils.4,72,73 Other 
sesquiterpenoids have pharmaceutical use, such as absisic acid, which is used as growth 
regulator.74 The monocyclic bisabolol, and the bicyclic compounds petasin and isopetasin are 
antiphlogistic and spasmolytic (Fig. 3.9).75 
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Fig. 3.9: Cyclic sesquiterpenoids which are used as flavor compounds or pharmaceuticals. 
Guaiazulene and chamazulenes are inflammatory. In addition to this, guaiazulene represents 
a flavor compound of essential oils, as it is a component of chamomile oil and occurs as a 
pigment in corals.76–78 The germancronolides, represented in Fig. 3.9 by costunolide, are a 
large group of sesquiterpenoid lactones which also show antitumor effects. Illusin S is a 
representative of tricyclic sesquiterpenoids. It occurs in different fungi and is highly toxic, 
but when used in therapeutical concentrations, it exhibits antibiotic and antitumor 
properties.36,79 Artemisinin is a well-known anti-malarial sesquiterpenoid which was found in 
annual wormwood (Artemisia annua).3,80,81 There are plenty of more examples for 
pharmaceutically useful sesquiterpenoids, such as the antibiotics and mycotoxines from the 
trichothecane family67, the immunosuppressive and antibiotic ovalicin from bergamote 
oil67,82, the pentalenolactones which offer antibiotic, antitumor and anti-inflammatory 
properties67,83, the eudesmane derivatives with their antifeedant, antibacterial, cytotoxic 
features84 and many others. 
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3.4 Diterpenoids 
Diterpenes are C20 compounds formed from geranylgeranyl diphosphate (GGPP). More than 
1000 diterpenes are known fitting into 20 major and four less common bi-, tri-, tetra and 
pentacyclic skeletons. Many diterpenoids are derived from the only acyclic diterpene phytol 
by ring closures, oxidations and substitutions.74 Similar to other classes of terpenoids there 
are hydrocarbons, alcohols, aldehydes, ketones and carboxylic acids all known in this group. 
The formation of most cyclic diterpenes is catalyzed by diterpene synthases but in contrast 
to the cyclization of mono- and sesquiterpenes, the cyclization of diterpenes can either 
occur via class I or class II mechanism. 
On the one hand, the substrate GGPP can be ionized by the cleavage of the diphosphate 
group, similar to the initiation of the cyclization of mono- and sesquiterpenes catalyzed by 
mono- and sesquiterpene synthases.7,85 On the other hand, some diterpene cyclases also 
show the ability to catalyze the cyclization of GGPP by a protonation-initiated mechanism, 
forming the initial reactive carbocation intermediate by protonation of the terminal C=C 
double bond of GGPP. In addition, there are also some types of diterpene cyclases which are 
able to catalyze cyclizations via both mechanisms.7,86 The formation of different products is 
traced to subsequent reaction steps, such as hydride and methyl shifts, Wagner-Meerwein 
rearrangements and further cyclizations as discussed for mono- and sesquiterpene 
cyclizations, as well as internal de- and reprotonations. 
 
Fig. 3.10: Cyclic diterpenes. 
Examples for ionization-dependent diterpene cyclases are the casbene and the taxadiene 
synthases. Accepting GGPP as substrate and starting the cyclization by Lewis-acid assisted 
cleavage of the diphosphate, the products formed are the antimicrobial and antifungal 
casbene and the antitumor compound taxadiene, respectively (Fig. 3.10).85,87,88 
Other diterpene synthases that were characterized did not show the presence of the DDxxD 
motif, which is characteristic for class I enzymes. The first carbocation is not generated by 
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ionization but by means of protonation of a C=C double bond of the substrate. This 
observation was in line with the mechanism assumed for the cyclases of longer chain 
terpenes, such as the triterpene cyclases. In this case, another aspartate-rich motif is 
conserved, the DxDD motif. The cyclization reaction is initiated by Brønsted acid-catalyzed 
protonation of a terminal C=C double bond of the substrate, generating the highly reactive 
carbocation.89 One example for a diterpene cyclase which is able to catalyze reactions via 
both mechanisms is the abietadiene synthase: firstly, the protonation-induced cyclization of 
GGPP leads to enzyme-bound (+)-copalyl diphosphate, then, the pimarenyl cation is created 
by departure of the diphosphate followed by cyclization. Finally, the scaffold of (-)-
abietadiene is created by reprotonation, methyl migration and deprotonation (Fig. 3.11).90 
 
Fig. 3.11: Cyclization of GGPP to (-)-abietadiene catalyzed by abietadiene synthases. 
Besides the already mentioned bioactive compounds casbene and taxadiene there are many 
other diterpenoids known to exhibit a variety of physiological functions. Paclitaxel, also 
called Taxol, is a derivative of taxadiene and known to be antileucemic. It is described as one 
of the most promising medications for cancer.5 Taxol is found in nature in the bark from the 
trees Taxus brevifolia (Pacific yew) and Taxus baccata (European yew).74 The previously 
discussed (-)-abietadiene is just occurring in low amounts and its use has not yet been 
investigated so far.90 Another group of interesting diterpenoids is represented by the 
steviosides. They have recently become a hot topic in Germany, as they can be used as 
sweeteners. The diterpenoid glycosides can be isolated from Stevia rebaudiana and exhibit a 
300-fold sweeter taste than sugar (Fig. 3.12).74,91  
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Fig. 3.12: Diterpenes with biological activity. 
3.5 Sesterpenoids 
The group of sesterpenoids, derived from the linear C25 precursor geranylfarnesyl 
diphosphate (GFPP), is probably the least investigated. This could be due to their rare 
occurrence as secondary metabolites or to their lack of value for humans. However, some 
research was done on the ophiobolins in the 1960s. Ophiobolins are the only cyclic 
sesterpenoids where a cyclization mechanism has been suggested, but there are no enzymes 
discussed catalyzing the reaction. Studies suggest that the GGFP cyclization is initiated by 
cleavage of the diphosphate and the cyclization reaction proceeds subsequently as shown in 
Fig. 3.13.92–96 
 
Fig. 3.13: Biosynthetic pathway forming the ophiobolin scaffold from GFPP.92–94 
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When this mechanism for orphiobolin biosynthesis was described, the gap between cyclic 
diterpenoids derived from GGPP and triterpenoids coming from squalene could be 
diminished. The structure of this group of compounds is indeed interesting, as the complex 
cyclization leading to the 5-8-5 ring product scaffold is unique (Fig. 3.13).92–95 
Produced by pathogenic fungi, representatives of this group display phytotoxic 
properties.95,97,98 In lower concentrations, they can be valuable in drugs. Ophiobolin A (Fig. 
3.14), in particular, is known to possess antibacterial, antitumor and nematodical functions 
showing inhibitory effects against Staphylococcus aureus, Aspergillus flavus, Candida 
albicans, Torulopsis cremoris and Torulopsis petrophilum.99,100 
 
Fig. 3.14: Sesterpenoids found in nature. 
Other common sesterpenoids are the genelopides, which are formally γ-lactones and were 
recently found in Mountain wormwood (Artemisia umbelliformis). Their biosynthesis is not 
clearly understood but it is suggested that these compounds are Diels-Alder adducts of 
costunolide and myrcene and that their formation is catalyzed by Diels-Alderases. They 
could be used for production of wormwood liqueurs (Fig. 3.14).101 Iricinin-1 and Iricinin-2 
and other furanoterpenes are forming a special class of sesterpenes. They were found in 
marine sponges and it was shown that these compounds are cytotoxic.102,103 The linear 
sesterpene group of the haslenes has been shown to exhibit cytostatic properties.99,104 
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3.6 Triterpenoids 
3.6.1 Functions and occurrences 
The class of triterpenoids is probably the largest and most ancient of all of the groups of 
different terpenoids. As they are found in all kinds of membranes bearing different 
structures, they are widely distributed all over the world. Thousands of different triterpenes 
with about 80 different carbon skeletons have been identified by now.6 Basically, the 
triterpenoids can be divided into several groups, among which the sterols, hopanes, 
oleananes, ursanes, lupanes, fernanes and arboranes should be mentioned (Fig. 3.15).6,105,106 
The most frequent and best investigated triterpenoids are the tetracyclic steroids, 
represented in Fig. 3.15 by lanosterol, cycloartenol and cholesterol, and the pentacyclic 
hopanoids with a common hopane scaffold. The other pentacyclic triterpenoids are based on 
the oleanane, urasene, lupane, fernane and arborane skeletons, occurring in different kinds 
of organisms.6,107–110 
 
Fig. 3.15: Scaffolds of cyclic triterpenes occuring in nature: sterols (lanosterol, cycloartenol, 
cholesterol), hopanes, oleananes, ursanes, lupanes, fernanes and arboranes. 
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The importance of steroids in eukaryotic organisms is displayed by their roles as hormones, 
membrane constituents and precursors of other steroids.111,112 Squalene is known as the key 
intermediate for their biosynthesis in plants and animals, leading to other metabolites with a 
variety of different functions and structures. They contain side chains characteristic for 
different types of organisms, such as plants or mammalians.6,112 
In this work, special focus is laid on the group of hopanoids. For many years, scientists 
investigated their function dependent occurrence in different organisms. They also tried to 
explain their contents in different organisms depending on the environmental conditions.113–
115 Their occurrence as “structural equivalents of sterols” was discussed several times, as 
these two classes of compounds provide several similar properties. They both play an 
important role as membrane constituents, regulating the fluidity of cell membranes.111,115,116 
In the following chapter (3.6.2), the biosynthesis of the cyclic triterpenoids will be described, 
explaining the backbone of the triterpene cyclases and the reaction mechanisms by which 
the cyclic triterpenoids are created. In chapter 3.6.3, a special class of bacterial triterpene 
cyclases, the squalene-hopene cyclases, will be introduced in detail, as they represent the 
centerpiece of this work. 
3.6.2 Biosynthesis of triterpenoids, reaction mechanisms and approaches 
for the evolution of the triterpene cyclases 
The basis for formation of triterpenoids is the common C30 precursor squalene which is 
generated by a prenyltransferase-catalyzed head-to-head condensation reaction of two FPP 
units (Fig. 3.3). Squalene is ubiquitous in nature and in its linear form it is especially found in 
olives, shark liver oil, and rice bran.99 The cyclic triterpenoids are derived by cyclization of 
squalene or 2,3-oxidosqualene which is formed from squalene by squalene epoxidases (Fig. 
3.16). From these two precursors all of the polycyclic triterpenoids, such as hopanoids and 
steroids, are derived.6 
The anaerobic formation of hopanoids is catalyzed by squalene-hopene cyclases (SHCs). In 
contrast to this, the cyclization of 2,3-oxidosqualene is catalyzed by oxidosqualene cyclases 
(OSCs) leading to steroids. SHCs and OSCs are closely related but it was shown that they 
differ in their folding due to minimal structural differences.6 The fact that the formation of 
2,3-oxidosqualene requires molecular oxygen led to the conclusion that steroids could just 
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be formed when the atmosphere yet contained oxygen. From these considerations, the 
theory that the steroid biosynthetic pathway was evolved from the hopanoid biosynthesis 
via minor mutations of the cyclase, was established.6,115–121 In addition to this, the 
occurrence of steroids in ancient sediments seemed to give valuable informations as 
biomarkers for the oxidation of the atmosphere and the first appearance of cyanobacteria 
starting to produce oxygen.122 
 
Fig. 3.16: The precursors for polycyclic triterpenoids: squalene and oxidosqualene. 
In principle, the distribution of SHCs and OSCs was suspected to be relatively clear: The 
hopanoids were found in prokaryotic organisms, especially in bacteria, while the steroids 
were found in eukaryotic organisms. One approach was discussed leading to the conclusion 
that hopanoids present in organic matter indicate prokaryotic existence, while steroids can 
be used as biomarkers for the appearance of higher organisms.6 However, this general 
declaration was disproved when the first steroids were found in prokaryots113,123,124, and 
especially when later also an OSC was found in the bacterial strain Methylococcus 
capsulatus.6,125–127 It was also discovered that some plants, e.g. ferns, gryophytes, lichens, 
fungi, are able to synthesize both steroids and hopanoids.6,128 A new theory was postulated 
arguing that earliest enzymes are expected to catalyze the simplest and energetically most 
favored reactions and that during evolution these enzymes developed to more potent 
catalysts, being able to overcome more and more energetic barriers generating specific 
products which are beneficial for the hosts. Thus, it was considered that SHCs and OSCs, 
evolved independently outgoing from a common ancestor.129,130 
However, it seems to be obvious that both steroids and hopanoids are similar regarding their 
functions in the different organisms and, thus, that SHCs and OSCs have many properties in 
common. Besides the sequence identity of SHC and OSC families of usually over 31 %, also 
important positions in the active cavity of these cyclases are often very similar. For example, 
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the prokaryotic SHC from Alicyclobacillus acidocaldarius (AacSHC) and the human lanosterol 
synthase OSC (HsaOSC) possess 20 % identical residues, what means that these cyclases are 
homologous.6 Studies on the crystal structure similarities revealed that both AacSHC and 
HsaOSC consist of two connected (α/α) barrels enclosing large hydrophobic cavity (Fig. 
3.14).131 The entrance to the active cavity is suggested to be placed in one of the two barrels, 
whereas the center of the active site, where the cyclization reaction is initiated, is located in 
the second barrel.8 
 
Fig. 3.17: Crystal structures of A) AacSHC and B) HsaOSC; the two (α/α) barrel domains are colored 
in blue and green; the catalytic aspartate (part of the catalytic motifs xxDC / DxDD) in red and the 
substrate analog azasqualene / the product lanosterol are colored in orange.
It was shown that both enzymes possess conserved amino acid motifs and that many of 
them are representative structural domains in their crystal structures.11,130,132 An explanation 
for this high conservation can be seen by considering the high similarity of the substrates 
they accept and the products they form. For these highly complex cyclization reactions a 
precise stereochemical conformation is required. The initial protonation of the substrate is 
performed by an aspartate residue (D376 for AacSHC and D455 for HsaOSC), which is part of 
a conserved motif. Also more π-electron rich positions responsible for stabilization of the 
carbocation intermediates and the protection against premature quenching of an 
intermediate, for example by water, are often homologous for both enzymes.11,132 This was 
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figured out by numerous mutational studies performed by several groups solving the 
reaction mechanisms of the cyclization cascades and identifying the crucial positions 
responsible for the stabilization of the carbocations.13,123,133–136 Several amino acid sequence 
repeats of the length of 16 amino acids each were found both in SHCs and OSCs. These QW 
motifs were shown to occur up to six times in the SHCs and four times in OSCs and are 
supposed to be responsible for the stability of these cyclases.10,135–137 
 
Fig. 3.18: Reaction mechanisms for the cyclization of squalene to hopene and hopanol and 
oxidosqualene to lanosterol; the nucleophilic attacks are marked as blue arrows; the methyl and 
hydride shifts in red and the nucleophilic attack of hydroxyl is marked in green, respectively. 
However, there also have to be mentioned several differences between SHCs and OSCs. 
They both accept a similar substrate, just differing in the presence or absence of an epoxide 
ring at the 2,3-position. However, it was shown that in the case of squalene cyclization in 
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AacSHC, the substrate is placed in the active cavity in chair-chair-chair conformation, 
whereas 2,3-oxidosqualene is positioned in the active site of HsaOSC in chair-boat-chair 
conformation (Fig. 3.18).9,58,130,132 For the initial protonation of the substrates it was 
observed that the relevant motif, the DxDD motif for SHCs and the xxDC motif for OSCs differ 
in strength. While the SHCs’ DxDD motif is strongly electrophilic and is also able to protonate 
the 2,3-oxidosqualene, the xxDC motif of the OSCs is weaker and no conversion of the SHCs’ 
substrate squalene was observed with OSCs.130,138,139 Regarding the cyclization steps 
following the initial protonation, there are several approaches discussed, suggesting the 
cyclization steps to occur in concerted manner or as multistep reactions via different 
intermediates.9,58 While SHCs cyclize the substrate by electrophilic additions to the double 
bonds of the carbocation intermediates, cyclization of the substrate by OSCs is accompanied 
by hydride and methyl shifts subsequent to the cyclization step. OSC-catalyzed cyclization of 
oxidosqualene in plants yields lanosterol (Fig. 3.18).9 The alkylations of the side-chains of the 
products are complex and play an essential role with respect to the biological 
functionalities.6 Alkylation of the hopanoid ring system was reported for some bacteria but it 
remains unclear when the methylation occurs and usually requires the presence of a C=C-
double bond or an aromatic ring.140 
3.6.3 Squalene-hopene cyclases 
Squalene-hopene cyclases (SHCs) are catalysts for the class II cyclization of the linear 
triterpenoid squalene to hopene and hopanol, which is one of the most complicated 
reactions known in biochemistry (Fig. 3.18). Most today’s knowledge has been derived from 
characterization of a squalene-hopene cyclase of the thermophilic organism Alicyclabacillus 
acidocaldarius (formerly Bacillus acidocaldarius). But also other SHCs have been investigated 
and partially characterized, such as Methylococcus capsulatus SHC125,139, Zymomonas mobilis 
SHC214,141,142, or Bradyrhyzobium japonicum SHC14,143. 
3.6.3.1 Alicyclobacillus acidocaldarius SHC (AacSHC) 
The crystal structure of AacSHC was solved in the 1990s, revealing new insights into the 
biocatalysis of squalene cyclization (Fig. 3.17 A).6,11,144 The active site of the enzyme is placed 
in the large central cavity and is enclosed by loops with aromatic residues that are estimated 
to be responsible for the binding of squalene in the required conformation and for the 
stabilization of the substrate during the cyclization process. The central active site cavity 
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consists of a large non-polar surface accompanied by a small polar area.6,144,145 Mutational 
analyses of the active site led to detailed information about the amino acid residues playing 
an important role for the complex cyclization mechanism. At the top position of the central 
cavity, the catalytic DxDD motif is located; in particular, Asp376 was shown to be crucial for 
initial protonation of the C=C-double bond.13,146 After the protonation, the first ring and 
probably also the second ring is suggested to be cyclized in concerted manner, followed by 
rearrangements of five-membered rings and Markovnikov-like ring closure reactions forming 
the third and fourth ring. After formation of the fifth ring, the final carbocation is 
deprotonated or quenched with water (Fig. 3.18).146 
 
Fig. 3.19: A) Schematic model of the SHCs’ active site displaying the amino acids which are crucial 
for the catalysis of squalene cyclization. The numbering of the amino acids refers to AacSHC and 
the values show the conservation of these residues in accordance to all 325 aligned SHCs. The 
letters indicate the product’s ring formed in this part of the active site. B) The indication of the five 
rings is shown exemplarily for hopene.10 
The amino acids which had been shown to be crucial for squalene cyclization with AacSHC 
were recently compared with the corresponding amino acids of other SHCs from the SHC 
database (TTCED10) containing 325 SHCs. These amino acid residues were shown to be highly 
conserved, as displayed in Fig. 3.19. 
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AacSHC is a monotopic membrane-anchored enzyme and it is assumed that the entrance 
into the active cavity is reached from the inner, non-polar part of the bacterial membrane, as 
shown in Fig. 3.20. This makes sense, as squalene is an unpolar substrate and the products 
are known to be membrane constituents and could be directly placed in the membrane after 
cyclization. 
 
Fig. 3.20: Draft of the membrane-anchored dimer AacSHC: the access to the active site is suggested 
to be from the non-polar membrane.58 
The fact that AacSHC and presumably also other SHCs are membrane-associated enzymes 
complicates experimental work. After cell disrupture soluble proteins from the cell lysate can 
be removed easily by centrifugation. However, membrane-anchored proteins remain in the 
cell debris and have to be solubilized using surfactants, such as Triton™ X-100, CHAPS, or 
Tween® 20 (Fig. 3.21), as suggested by numerous studies in this field.147,148 Within this 
solubilization step, lipid components of the membrane are disrupted and the membrane 
proteins are achieved in an aqueous solution complexed with detergents.149 
But although solubilization is possible by selecting a suitable surfactant, the protocol for 
biotransformations has to be worked out carefully. Different facts have to be considered, 
such as the critical micelle concentrations (cmc) of the selected detergent, effects of the 
  Theoretical Background 
 - 30 -  
detergent on protein determination assays or on extraction after the biotransformations and 
disturbance of analytical systems such as GC. 
 
Fig. 3.21: Detergents that can be used for solubilization of membrane associated proteins. 
Plenty of mutational and biochemical analyses was performed on the SHCs during the last 
decades, revealing information about the biochemical catalysis performed by these cyclases. 
Especially the ability of this enzyme to accept other substrates than squalene triggered our 
interest. The reported activity of AacSHC towards unnatural substrates will be described in 
3.6.4. 
3.6.3.2 Zymomonas mobilis SHCs (ZmoSHC1 and ZmoSHC2) 
While AacSHC had been investigated profoundly in many previous studies, less focus had 
been laid on other SHCs, such as the SHCs from the ethanol-producing bacterial strain 
Zymomonas mobilis.15 Zymomonas mobilis is a gram-negative bacterium which is remarkable 
because of its high amount of hopanoids with different side chains. It was assumed that this 
high hopanoid content is implicated in the high ethanol and sugar tolerance of Zymomonas 
mobilis.14,15,142,150–152 In 1995, a SHC of Zymomonas mobilis (ZmoSHC2) was heterologously 
expressed and its activity towards squalene was shown.15 The complete genome of 
Zymomonas mobilis was sequenced in 2005 and, besides ZmoSHC2, a second SHC could be 
described in this strain (ZmoSHC1). While the crystal structures of ZmoSHC1 and ZmoSHC2 
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remain unknown, multiple sequence alignments of these SHCs with AacSHC can reveal 
information (Fig. 3.22 and 11.1).  
 
Fig. 3.22: Multiple sequence alignment of ZmoSHC1, ZmoSHC2 and AacSHC. The aspartate residues 
in the active site (DxDD motif) are highlighted in blue, the residues which are predicted to interact 
in with the squalene analog in the active site of AacSHC and the corresponding residues in 
ZmoSHC1 and ZmoSHC2 are marked in grey, the 26 amino acid insertion in ZmoSHC1 is marked in 
yellow and the N-terminal residue of ZmoSHC1 is highlighted in green. 
The global sequence identities were determined as 33.6 % (ZmoSHC1 with ZmoSHC2), 40.6 % 
(ZmoSHC1 with AacSHC) and 37.2 % (ZmoSHC2 with AacSHC), respectively (see also chapter 
11.1).153 As many of the amino acid residues in the active sites of these SHCs which have 
been reported to be in direct contact with the substrate in case of AacSHC are 
corresponding, one could expect similar behaviors of the SHCs regarding their enzymatic 
performances. But also several obvious differences already discovered by multisequence 
alignment of the SHCs should be pointed out. First of all, ZmoSHC1 shows a residue of about 
45 amino acids length at the N-terminal end of the sequence. Another difference is the 26 
amino acid long insertion at the C-terminal end of ZmoSHC1. As the crystal structure of 
ZmoSHC1 is unknown, a homology model of ZmoSHC1 was designed for a better 
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understanding of the insights of this enzyme. The homology model of ZmoSHC1 created by 
Benjamin Juhl and Alexander Steudle (ITB) is displayed in Fig. 3.23, highlighting the N-
terminal residue in grey and the insertion at the C-terminal end in yellow. 
 
Fig. 3.23: Homology model of ZmoSHC1. The domains are colored in blue and green, the loop region 
in yellow and the long residue at the N-terminal end in grey; the catalytic aspartate is colored in 
red and the substrate analog azasqualene in orange. 
3.6.3.3 Other SHCs 
By now, 325 SHCs have been identified by annotation. The phylogenetic tree highlighting 
SHCs discussed in this work is shown in Fig. 3.24. 
Some of these representatives were emphasized due to their occurrence in different 
branches of the tree and their origin from thermophilic bacterial strains which could be 
interesting for stability reasons. These SHCs are namely GthSHC from Geobacillus 
thermodentrificans
154, McaSHC from Methylococcus capsulatus155 and TelSHC from 
Thermosynechococcus elongatus
156. Other SHCs were highlighted due to their global 
proximity to ZmoSHC1 and AacSHC, such as AaciSHC from Alicyclobacillus acidoterrestris136, 
AceSHC from Acidothermus cellolyticus157, CacSHC from Catenulispora acidiphila158, ScoSHC 
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from Streptomyces coelicolor159, SscSHC from Streptomyces scabiei160, SsvSHC from 
Streptomyces sviceus
161, SthSHC from Spherobacter thermophilus162, SviSHC from 
Saccharomonospora viridis
163, and TtuSHC from Teredinibacter turnerae164. An overview of 
these SHCs and the determined global sequence identities are shown in Table 3.1. For more 
detailed information see 11.2 and the supplementary data on CD-ROM. 
 
Fig. 3.24: Phylogenetic tree of the 325 identified SHCs. Several SHCs are highlighted. 
Remarkably, there are several strains which contain two SHCs, as the already described 
Zymomonas mobilis which possesses ZmoSHC1 and ZmoSHC2 (Table 3.2). The differences 
between these two enzymes were already discussed; the amino acid sequence of ZmoSHC1 
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is longer, revealing 67 amino acids more than ZmoSHC2 and shows a long residue at the N-
terminal end of the protein and a 26 amino acid insertion at the C-terminus. Acetobacter 
pasteurians
165 is another bacterial strain with two SHCs (ApaSHC1 and ApaSHC2, alignment 
see 11.3.1 b), showing similar characteristics like Zymomonas mobilis. 
Table 3.1: Overview of several SHCs highlighted in the phylogenetic tree (Fig. 3.24). 
Name Strain 
amino 
acids 
molecular 
weight 
[kDa] 
global sequence identity [%] with 
 Z
m
o
S
H
C
1
 
 Z
m
o
S
H
C
2
 
 A
a
cS
H
C
 
AacSHC 
Alicyclobacillus 
acidocaldarius89 
637 71.6 41 37 - 
AaciSHC 
Alicyclobacillus 
acidoterrestris136 
634 70.8 39 35 63 
AceSHC 
Acidothermus 
cellolyticus157 
633 70.2 39 40 51 
CacSHC 
Catenulispora 
acidiphila158 
644 71.0 39 39 48 
GthSHC 
Geobacillus 
thermodentrificans154 
617 69.5 29 32 32 
McaSHC 
Methylococcus 
capsulatus155 
654 74.0 31 48 38 
ScoSHC 
Streptomyces 
coelicolor159 
680 75.2 41 39 47 
SscSHC Streptomyces scabiei160 664 73.2 42 40 49 
SsvSHC Streptomyces sviceus161 669 74.2 41 39 49 
SthSHC 
Spherobacter 
thermophilus162 
617 68.5 39 36 47 
SviSHC 
Saccharomonospora 
viridis163 
640 71.6 41 40 49 
TelSHC 
Thermosynechococcus 
elongatus156 
642 72.7 37 40 43 
TtuSHC 
Teredinibacter 
turnerae164 
671 75.5 51 35 44 
       
       
First of all the sequence of ApaSHC1 is longer than ApaSHC2, containing 64 amino acids 
more. Secondly, ApaSHC1 exhibits a long residue at the N-terminal end, which had already 
been observed for ZmoSHC1. And lastly, ApaSHC1 contains a 26 amino acid insertion at the 
C-terminal end, similar to ZmoSHC1. Similar observations regarding this insertion were made 
for RpaSHC1 and RpaSHC2 from Rhodopseudomonas palustris166 and SfuSHC1 and SfuSHC2 
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from Syntrophobacter fumaroxidans167. These SHCs do not possess a residue at the N-
terminal end. The last strain with two SHCs which is described here, Pelobacter 
carbinolicus
168, shows slight differences. In this case, the shorter of the SHCs, PcaSHC2, 
contains a loop region at the C-terminus. In contrast to this, PcaSHC1 contains two small 
insertions in the center of the sequence, as shown in 11.3.1 e). Regarding their global 
sequence identities with Zymomonas mobilis SHCs, PcaSHC2 shows a higher identity with 
ZmoSHC1 (48 %) whereas PcaSHC1 is more similar to ZmoSHC2 with a global sequence 
identity of 41 %. For more detailed information see 11.2 and the supplementary data on CD-
ROM. 
Table 3.2: Overview of SHCs from strains containing two SHCs. 
Name Strain 
amino 
acids 
molecular 
weight 
[kDa] Residue? Loop? 
global sequence 
identity [%] with 
 Z
m
o
S
H
C
1
 
 Z
m
o
S
H
C
2
 
 A
a
cS
H
C
 
ZmoSHC1 Zymomonas 
mobilis169,170 
725 81.7 
yes 
(45 aa) 
yes 
(26 aa) 
- 34 41 
ZmoSHC2 658 74.1 no no 34 - 37 
ApaSHC1 Acetobacter 
pasteurianus165 
720 80.1 
yes 
(41 aa) 
yes 
(26 aa) 
78 33 40 
ApaSHC2 656 72.9 no no 33 54 39 
RpaSHC1 Rhodopseudomonas 
palustris166 
685 77.3 no 
yes 
(26 aa) 
61 34 44 
RpaSHC2 654 72.6 no no 33 57 39 
SfuSHC1 Syntrophobacter 
fumaroxidans167 
710 79.2 no 
yes 
(24 aa) 
48 34 41 
SfuSHC2 688 78.1 no no 37 35 42 
PcaSHC1 
Pelobacter 
carbinolicus168 
737 82.2 no no 35 41 36 
PcaSHC2 695 77.5 
yes 
(26 aa) 
yes 
(24 aa) 
48 35 42 
         
         
For ApaSHC1 and RpaSHC1 the high global sequence identities of 78 % and 61 % to ZmoSHC1 
have to be emphasized. Analog to this, their second SHCs, ApaSHC2 and RpaSHC2 show good 
similarity with ZmoSHC2. Regarding the placement of the mentioned SHCs in the 
phylogenetic tree (Fig. 3.24), it has to be noted that the loop-containing SHCs, namely 
ApaSHC1, RpaSHC1, SfuSHC1 and PcaSHC2) are all placed close to ZmoSHC1. This can be 
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observed analogously for the second SHCs ApaSHC2 and RpaSHC2 which are located in 
proximity to ZmoSHC2. However, SfuSHC2 and PcaSHC1 are positioned in completely 
different branches as ZmoSHC2. Additionally, their global sequence identities with ZmoSHC2 
are about 35 %, which is relatively low. 
Regarding the sequences of the insertions observed for ZmoSHC1, ApaSHC1, RpaSHC1, 
SfuSHC1 and PcaSHC2, their high similarity has to be mentioned. This is illustrated in Fig. 
3.25 showing an alignment of the 24 to 26 amino acid long sequences. 
 
Fig. 3.25: Alignment of the loops of ZmoSHC1, ApaSHC1, RpaSHC1, SfuSHC1 and PcaSHC2. 
3.6.4 Substrate specificity of SHCs 
As already mentioned, it was shown that SHCs are not highly substrate specific and cyclize 
both squalene and 2,3-oxidosqualene.6 In several works it could be shown that besides this 
also diverse linear terpenoids were converted into cyclic products by AacSHC. Hoshino et al. 
showed the cyclization of the C15 alcohol farnesol and the C25 alcohol geranylgeraniol as well 
as the cyclization of two C20 and C25 terpenes. The reactions of these truncated squalene 
analogs catalyzed by AacSHC led to bi-, tri- and tetracyclic products (Fig. 3.26, Fig. 3.27).17 
Even 18 years before, in 1986, Neumann et al. already had shown the cyclization of the C16 
alcohol homofarnesol to the heterocyclic flavor compound ambroxan. In this pioneering 
work, the group also presented the cyclization reactions of a homofarnesyl-ether and the 
cyclization of the C11 homogeraniol (Fig. 3.27).
16 Also more bulky substrates, such as pyrrole- 
and indole-containing terpenes have been shown to be accepted as substrates and also the 
cyclization of 26- and 27-methylidenesqualene to novel unnatural C31 polyprenoids as well as 
2,3-dihydrosqualene and squalene 2,3-epoxide was observed with AacSHC.18,19,171 
ZmoSHC1         GYGVGQTIKLDDPALSKRLLQGAELS 
ApaSHC1         GYGVGQTIKLDDPAISKRLMQGAELS 
RpaSHC1         GYGVGQTIKLNDPLLSKRLMQGPELS 
SfuSHC1         GYSVGERIRLRD--MGASLKQGTELQ 
PcaSHC2         GYGVGERTNLKE--AGATLDQGCELA 
                **.**:  .* :   .  * ** **  
  Theoretical Background 
 - 37 -  
 
Fig. 3.26: Biotransformations catalyzed with AacSHC: The linear sesterpene (C25; (6E,10E,14E)-
2,6,10,15,19-pentamethylicosa-2,6,10,14,18-pentaene) and the diterpene (C20; (6E,10E)-2,6,10,15-
tetramethylhexadeca-2,6,10,14-tetraene) were converted to the corresponding cyclic products.17 
The C20-indole containing substrate and the C20-pyrrole were also converted into cyclic 
products.18,19 
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Fig. 3.27: Cyclization reactions of terpenoid alcohols shown with AacSHC: geranylgeraniol (C20), 
homofarnesol (C16), farnesol (C15) and homogeraniol (C11) were converted into the cyclic 
products.16,17 Homofarnesyl-(1,5,9)-trimethyl-4,8-dodecadienyl-ether was converted to ambroxan 
and the corresponding alcohol.16 
3.7 Organic syntheses of cyclic terpenoids 
Inspired by nature, many organic chemists started to investigate on cyclization reactions 
catalyzed by traditional catalysts.172 Pioneering work on polyolefin cyclizations was 
performed by the groups of Stork and Eschenmoser in the 1950s.28,29 The cyclization of 
polyenes such as farnesoic acid catalyzed by mixtures of Brønsted acids like sulfuric acid, 
formic acid or acetic acid, was demonstrated. Mechanistical studies on the cyclization of 
squalene and analogs were especially performed by the group of E. J. Corey and first studies 
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for Lewis and Brønsted acid catalyzed non-enzymatic biomimetic polyene tetra- and 
pentacyclization of polyprenoic acetals or chiral terminal epoxides of polyprenes were 
described.173–176 From these publications in the 1960s until now, the mechanism of the 
squalene cyclization was elucidated leading to biomimetic approaches for the in vitro 
synthesis of steroids and further cyclic terpenoids of common interest.55,59,177 
Outgoing from these first total syntheses, both yields and stereoselectivity were improved 
during the last decades. Later, the enantioselective formation of bi- and tricyclic terpenoids 
from linear precursors was described with Lewis acid-assisted chiral Brønsted acids as 
catalysts (chiral LBAs, Fig. 3.28). Using this artificial cyclase, the enantioselective synthesis of 
the flavor compound ambroxan or the bicyclic ether caparrapioxide was described.178,179 
 
Fig. 3.28: Lewis acid-assisted chiral Brønsted acid (LBA).179 
Recently, the enantioselective polycyclization of different achiral polyene precursors leading 
to tri-, tetra- and pentacyclic products was shown via a proton-initiated mechanism 
catalyzed by a chiral LBA containing SbCl5 as Lewis acid.
180 However, the enantiospecific 
formation of certain cyclic products remains challenging. 
3.7.1 Ambroxan and sclareolide 
In nature, ambroxan is found as metabolite of the sperm whale (Physeter macrocephalus L.), 
occurring in the concretions in its gut, in the ambra. The ambra is composed of several 
constituents, such as (+)-ambrein (Fig. 3.29). 
 
Fig. 3.29: The major constituents of the ambra. 
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Due to the exposure to sunlight and air, ambrein is decomposed to several odorous 
compounds, such as (-)-ambroxan, which will just be named ambroxan in the present work, 
γ-dihydroionone or dehydroambraoxide (Fig. 3.29).20,181 
With a price of about $ 1,000 / kg ambroxan is the most valuable flavor compound among 
the amber odorants and has been used in the flavor and fragrance industry for a long 
time.20,182 Until today, ambroxan is widely used in the perfume industry with a production of 
about 30 tons per year.20 
 
Fig. 3.30: Stereoisomers of ambroxan. 
The special organoleptic properties of ambroxan make this compound desirable. Its odor is 
described as musk-like, woody, warm or animalic. In contrast to this, the odor of (+)-
ambroxan is described as exotic and spicy. Although the four isomers shown in Fig. 3.30 
seem to be very similar, both their odors and especially the odor threshold are differing. The 
most powerful flavors are representing ambroxan and (-)-epi-ambroxan.183–186 
The second product discussed in this chapter, sclareolide, or also called norambreinolide, is a 
tricyclic lactone occurring in nature as a component of Arnica angustifolia, Sideritis nutans, 
and Kyllinga erecta.21 However, it occurs in much smaller amounts than the above 
mentioned sclareol. Sclareolide possesses several bioactive properties.187 It is described to 
have phytotoxic, cytotoxic and antifungal properties. In addition to this, it can be used as an 
additive in foodstuffs enhancing the organoleptic properties and it is assumed to be an 
useful supplement for weight loss.21,22 
Sclareolide is the most important intermediate in the chemical route from sclareol to 
ambroxan and other natural products, such as (-)-hyatellaquinone, a marine compound that 
was found to be an inhibitor of the reverse transcriptase of Human Immunodeficiency Virus 
(HIV) and, thus, can be pharmaceutically used (Fig. 3.31).188,189 Another example for the use 
of sclareolide was described for the synthesis of γ-bicyclohomofarnesal, a strong odor 
compound.190 (+)-Zerumbin B was also synthesized from sclareolide, representing a 
pharmaceutical compound valuable for several uses, such as its use against stomach ache, 
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chest pain or fever.21,191,192 Another pharmaceutical product that was shown to be generated 
from sclareolide is ottensinin, used for lumbago or convulsions (Fig. 3.31).193 
 
Fig. 3.31: Compounds generated from sclareolide in organic synthesis. 
Ambroxan and sclareolide consist of 16 carbon atoms and do not obey the “empiric isoprene 
rule” and, thus, are not easily available from natural sources.49–51 However, both substrates 
can be synthesized via different routes from farnesol, farnesylchloride or other substrates.179 
Due to excessive whaling, natural ambroxan is disappearing from the world market, and an 
alternative access had to be found.186 In order to do this, many organic chemists investigated 
the chemical synthesis of ambroxan from starting materials that are easy available. First 
approaches were established in the 1950s by Hinder and Stoll from the company Firmenich, 
producing to ambroxan from the natural compound sclareol which is derived from clary sage 
(Salvia sclarea).20,194,195 
After conversion of sclareol to sclareoloxide using sodium permanganate under acidic 
conditions (Fig. 3.32, route a), an oxidized intermediate is formed by ozonolysis.20,194,195 
Saponification leads to sclareolide, one of the important key intermediates in the partial 
synthesis of ambroxan. Reduction with LiAlH4 finally yields ambroxan. Using this synthetic 
route, the thermodynamically favored (-)-9-epi-ambroxan is formed as a side product. An 
alternative route from sclareol to sclareolide uses chrome trioxide or KMnO4 as catalyst.
196 A 
similar route was patented in 1962 starting with oxidation of sclareol to the corresponding 
hydroxyketone using potassium permanganate under alkaline reaction conditions prior to 
conversion into sclareoloxide with glacial acetic acid (Fig. 3.32, route b).196 Further oxidation 
was described with sodium permanganate or chromic acid yielding the oxidized intermediate 
which could afterwards be saponified to sclareolide. As side product, acetoxy acid is formed. 
One big drawback of this route is the toxicity of chromic acid and the difficulties in the 
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removal of the MnO2 which is formed. In addition to this, the oxidation of sclareoloxide is 
time consuming, resulting in a total process time of approximately 20 h. 
 
Fig. 3.32: Semi-synthetic routes to ambroxan from sclareol: After oxidation to sclareoloxide with 
KMnO4 under acidic conditions (route a) or with KMnO4 to the corresponding hydroxyketone and 
further oxidation with glacial acetic acid (route b), the intermediate sclareoloxide can be oxidized 
via ozonolysis20,194,195, with sodium permanganate or chromic acid196, leading to an oxidized 
intermediate. Saponification yields sclareolide which can be reduced to ambroxan. As side 
products, acetoxy acid and 9-epi-ambroxan can be formed. 
An improvement of this process was developed and patented in the 1990s be the company 
Henkel where the process could be improved using sodium hypochlorite for the oxidation of 
sclareol to the corresponding hydroxyketone and / or sclareoloxide prior to oxidation to 
sclareolide using peracids or peracid salts.197,198 This process was found to be much faster, 
leading to yields of 65 – 70 % after just about 3 h. Oxidation of sclareol to the hydroperoxide 
under acidic conditions prior to cyclization to ambroxan in presence of a redox catalyst 
(Fe2+ / Cu2+) is another method which was established and patented. 
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Fig. 3.33: Synthetical route from sclareol to ambroxan starts by ozonolysis using using osmium 
tetroxide199 or the sodium periodate.200 Ambroxan is achieved after Baeyer-Villiger oxidation and 
Lewis acid-catalyzed reduction. 
Another route was discovered and patented using osmium tetroxide or sodium periodate for 
ozonolysis of sclareol (Fig. 3.33). 199,200 The disadvantage of this process is the rather time 
consuming oxidation step, which needs several days, and the toxicity of osmium tetroxide.201 
A biochemical approach was discovered using the microorganisms Hyphozyma roseoniger, 
Cryptococcus albidus, Cryptococcus laurentii or Bensingtonia ciliata for the reaction 
described in Fig. 3.34.202,203 The formed diol can be cyclized to ambroxan using toluene-p-
sulfonylchloride in pyridine.204 
 
Fig. 3.34: Fermentation of sclareol leading to the corresponding diol shown with several 
microorganisms.202,203 
As alternative precursors to the access of ambroxan from sclareol, several routes have been 
discovered from natural products. An overview is given in Fig. 3.35. For example, one access 
of ambroxan was found from linalool via nerolidol and homofarnesoic acid or homofarnesol 
followed by polyene cyclization.179 The formation of ambroxan from communic acids was 
published in 1993 and recently reviewed.187 Another access was found from (+)-cis-abienol 
or β-ionone.194,195,205–207 
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Fig. 3.35: Precursors for organic synthesis of ambroxan: (S)-(+)-carvone208, drimenol209, 
geranylacetone186, (-)-manoyl oxide204, thujone210, (-)-abietic acid211, (-)-levopimaric acid212, 
communic acids207, homofarnesol179 and (+)-cis-abienol213. 
3.7.2 Caparrapioxide 
The caparrapioxides (Fig. 3.36) have been found to occur in nature in the defense secretion 
of the termite species Amitermes evuncifer214, in the sea hare Aplysia dactylomela215 and in 
the extract of sun-cured Greek tobacco (Nicotiana tabacum)216. Due to their unusual 
structural features they are interesting compounds that offer special biological activities.217 
It was described that (-)-8-epi-caparrapioxide exhibits an ambergis, wooden flavor.24 
 
Fig. 3.36: Structures of the nerolidol cyclization products: (-)-caparrapioxide and (-)-8-epi-
caparrapioxide. 
However, the synthesis of these compounds was found to be challenging due to the 
complicated polycylization reaction. In 1976, Lombardi et al. were the first in synthesizing 
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both caparrapioxides and presenting the first NMR data for each stereoisomer. The reaction 
started from ethinedihydroionol catalyzing the ring closure by SnCl4 prior to partial 
hydrogenation in presence of a Lindlar catalyst (Fig. 3.37).178,218  
 
Fig. 3.37: Process for production of caparrapioxides from ethinedihydroionol.218 
The separation of the caparrapioxide isomers was performed via bromation. As the 
equatorial vinyl group of (-)-caparrapioxide was found to be bromated much faster than the 
axial vinyl group of (-)-8-epi-caparrapioxide, the mixture was separated on silica gel 
column.219,220 After the separation, the (-)-caparrapioxide could be recovered using zinc 
powder.220 
In the following years, investigation on the chemical synthesis of the caparrapioxides 
proceeded further.217,219,220 Enantiospecific synthesis was shown from farnesol or nerolidol 
using Lewis acid-assisted chiral Brønsted acid (LBA) catalysis.178 While the synthesis starting 
from farnesol required several steps, nerolidol could be converted directly. The drawbacks of 
this route are the low yields of maximal 32 % and the long reaction times of one day. The 
preparation of the chiral LBAs is described to be easy but requires several steps from 
commercially available binaphtol (BINOL).221 
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3.7.3 Sclareoloxide and hexahydrochromene 
The in nature manifold occurring222–226 and commercially available ketones farnesylacetone 
and geranylacetone can be converted into to the cyclic enol ether compounds sclareoloxide 
and a derivative of hexahydrochromene (named hexahydrochromene in the peresent work) 
which can both be of economic interest (Fig. 3.38). 
 
Fig. 3.38: Cyclic enol ethers sclareoloxide and hexahydrochromene. 
Enol ethers in general are a versatile class of compounds used in organic chemistry, as they 
are able to participate in olefin metathesis reactions.227 In addition to this, sclareoloxide 
embodies an attractive compound representing a valuable precursor or intermediate for the 
production of many flavor components as being an intermediate in the synthesis of drimane 
sesquiterpenoids and ambroxan (Fig. 3.32).182,228 This tricyclic enol ether also provides access 
to puupehenones, which appeared to be an important group of marine metabolites of mixed 
biosynthesis (Fig. 3.39).229 
 
Fig. 3.39: Examples for bioactive products that can be synthesized from sclareoloxide and 
hexahydrochromene: (8S)-puupehenone, dihydroedulan and tetrahydroedulan. 
These products are of interest, as they exhibit various biological activities as well as 
antimicrobial, antifungal230,231 and cytotoxic232 activities and they have been found to be 
inhibitors for the replication of the HIV virus25,26. The cyclization product of geranylacetone, 
hexahydrochromene, enables an access for production of edulans, which show rose-like 
aromas.27 Dihydroedulans have been found to be valuable flavor compounds, occurring for 
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example in passion fruit (Passiflora edulis, Fig. 3.39).233 It can also be a valuable precursor for 
production of octahydrobenzopyran (also called tetrahydroedulan) derivatives which are 
compounds that exhibit amber odor.24,234 
The development of such a cyclization reaction is very interesting from the chemical point of 
view, as the created products are difficult to achieve in traditional chemical synthesis. The 
synthesis of sclareoloxide has been described by oxidation of sclareol, as already discussed in 
chapter 3.7.1 on the route to ambroxan (Fig. 3.32) or by degradation of manoyl oxide (Fig. 
3.35).20,194–196,228 
3.7.4 Ambraoxide, ambreinolide and unsaturated ambraoxide 
 
Fig. 3.40: Cyclic products of bishomofarnesol: (±)-ambraoxide, (±)-epi-ambraoxide and (±)-9-epi-
ambraoxide; and cyclic products derived from bishomofarnesoic acid: (±)-ambreinolide, (±)-10-
epi-ambreinolide and (±)-9-epi-ambreinolide. 
Ambraxoide and ambreinolide are useful compounds in the tobacco and perfume 
industry.235,236 Cyclization of the corresponding aldehyde, bishomofarnesal, leads 
analogously to an unsaturated ambraoxide, a compound which has also been reported to 
offer a strong ambergris odor and, thus, representing another valuable product.237 
As already mentioned for their C16 homologs, these C17 compounds also do not follow the 
“empiric isoprene rule” and, thus, are not easily found from natural sources and have to be 
synthesized.49–51 One possible educt is farnesol, for example.238–243 Bromation to 
farnesylbromide followed by substitution with diethyl malonate and ester cleavage, 
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bishomofarnesoic acid is achieved after decarboxylation. Reduction leads to 
bishomofarnesol which can be oxidized further to bishomofarnesal (Fig. 3.41). 
 
Fig. 3.41: Synthesis of the C17 substrates bishomofarnesoic acid, bishomofarnesol and 
bishomofarnesal starting from farnesol. 
Several routes for the syntheses of the tricyclic products were described, such as synthesis of 
ambreinolide from manool.244,245 Another access was presented by superacid-catalyzed 
cyclization of bishomofarnesoic acid or bicyclobishomofarnesoic acid (Fig. 3.42)246 or from 
dihydro-β-pseudoionone.235 Ambraoxide can be derived by reduction of ambreinolide.235 
The natural product isoabienol can both be oxidized with potassium permanganate to 
ambreinolide and converted into unsaturated ambraoxide by ozonolysis.247,248 Ambraoxides 
were also synthesized from the natural compound larixol.236 An overview of the substrates 
used in the syntheses is given in Fig. 3.42. 
 
Fig. 3.42: Educts for the syntheses of the tricyclic ambergris products.247,248 
3.7.5 Isopulegol and menthol 
Cyclization of racemic citronellal leads to eight isopulegol isomers due to the presence of 
three stereocenters (Fig. 3.43). 
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Fig. 3.43: Cyclization of citronellal showing the different isopulegol isomers.249 
The cyclic isopulegol is present in several essential oils, for example in the leafs and peel of 
Citrus medica L.250,251 The monocyclic monoterpene alcohol was shown to exhibit depressant 
and anxiolytic-like properties and is suggested to exhibit anti-tumor effects.251–253 Isopulegol 
is an important intermediate in the synthesis of the flavor compound menthol. Among the 
different isomers of menthol, (-)-menthol is the most desired one, as it exhibits a unique 
flavor and is widely used in products like chewing gum or toothpastes and also for 
pharmaceutical applications because of its cooling effect.254,255 
 
Fig. 3.44: Takasago process starting from myrcene.255 
Citronellal can be cyclized to isopulegol using different chemical catalysts, such as 
zirconia256–258 or other Lewis acids, for example ZnBr2, AlCl3, BF3, SbCl3.
259 Green synthesis of 
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(-)-isopulegol from (+)-citronellal was reported using SiO2/ZnCl2 as catalysts under solvent-
free conditions.260 (-)-Isopulegol is an intermediate in the industrial synthesis of (-)-menthol 
via the Takasago process.261 This process starts with lithium-catalyzed addition of 
diethylamine to myrcene yielding diethylgeranylamine. Isomerization catalyzed by a chiral 
rhodium phosphine catalyst ((S)-binap-Rh) forms N,N-diethylenamine. This intermediate is 
hydrolyzed to (+)-citronellal and cyclized to (-)-isopulegol under presence of ZnBr2. In the last 
step, hydrogenation leads to the final product (-)-menthol.255 The crucial step of this 
synthetic route is the formation of 96-99 % enantiomeric pure N,N-diethylenamine leading 
to (+)-citronellal of a higher optical purity than it can be obtained from natural sources such 
as citronella oil (Fig. 3.44).255,262 
Another method for the production of (-)-menthol was established from m-cresol and 
propylene in the Haarmann and Reimer-process (Fig. 3.45).254,255 Hydration of thymol yields 
a mixture of menthol isomers. A racemic mixture of (-)-menthol and (+)-menthol is derived 
by fractional distillation. The menthyl benzoates are achieved by trans-esterification with 
methyl benzoate and can be separated by selective crystallization. The desired product (-)-
menthol is derived after hydrolysis. Several recycles lead to a 90 % overall yield of (-)-
menthol.254,255 
 
Fig. 3.45: Haarmann and Reimer-process for the production of menthol. 
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Another process for the industrial production of (-)-menthol from citral was established by 
BASF SE.263–266 Rectification of citral concentrates Z-citral which is reduced to (+)-citronellal 
by use of a rhodium catalyst which is soluble in the reaction mixture, such as Rh(OAc)3 for 
example. (+)-citronellal is cyclized to (-)-isopulegol in presence of ZnBr2. Further reduction 
catalyzed by a heterogenous nickel- and copper-containing catalysts furnishes (-)-menthol 
(Fig. 3.46). 
 
Fig. 3.46: BASF SE-process for industrial production of (-)-menthol from citral. 
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4 Aim of the project 
In the scope of the present work, the SHCs AacSHC, ZmoSHC1and ZmoSHC2 were selected as 
model squalene-hopene cyclases aiming to explore the substrate specificity of these 
enzymes. After cloning of the SHCs into the expression strain, a reproducible system for 
protein expression, enzyme purification and biotransformation was established. A special 
focus was laid on the partial purification of the membrane-anchored SHCs by use of 
detergents. The conditions for the biotransformations were selected carefully in order to 
generate a system enabling comparison both of the activity of different enzymes towards 
one substrate as well as the activity of the same enzymes for catalysis of different cyclization 
reactions. 
Unnatural substrates on terpenoid basis were selected containing different carbon chain 
lengths and different functionalities regarding the positions relevant for initiation or 
termination of the cyclization reactions. Thirteen different substrates of carbon chain 
lengths of ten to 18 bearing different functional groups, such as alcohol-, carboxy-, keto- or 
aldehyde-groups, were tested. Cyclization of eight of these unnatural substrates could be 
confirmed and unknown products were characterized after preparative biotransformations. 
The activities of the SHCs towards the unnatural substrates were explored and discussed, 
revealing a new understanding of the properties of this class of enzymes. The studies 
exhibited new insights into the substrate specificity and possible applications of the SHCs, 
since the cyclic products possess attractive properties, as they are flavors or fragrances, 
intermediates in the synthesis of other compounds or difficult to achieve in traditional 
organic syntheses. Among the three mentioned SHCs, special focus was laid on ZmoSHC1 
because of its individual substrate activity pattern and remarkable differences regarding its 
amino acid sequence in contrast to the other SHCs. As one of the most obvious differences is 
displayed by the 26 amino acid insertion at the C-terminal end of ZmoSHC1 (“loop”), 
mutational analysis of this insertion was performed. The deletion mutant was generated, 
characterized and compared to the wildtype SHCs. 
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5 Results 
5.1 Squalene-hopene cyclases: Cloning, expression, enzyme 
preparation and biotransformations 
5.1.1 Cloning, expression and partial purification 
The SHCs were cloned in the expression vector pET-22b(+) as described in section 9.6 (Fig. 
5.1). The genes were verified by sequencing (GATC-Biotech AG). 
 
Fig. 5.1: Vector map for pET-22b(+)_ZmoSHC1, showing the restriction sites BamHI and NdeI. 
The expression was optimized to the parameters described in detail in 9.7 (30°C, 4 h, 0.2 mM 
IPTG). The following expressions were carried out as described and controlled by SDS-PAGE 
(Fig. 5.2). 
For partial purification of the SHCs, the cells were disrupted by ultrasonification and the cell 
membranes were subsequently incubated with a buffer containing 1 % Triton X-100 
(1 g/100 mL) as detergent, solubilizing the membrane-anchored SHCs from the cell 
membranes. The procedure described in 9.8.1 yielded partially purified enzyme solution. The 
fractions were controlled on SDS-Gels (see Fig. 5.3 and for the protocol 9.8.2) and 
densitometric evaluation revealed cyclase contents of 90-95 % of the total protein which 
was determined as 3.5 to 6 mg/mL. As shown in Fig. 5.3 and Fig. 5.4, the purification was 
successful, although a high amount of enzyme remained in the pellet fraction. 
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Fig. 5.2: SDS-gel showing cells expressing ZmoSHC1 and AacSHC. The negative control for empty 
vector cells is shown on the two lanes on the right. The bands for 81 kDa ZmoSHC1 are marked 
with *, the bands for 74 kDa AacSHC are marked with **. 
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Fig. 5.3: SDS-gel showing the different steps during partial purification of ZmoSHC1. The bands for 
81 kDa ZmoSHC1 are marked with *. 
 
Fig. 5.4: SDS-gel showing partially purified ZmoSHC1 from different expression set ups in two 
dilutions and the pellet remaining after the solubilization. The bands for 81 kDa ZmoSHC1 are 
marked with *. 
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As shown in Fig. 5.4, comparable solutions of partially purified SHC were derived from 
different expressions of the same SHC as well as from different SHCs. Thus, this partially 
purified enzyme could be used for biotransformations of varying enzymes and their activities 
could be compared to each other. 
5.1.2 Biotransformations – Elaboration of a reliable standard protocol 
As a starting point of the studies, the three cyclization reactions displayed in Fig. 5.5 were 
selected as model reactions for the development of a comparable and stable 
biotransformation system. These reactions were namely the cyclization of the natural 
substrate squalene to the membrane constituents hopene and hopanol, the conversion of 
the C16 alcohol homofarnesol to the tricyclic flavor compound ambroxan and the 
biotransformation of the C10 monoterpenoid citronellal to the menthol precursor isopulegol. 
In the subsequent pages, optimization of the biotransformations leading to a reproducible 
and comparably setup is described in detail. 
 
Fig. 5.5: Model reactions catalyzed by SHCs: squalene to hopene and hopanol, homofarnesol to 
ambroxan and (S)-citronellal to (-)-isopulegol. 
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5.1.2.1 Biotransformations with whole cells 
First of all, biotransformations using whole cells expressing ZmoSHC1, ZmoSHC2 and AacSHC 
were carried out with the three model substrates squalene, homofarnesol and citronellal.  
Table 5.1: Conversion of the different substrates (10 mM) after 20 / 5 h using whole cells 
expressing ZmoSHC1, ZmoSHC2 and AacSHC (OD600 = 10 / 80). The results are given as percentage 
of the product peaks in relation to the total GC peak areas; the ratio of hopene/hopanol for 
conversion of < 0.5 % was determined as a6.6 and b7.1. 
substrate 
ZmoSHC1 ZmoSHC2 AacSHC 
OD600 = 10, 
20 h 
OD600 = 80, 
5 h 
OD600 = 10, 
20 h 
OD600 = 80, 
5 h 
OD600 = 10, 
20 h 
OD600 = 80, 
5 h 
squalene 0.3 ± 0.2 n.d. 2.2 ± 1.1a < 0.1 96.9 ± 1.9b 0.3 ± 0.2 
homofarnesol 22.9 ± 6.8 29.2 ± 7.8 n.d. n.d. 3.4 ± 0.5 11.3 ± 1.9 
(S)-citronellal 0.8 ± 0.1 13.3 ± 5.4 n.d. n.d. n.d. 2.6 ±  0.4 
 
      
       
The cells were applied in two different cell densities of OD600 = 80 and OD600 = 10 and the 
incubation times were varied between 5 and 20 h (see 9.9.1 a). The results are shown in 
Table 5.1. 
Functional expression of all of the three SHCs was confirmed by conversion of at least one of 
the three model substrates. 
5.1.2.2 Biotransformations with partially purified cyclase 
In order to achieve conversion rates comparable for different enzymes, partially purified 
cyclase was used for biotransformations (see 9.9.2 a). The fractions were diluted to the same 
protein content. All of the three enzymes were functional, as they could at least convert one 
of the three substrates. The best conversion was shown for squalene with AacSHC. ZmoSHC1 
showed very low activity towards squalene and much higher activity towards homofarnesol. 
The results are shown in Table 5.2. 
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Table 5.2: Conversion of the different substrates (10 mM) after 20 h using 0.1 mg/mL partially 
purified ZmoSHC1, ZmoSHC2 and AacSHC. The results are given as percentage of the product peaks 
in relation to the total GC peak areas; the ratio of hopene/hopanol for conversion of > 0.5 % was 
determined as a7.9 and b5.5. 
substrate ZmoSHC1 ZmoSHC2 AacSHC 
squalene 0.2 ± 0.0 1.8 ± 1.0a 79.0 ± 9.9b 
homofarnesol 9.5 ± 0.6 n.d. n.d. 
(S)-citronellal 0.4 ± 0.1 n.d. n.d. 
    
    
5.1.2.3 Stability experiments 
One very important aspect for enzymatic systems is the biocatalytic stability. In order to 
examine the stability of the novel enzyme ZmoSHC1, several tests were performed. Both the 
whole cell system and the partially purified SHC were explored. 
As first parameters, the incubation time and temperature were examined by measuring 
biotransformation of 10 mM of homofarnesol at different temperatures (30 / 37 / 42°C) with 
whole cells expressing ZmoSHC1 (cell density OD600 = 5) after 12, 24, 48, 72 and 96 h (see 
9.9.1 b). As shown in Fig. 5.6, stability of the setup at 30°C with highest conversion rates 
during the first 24 h of the experiment could be confirmed. Lower conversion and loss of 
activity after 12 h was observed at 37°C. No cyclization of homofarnesol could be 
determined at all when the incubation temperature was 42°C. 
In continuation, the biocatalytic stability of partially purified ZmoSHC1 was analyzed. In this 
setup, the substrate was not added to the samples right at the beginning but after a certain 
pre-incubation time. Partially purified ZmoSHC1 (approx. 1 mg/mL) was provided in reaction 
tubes and after 0 / 12 / 24 / 48 / 72 and 96 h of incubating at 30 / 37 / 42°C, homofarnesol 
was added to a final concentration of 10 mM. The biotransformations were carried out for 
5 h. After extraction, the conversion rates were determined (for more details see 9.9.2 b). 
The results are shown in Fig. 5.7. 
Without any pre-incubation, the highest activity could be observed at 42°C. As the pre-
incubation time increased, the activity of ZmoSHC1 decreased significantly. At 30°C and 
37°C, the enzymatic activity was stable, still representing similar rates after 120 h of pre-
incubation. The activity at 37°C was slightly higher than at 30°C (Fig. 5.7). 
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Fig. 5.6: Stability test with whole cells (OD600 = 5) expressing ZmoSHC1 showing the conversion of 
10 mM homofarnesol after 12-96 h at 30°C (red) / 37°C (green) and 42°C (blue), respectively. The 
values are shown as percentage of total GC peak areas. 
 
Fig. 5.7: Stability test with partially purified ZmoSHC1 (approx. 1 mg/mL) showing the conversion 
of 10 mM homofarnesol after 5 h relative to the pre-incubation time after 12-96 h at 30°C (red) / 
37°C (green) and 42°C (blue), respectively. The values are shown as percentage of total GC peak 
areas.  
However, the two previously discussed stability experiments had been carried out under the 
conditions used right in the beginning of this work. Afterwards, the buffer system was 
changed from Tris/HCl to the temperature-independent citrate-buffer and the enzyme 
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concentration of the partially purified SHC was adjusted properly, as the solution used in the 
previously described stability assays was very concentrated. Thus, the observations were 
only taken as qualitative results. In order to derive reproducible values, two additional tests 
were performed. 
 
Fig. 5.8: Stability tests with whole cells expressing ZmoSHC1 (green) and 0.1 mg/mL partially 
purified ZmoSHC1 (red) showing the conversion of 10 mM of homofarnesol after 5 h relative to the 
pre-incubation time at 30°C. The values are shown as percentage of total GC peak areas. 
Similar to the previously carried out experiment with partially purified ZmoSHC1, mixtures of 
cells or partially purified enzyme and buffers were incubated for a distinct period. Then the 
substrate (homofarnesol, final concentration 10 mM) was added and after 5 h of additional 
incubation, the conversion was determined. This experiment was carried out both with cells 
expressing ZmoSHC1 (OD600 = 80, see 9.9.1 c) as well as with partially purified ZmoSHC1 
(0.1 mg/mL final concentration, see 9.9.2 c). A high cell density was chosen in order to obtain 
a high activity as the incubation was just carried out for 5 h. The experiments were carried 
out at 30°C. 
Under the given conditions, the partially purified cyclase demonstrated stability over 96 h 
(Fig. 5.8, red line). The conversion rate was found to be 7.9 % after 12 h of pre-incubation 
and 8.3 % after 96 h of pre-incubation. The highest activity of 8.5 % was found after 72 h. 
Interestingly, without any pre-incubation, the activity was low (4.3 %). For whole cell 
biotransformations, the conversion rate was determined as 22.2 % without any pre-
incubation, which was just about half as high as after 12 h of pre-incubation (40.7 %). Then 
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the activity decreased constantly. After 96 h of pre-incubation, a rate of 30.5 % was 
determined. 
In order to explore the stability of cells expressing ZmoSHC1 in different cell densities, 
another assay screening for long time biotransformations was generated. Different cell 
densities (OD600 = 1 / 5 / 10 / 20 / 30) were selected to convert 10 mM of the substrate 
homofarnesol in a time period of 24 / 48 / 72 / 96 / 120 h (see 9.9.1 d). The results obtained 
from this experiment are displayed in Fig. 5.9. Low cell density (OD600 = 1) did not lead to a 
significantly higher conversion with longer incubation time (1.7 % after 24 h to 1.9 % after 
120 h). For cell densities of OD600 = 5, the rate increased slightly from 6.7 % (24 h) to 10.5 % 
(120 h). Using whole cells expressing ZmoSHC1 of a cell density of OD600 = 10, the conversion 
raised from 14.7 % to 24.9 % and with cells of a density of OD600 = 20 from 26.9 % to 48.4 %, 
respectively. A similar pattern was found for the experiment carried out with cells of the 
density OD600 = 30; the rate increased from 35.4 % (24 h) to 65.6 % (120 h). 
 
Fig. 5.9: Stability experiments with cells expressing ZmoSHC1. The conversion of 10 mM of 
homofarnesol was performed for 24 – 120 h at 30°C with different cell densities (OD600 = 1 to 
OD600 = 30). The values are shown as percentage of total GC peak areas. 
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5.1.2.4 Substrate and product inhibition 
Enzymatic activity can be influenced negatively by inhibiting effects of substrates and / or 
products. In order to test possible effects of the compounds on the activity of the SHCs, 
different experiments were carried out. 
In the first experimental setup, a substrate mixture of homofarnesol and squalene was 
added to both cells expressing ZmoSHC1 and AacSHC (OD600 = 10 / 80) (see 9.9.1 e). The 
activities of the whole cell systems in the two different cell densities were tested with 5 mM 
homofarnesol and 5 mM squalene. Analogously, partially purified ZmoSHC1 and AacSHC 
(0.1 mg/mL) were tested. As shown in Fig. 5.10, both homofarnesol and squalene were 
converted with ZmoSHC1 and AacSHC. 
 
Fig. 5.10: Conversion of 5 mM homofarnesol and 5 mM squalene using cells expressing ZmoSHC1 
and AacSHC (OD600 = 80 / OD600 = 10) and partially purified ZmoSHC1 and AacSHC (0.1 mg/mL) in 
20 h. The conversions of homofarnesol are shown as green, squalene as blue bars, respectively. 
The results are shown as percentages of the product GC peak areas in relation to the sum of all GC 
peak areas. 
Regarding the results obtained from biotransformations carried out with whole cells 
expressing ZmoSHC1, good squalene conversion was found in presence of homofarnesol (Fig. 
5.10). Using 10 mM of squalene as unique substrate, a low rate of 0.3 % was observed (Table 
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5.3). The conversion of 5 mM squalene was strongly increased to 4.1 % by addition of 5 mM 
of homofarnesol using cells expressing ZmoSHC1 in a density of OD600 = 10. Increasing the 
cell density to OD600 = 80, the biotransformation of squalene was also higher in presence of 
homofarnesol. Remarkably, squalene conversion was higher with cells of lower cell density 
(4.1 % with OD600 = 10 vs 0.9 % with OD600 = 80; Fig. 5.10). 
Table 5.3: Substrate conversion using cells expressing ZmoSHC1. The results are shown as 
percentages of the product GC peak areas in relation to the sum of all GC peak areas. 
substrate 
cells expressing ZmoSHC1 
OD600 = 80 
cells expressing ZmoSHC1 
OD600 = 10 
partially purified ZmoSHC1 
0.1 mg/mL 
homo-
farnesol 
conversion 
squalene 
conversion 
homo-
farnesol 
conversion 
squalene 
conversion 
homo-
farnesol 
conversion 
squalene 
conversion 
5 mM 
homofarnesol 
+ 5 mM 
squalene 
71.1 ± 1.4 0.9 ± 0.3 38.4 ± 0.4 4.1 ± 0.2 17.5 ± 0.6 2.9 ± 0.5 
10 mM 
homofarnesol 
50.3 ± 6.6 - 22.9 ± 6.8 - 9.5 ± 0.6 - 
10 mM 
squalene 
- 0.5 ± 0.2 - 0.3 ± 0.2 - 0.2 ± 0.04 
       
       
Similar results were observed using 0.1 mg/mL of partially purified ZmoSHC1 (see 9.9.2 d). In 
the presence of both 5 mM of squalene and homofarnesol, the activity of ZmoSHC1 towards 
squalene was highly increased (2.9 %) in comparison to its activity when no homofarnesol 
was added (0.2 %; 10 mM of squalene, see Table 5.3). 
Good homofarnesol conversion was observed with cells of a high density (71.1 %) in 
presence of bot 5 mM of homofarnesol and squalene. In contrast to this, by just adding 
10 mM of homofarnesol, a much lower rate of 50.3 % had been observed. Similar results 
were obtained with cells of lower density and partially purified cyclase. 
Different observations were made for biotransformations carried out with AacSHC as 
biocatalyst. As shown in Fig. 5.10, in all of the three setups (whole cells OD600 = 80, whole 
cells OD600 = 10 and 0.1 mg/mL partially purified SHC) both squalene and homofarnesol were 
converted and the squalene conversion was enhanced over that of homofarnesol. 
However, the different substrate concentrations of 5 and 10 mM in the approaches have to 
be considered. In order to obtain representative results for the inhibiting effects of the 
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substrates, several additional experiments were performed using partially purified SHCs (see 
9.9.2 d). The conversions of 2 mM squalene or 2 mM homofarnesol using 0.1 mg/mL 
partially purified ZmoSHC1 or AacSHC under presence of additional 2 mM of homofarnesol, 
squalene or ambroxan were determined. The results are shown in Table 5.4 and Table 5.5. 
Table 5.4: Conversion of 2 mM squalene using 0.1 mg/mL partially purified ZmoSHC1 or AacSHC; 
shown as percentage of the product concentration in respect to the total concentration of both 
substrates and products calculated with ISTD1 calibration. 
substrate 
enzyme 
ZmoSHC1 AacSHC 
2 mM squalene 1.0 ± 0.3 98.4 ± 0.3 
2 mM squalene + 2 mM homofarnesol 4.2 ± 0.5 39.0 ± 1.4 
2 mM squalene + 2 mM ambroxan 1.1 ± 0.2 44.1 ± 0.4 
2 mM squalene + 2 mM homofarnesol + 2 mM ambroxan 3.1 ± 0.5 12.5 ± 1.0 
   
   
Using AacSHC as biocatalyst, 2 mM of squalene as single substrate was converted almost 
completely. The conversion rate was strongly decreased in the presence of homofarnesol. 
The addition of ambroxan did not show significant influences on the activity of AacSHC 
towards squalene. However, when both homofarnesol and ambroxan were added to the 
system, the conversion rate of squalene decreased significantly (Table 5.4). 
Table 5.5: Conversion of 2 mM homofarnesol using 0.1 mg/mL partially purified ZmoSHC1 or 
AacSHC; shown as percentage of the product concentration in respect to the total concentration of 
both substrates and products calculated with ISTD1 calibration. 
substrate 
enzyme 
ZmoSHC1 AacSHC 
2 mM homofarnesol 41.4 ± 1.8 2.0 ± 0.2 
2 mM homofarnesol + 2 mM squalene 30.1 ± 1.0 1.6 ± 0.1 
2 mM homofarnesol + 2 mM ambroxan 15.8 ± 1.8 n.d. 
2 mM homofarnesol + 2 mM squalene + 2 mM ambroxan 5.7 ± 0.6 n.d. 
   
   
The same approach was performed for analyzing the influence of squalene and ambroxan on 
homofarnesol conversion (Table 5.5). For biotransformations using 0.1 mg/mL partially 
purified ZmoSHC1, the following observations were made: Addition of both squalene and / 
or ambroxan caused a decrease in homofarnesol conversion. The inhibiting effect of 
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ambroxan was stronger than that of squalene. The lowest conversion was observed when 
both ambroxan and squalene were added. 
For AacSHC the observations were different. The addition of squalene did not influence the 
activity of AacSHC towards homofarnesol. The presence of ambroxan caused a complete loss 
of the activity of AacSHC towards homofarnesol. 
The results suggested that there are inhibitory effects of ambroxan on the enzymatic activity 
of ZmoSHC1 towards homofarnesol. In order to define inhibiting effects of the product 
ambroxan on the homofarnesol conversion, one additional experiment was carried out. 
Biotransformations of 0.1 – 10 mM of homofarnesol were performed with 0.1 mg/mL 
partially purified ZmoSHC1 (see 9.9.2 d). The results are displayed in Fig. 5.11 A, showing 
percentages of substrate and product GC peak areas achieved after 20 h of incubation. Using 
substrate starting concentrations of 0.1, 0.5 and 1.0 mM, high rates were observed (81.0 %, 
82.8 % and 78.4 %). An increase of the substrate starting concentration led to a continuous 
decrease of conversion from 60.7 % starting with 2 mM substrate concentration, over 
41.7 %, 29.3 % and 20.9 % with 4, 6 and 8 mM of homofarnesol substrate concentration to 
the lowest rate of 17.1 % (10 mM of substrate). Another visualization of the results is given 
in Fig. 5.11 B, where the absolute GC peak areas of homofarnesol and ambroxan are 
displayed as a function of the starting concentrations of homofarnesol. Using 0.1 mg/mL of 
partially purified ZmoSHC1 and substrate concentrations of more than 6 mM in the 
beginning of the biotransformations did not result in higher end concentrations of the 
product ambroxan.  
 
Fig. 5.11: Conversion of 0.1 - 10 mM of homofarnesol using 0.1 mg/mL of partially purified 
ZmoSHC1 in 20 h. The values represent A) the percentages of the GC peak areas / B) the GC peak 
areas of the substrate homofarnesol (red) and the product ambroxan (green). 
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5.1.2.5 Internal standard experiments 
For quantitative determination of the substrates and products, the use of an internal 
standard is the method of choice when calibration with an external standard is not possible 
or an instrument’s response is varying from one run to the next for certain reasons. It should 
also be mentioned that there are deviations that are almost impossible to avoid during 
sample preparation, for example differences in substrate addition or product extraction. In 
order to develop an assay for the use of an internal standard, we tested the influence of 1-
decanol to the enzymatic activity of the SHCs ZmoSHC1 and AacSHC.  
As an internal standard, 1-decanol was selected because its chemical and physical properties 
are similar to homofarnesol, it is cheap and easy to achieve and no cyclization reaction is 
expected. In order to test the influence of 1-decanol on the enzymatic activity of ZmoSHC1, 
homofarnesol was used as a substrate; for AacSHC, squalene was the substrate of choice. At 
the beginning of biotransformation using partially purified SHCs (0.1 mg/mL, 5 mM 
substrate), 5 mM of 1-decanol (ISTD1) was added to the reaction mixture (see 9.9.2 e). The 
conversion rates were determined and compared to assays performed in the absence of 1-
decanol (Fig. 5.12). 
 
Fig. 5.12: Conversion of 5 mM homofarnesol using 0.1 mg/mL partially purified ZmoSHC1 (green 
bars) / 5 mM squalene using 0.1 mg/mL of partially purified AacSHC (blue bars) with 5 mM ISTD1 
1-decanol added prior to incubation (+ISTD, left side) / without ISTD1-addition (-ISTD, right side). 
The values are shown as percentage of total GC peak areas. 
As shown in Fig. 5.12, the conversions were strongly affected when 1-decanol was added to 
the systems. Homofarnesol biotransformation catalyzed by partially purified ZmoSHC1 was 
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determined as 8.0 % under presence of 1-decanol whereas a rate of 15.9 % was found 
without addition of the internal standard. The biotransformation of squalene catalyzed by 
AacSHC was influenced even stronger, as the rates were found as 31.8 % with internal 
standard and 97.8 % without 1-decanol. 
5.1.2.6 pH Studies 
While the optimal pH for growth of the bacterial strain Alicyclobacillus acidocaldarius had 
been reported to be at pH 3, the best pH for squalene biotransformation with AacSHC was 
determined as pH 6 according to the intracellular conditions of the bacteria.114,267,268 In order 
to test the influence of the pH on the activities of ZmoSHC1, ZmoSHC2 and AacSHC towards 
the model substrates citronellal, homofarnesol and squalene, biotransformations of 10 mM 
of the substrates were carried out using 0.1 mg/mL partially purified ZmoSHC1, ZmoSHC2 
and AacSHC at pH 4.5, pH  5.0 and pH 6.0 (see 9.9.2 f). 
Table 5.6: Conversion of 10 mM of the model substrates at different pH values using 0.1 mg/mL of 
partially purified ZmoSHC1, ZmoSHC2 and AacSHC. The results are given as percentages of total GC 
peak area. 
    (S)-citronellal homofarnesol squalene 
ZmoSHC1 
pH 4.5 0.5 ± 0.1 4.7 ± 0.6 < 0.1 
pH 5.0 0.3 ± 0.1 12.4 ± 4.8 0.1 ± 0.0 
pH 6.0 0.4 ± 0.1 9.5 ± 1.2 0.2 ± 0.1 
ZmoSHC2 
pH 4.5 n.d. n.d. < 0.1 
pH 5.0 n.d. n.d. 0.7 ± 0.3 
pH 6.0 n.d. n.d. 1.8 ± 1.0 
AacSHC 
pH 4.5 n.d. n.d. 57.6 ± 9.9 
pH 5.0 n.d. n.d. 69.9 ± 14.8 
pH 6.0 n.d. n.d. 79.0 ± 9.4 
     
     
As shown in Table 5.6, differences in the conversion rates were observed at varying pHs. The 
biotransformation of citronellal using ZmoSHC1 was found to be similar for all of the three 
tested values. The best conversion of homofarnesol with ZmoSHC1 was found to be at pH 
5.0. Squalene was converted best at pH 6.0, as expected. The subsequent reactions were 
carried out at pH 6.0. However, citronellal biotransformations were performed at pH 4.5 due 
to the increased reduction rate of citronellal to citronellol at higher pH values (Fig. 5.13, Fig. 
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5.14). In order to avoid this side reaction, the pH of choice for the citronellal conversions was 
4.5. 
 
Fig. 5.13: Conversion of citronellal to citronellol or isopulegol. 
 
Fig. 5.14: Conversion of citronellal using 0.1 mg/mL partially purified ZmoSHC1. The 
biotransformations were performed at pH 4.5 (red bars) / pH 5.0 (green bars) / pH 6.0 (blue bars). 
The formation of the desired product isopulegol is shown on the left (values after subtraction of 
the values of the negative control), the formation of the side product citronellol is displayed on the 
right side. The values are shown as percentage of total GC peak areas. 
5.2 Substrate specificity of SHCs 
In order to explore the substrate specificity of the SHCs, several linear terpenoids varying in 
carbon chain lengths and functional groups were tested as substrates for ZmoSHC1, 
ZmoSHC2 and AacSHC. When conversion was observed by new occurring peaks in GC 
analyses, large scale biotransformations were carried out; the products were isolated and 
characterized as described in 9.9 and 9.10. A short overview is given in Table 5.7. 
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Table 5.7: Overview of the substrates tested with SHCs sorted by their functional groups. Positive 
conversion with SHCs is signed as green √ and no conversion is marked as red X. 
substrate functionality no. of C-atoms conversion 
geraniol 
alcohols 
primary 
10 X 
homofarnesol 16 √ 
bishomofarnesol 17 √ 
linalool 
tertiary 
10 X 
nerolidol 15 √ 
geranylacetone 
ketones 
13 √ 
pseudoionone 13 X 
farnesylacetone 18 √ 
geranic acid 
carboxylic acids 
10 X 
homofarnesoic acid 16 √ 
bishomofarnesoic acid 17 √ 
citronellal 
aldehydes 
10 √ 
citral 10 X 
bishomofarnesal 17 √ 
    
    
5.2.1 Alcohols 
The primary alcohols geraniol (C10), homofarnesol (C16) and bishomofarnesol (C17) were 
tested as substrates (Fig. 5.15). Geraniol did not show conversion with the SHCs under the 
standard conditions (9.9.2). Homofarnesol was converted to ambroxan with ZmoSHC1 and 
AacSHC as biocatalysts. The product was identified by comparison with authentic standard. 
Bishomofarnesol was converted into two products by ZmoSHC1, seen as new occurring 
peaks in both GC-FID and GC-MS chromatograms in comparison to negative controls. For the 
major cyclization product, the literature MS data corresponds nicely with (±)-ambraoxide 
and (±)-9-epi-ambraoxide (Fig. 5.15).235 
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Fig. 5.15: Alcohols as substrates: geraniol did not show conversion into the suggested cyclization 
product cyclogeraniol; homofarnesol was converted to ambroxan by ZmoSHC1 and AacSHC; 
bishomofarnesol was converted into two new products by ZmoSHC1, for which GC-MS analysis 
suggested to be (±)-ambraoxide and (±)-9-epi-ambraoxide. 
 
Fig. 5.16: Tertiary alcohols as substrates: nerolidol was converted to (-)-caparrapioxide and (-)-8-
epi-caparrapioxide.Linalool did not show any product formation. 
The tertiary alcohols linalool (C10) and nerolidol (C15) were tested as substrates (Fig. 5.16). 
While linalool was not cyclized by any of the SHCs, nerolidol conversion into two products 
could be shown with ZmoSHC1 and AacSHC. After preparative biotransformation of nerolidol 
using partially purified ZmoSHC1, the products (-)-caparrapioxide and (-)-8-epi-
caparrapioxide were successfully isolated (Fig. 5.16). The separation of both products was 
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achieved with preparative HPLC, leading to small amounts of the isomers that could be 
analyzed, as described in 9.9.4 and 9.10.3. The products were confirmed by NMR (1D and 
2D) and MS (9.10).178,218 
The cyclization reaction is stereoselective yielding (-)-caparrapioxide and (-)-8-epi-
caparrapioxide from racemic nerolidol (Fig. 5.17). 
 
Fig. 5.17: Cyclization of (S)- or (R)-nerolidol catalyzed by SHCs forming the cyclic products (-)-
caparrapioxide or (-)-8-epi-caparrapioxide. 
5.2.2 Ketones 
The ketones geranylacetone (C13), pesudoionone (C13) and farnesylacetone (C18) were tested 
as substrates (Fig. 5.18). Geranylactone was cyclized to a bicyclic product containing a 
hexahydrochromene by ZmoSHC1 and AacSHC. Pseudoionone was not converted under the 
given conditions. Farnesylacetone showed low but significant conversion to one product, 
sclareoloxide. The corresponding cyclic products were isolated and characterized (9.9.4 and 
9.10.3). 
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Fig. 5.18: Ketones as substrates: farnesylacetone was converted to sclareoloxide and 
geranylacetone to hexahydrochromene. Pseudoionone was not accepted as a substrate. 
5.2.3 Carboxylic acids 
Three carboxylic acids were tested as substrates, namely geranic acid (C10), 
homofarnesoic acid (C16) and bishomofarnesoic acid (C17) (Fig. 5.19). Geranic acid did not 
show conversion with the SHCs. Biotransformation of homofarnesoic acid was shown using 
ZmoSHC1 and AacSHC as biocatalysts, leading to one single product identified with GC-FID 
and GC-MS. After preparative biotransformation of homofarnesoic acid using partially 
purified ZmoSHC1, the product sclareolide was successfully isolated and the structure was 
confirmed by NMR (1D and 2D), MS and IR (9.9.4 and 9.10.3).269 
Bishomofarnesoic acid showed three new peaks in the GC chromatogram after conversion 
with ZmoSHC1. The mass spectra were compared to literature data. The major cyclization 
product is in good agreement with the literature MS spectra of (±)-ambreinolide and (±)-10-
epi-ambreinolide.235 The MS data of the minor product show some of the characteristic 
peaks of the comparison data for (±)-10-epi-ambreinolide (Fig. 5.19). The third product does 
not show any correspondence to literature data. 
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Fig. 5.19: Carboxylic acids tested as substrates: geranic acid did not show a conversion with SHCs, 
homofarnesoic acid was converted to sclareolide, bishomofarnesoic acid was converted into two 
products which are supposed to be (±)-ambreinolide and (±)-9-epi-ambreinolide. 
5.2.4 Aldehydes 
Three aldehydes were tested as substrates: (S)-citronellal (C10), cis-citral (C10) and 
bishomofarnesal (C17).
238 Incubation of (S)-citronellal led to the cyclic (-)-isopulegol. Due to 
acid-catalyzed autocyclization, which also occurred using the described parameters, the 
resulting isopulegol production in negative controls was substracted. Cis-citral was not 
accepted as substrate (Fig. 5.20). 
Biotransformations of the C17 aldehyde bishomofarnesal with ZmoSHC1 showed occurrence 
of two new peaks in comparison to the negative control. In order to characterize the 
product, all of the remaining substrate was converted using partially purified ZmoSHC1. 
Unfortunately, after extraction, silica gel column purification and preparative HPLC, the 
product could not be isolated in the necessary purity. No literature MS spectra of the 
expected cyclic product were found for comparison and the resulting amount of product was 
too small for any other purification steps and further characterization. 
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Fig. 5.20: Cyclization of the aldehydes (S)-citronellal to isopulegol and bishomofarnesol to the 
supposed cyclization product. 
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5.3 Comparison of the substrate specificities of ZmoSHC1, 
ZmoSHC2 and AacSHC 
 
Fig. 5.21: Cyclization reactions catalyzed by SHCs: squalene to hopene and hopanol; 
farnesylacetone to sclareoloxide; homofarnesoic acid to sclareolide; homofarnesol to ambroxan; 
nerolidol to (-)-caparrapioxide and (-)-8-epi-caparrapioxide; geranylacetone to 
hexahydrochromene. 
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The activities of the SHCs ZmoSHC1, ZmoSHC2 and AacSHC towards the novel substrates 
farnesylacetone, homofarnesoic acid, nerolidol and geranylacetone were determined and 
compared to the conversion rates obtained with the model substrates homofarnesol and 
squalene. An overview of all the catalyzed cyclization reactions is shown in Fig. 5.21. 
 
Fig. 5.22: Conversion rates of the substrates geranylacetone (orange), nerolidol (yellow), 
homofarnesoic acid (red), homofarnesol (green), farnesylacetone (purple), squalene (blue) using 
0.35 mg/mL partially purified ZmoSHC1 / ZmoSHC2 / AacSHC. The values are shown as percentage 
of the product concentration in respect to the total concentration of both substrates and products 
calculated with ISTD1 calibration. 
In order to compare the biotransformations of the different substrates catalyzed by the 
cyclases ZmoSHC1, ZmoSHC2 and AacSHC, conversions were performed using 0.35 mg/mL 
partially purified SHCs and 10 mM substrate starting concentrations. The biotransformations 
were carried out for 20 h (see 9.9.2 a). The rates were determined with the effective carbon 
number concept (ECN) as described in 9.10.6. Using this concept of quantification, the 
concentrations of both substrates and products could be defined. The conversions were 
determined by calculating the percentage of the product concentration in respect to the 
total concentration of both substrates and products (Fig. 5.22 and Table 5.8). 
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Table 5.8: Conversion of the different substrates (10 mM) after 20 h using 0.35 mg/mL partially 
purified SHCs, shown as percentage of the product concentration in respect to the total 
concentration of both substrates and products calculated with ISTD1 calibration; aratio 
hopene:hopanol; bratio (-)-caparrapioxide:(-)-8-epi-caparrapioxide.  
substrate ZmoSHC1 ZmoSHC2 AacSHC 
squalene 0.8 ± 0.1 (2.6)a 4.4 ± 1.1 (3.3)a 97.3 ± 2.9 (6.3)a 
farnesylacetone 0.2 ± 0.0 0.1 ± 0.0 0.7 ± 0.1 
homofarnesol 34.8 ± 1.4 n.d. 4.4 ± 0.5 
homofarnesoic acid 7.7 ± 0.2 n.d. 2.3 ± 0.3 
nerolidol 0.5 ± 0.0 (3.4)b n.d. 1.4 ± 0.1 (1.8)b 
geranylacetone 1.7 ± 0.1 n.d. 1.1 ± 0.1 
    
    
Homofarnesoic acid was accepted as substrate by ZmoSHC1 and AacSHC and cyclized to the 
tricyclic lactone sclareolide. The conversion of homofarnesoic acid with ZmoSHC1 (7.7 %) 
was about 7-fold higher than the biotransformation of squalene (0.8 %). Homofarnesol was 
converted even better with both ZmoSHC1 and AacSHC, displaying more than 6-fold higher 
conversion with ZmoSHC1 and 3-fold higher conversion using AacSHC as biocatalyst in 
comparison to biotransformations of homofarnesoic acid. 
Table 5.9: Conversion of nerolidol to (-)-caparrapioxide and (-)-8-epi-caparrapioxide; shown as 
percentage of the product concentration in respect to the total concentration of both substrates 
and products calculated with ISTD1 calibration. 
  
total conversion [%] (-)-caparrapioxide [%] 
(-)-8-epi-caparrapioxide 
[%] 
ratio 
ZmoSHC1 0.5 ± 0.0 0.4 ± 0.0 0.1 ± 0.0 3.4 
ZmoSHC2 n.d. n.d. n.d. - 
AacSHC 1.4 ± 0.1 0.9 ± 0.1 0.5 ± 0.0 1.8 
     
     
The total conversion of nerolidol with ZmoSHC1 and AacSHC was found to be 0.5 % and 
1.4 %. (-)-caparrapioxide was the main product for biotransformation with both enzymes, 
the ratio between (-)-caparrapioxide and (-)-8-epi-caparrapioxide was determined to be 3.4 
and 1.8 for ZmoSHC1 and AacSHC, respectively (Table 5.9). Using ZmoSHC2 as biocatalyst, 
nerolidol was not accepted as a substrate. 
The ketone farnesylacetone was converted by all of the three tested SHCs in low rates (0.2 % 
with ZmoSHC1, 0.1 % with ZmoSHC2 and 0.7 % with AacSHC), representing the first substrate 
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besides squalene which was cyclized by ZmoSHC2. Geranylacetone was converted with 
ZmoSHC1 (1.7 %) and AacSHC (1.1 %) into the corresponding cyclic enol ether. 
5.3.1 Enhanced conversions 
In order to increase the yield of the ambroxan and isopulegol formed from homofarnesol 
and citronellal using ZmoSHC1 as biocatalyst, the cell density of cells expressing ZmoSHC1 
was increased to OD600 = 80 and the substrates were incubated for 20 h (see 9.9.2 a). The 
results shown increased rates of homofarnesol (50.3 %) and (S)-citronellal (16.4 %) besides 
low squalene conversion (0.5 %, Table 5.10). 
Table 5.10: Biotransformations with cells expressing ZmoSHC1, carried out for 20 h using a cell 
density of OD600 = 80. The results are given as percentage of the product peaks in relation to the 
total GC peak areas. 
substrate conversion [% of total GC peak area] 
(S)-citronellal 16.4 ± 2.2 
homofarnesol 50.3 ± 6.6 
squalene 0.5 ± 0.2 
  
  
Furthermore, the conversion rates of the new, unnatural substrates were found to be quite 
low under the present conditions. In order to test whether these rates could be increased, 
the biotransformations were repeated using an enhanced enzyme concentration of 4 mg/mL 
(see 9.9.2 g). The results obtained with partially purified ZmoSHC1 are shown in Table 5.11. 
The biotransformation rates could be increased when a higher concentration of enzyme was 
used for the biotransformations. The best increase of conversion could be achieved for 
farnesylacetone and geranylacetone showing a 13- and 14-fold higher rate than observed 
formerly using 0.35 mg/mL enzyme. Squalene was converted 5-fold better and 
homofarnesoic acid 3-fold. Lowest increase was displayed for homofarnesol and nerolidol, as 
these substrates were just converted twice more than shown before. The results are 
displayed in Fig. 5.23. 
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Table 5.11: Conversion of the substrates (10 mM, 20 h) using 4 mg/mL partially purified ZmoSHC1. 
The results are shown as percentage of the product concentration in respect to the total 
concentration of both substrates and products calculated with ISTD1 calibration; aratio 
hopene:hopanol; bratio (-)-caparrapioxide:(-)-8-epi-caparrapioxide. 
substrate conversion [%] 
squalene 4.1 ± 0.4 (9.2)a 
farnesylacetone 2.5 ± 0.2 
homofarnesoic acid 22.9 ± 3.2 
homofarnesol 65.6 ± 0.8 
nerolidol 0.9 ± 0.1 (2.7)b 
geranylacetone 23.0 ± 0.6 
  
  
 
Fig. 5.23: Conversion of the substrates using 0.35 mg/mL or 4.00 mg/mL partially purified 
ZmoSHC1. The values are shown as percentage of the product concentration in respect to the total 
concentration of both substrates and products calculated with ISTD1 calibration. 
5.3.2 Limits of substrate specificity 
After description of the reactions catalyzed by the SHCs, there also have to be mentioned 
the substrates that were not cyclized. 
All of these substrates, namely geraniol, linalool, pseudoionone, geranic acid and citral, 
consist of chain lengths of 13 or less carbon atoms and were expected to yield monocyclic 
products. In theory, the substrates geraniol and geranic acid were expected to be converted 
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to one or several of the products shown in Fig. 5.24, and linalool should be cyclized to a 
heterocyclic compound. However, no conversion could be determined under the given 
conditions. Also the C10 aldehyde cis-citral and the C13 ketone pseudoionone were not 
converted. 
 
Fig. 5.24: Not SHC-catalyzed cyclization reactions of the C10 substrates geraniol, geranic acid, 
linalool and cis-citral and the C13 substrate pseudoionone. 
5.4 Directed mutagenesis 
5.4.1 Selection of spots for single mutants and screening 
The single mutants ZmoSHC1_F486Y and AacSHC_Y420C were created (for details see 9.6 
and 0) by side-directed mutagenesis of the genes encoding for ZmoSHC1 and AacSHC. 
Functional expression and partial purification was successful. Their activities towards the 
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substrates was determined and could be compared to the activity of the wildtype SHCs. The 
results are shown in Table 5.12. 
Table 5.12: Conversion of the different substrates (10 mM) after 20 h using 0.35 mg/mL partially 
purified SHCs, shown as percentage of the concentrations of both substrates and products 
calculated with ISTD1 calibration; aratio hopene:hopanol; bratio (-)-caparrapioxide:(-)-8-epi-
caparrapioxide.  
substrate ZmoSHC1 ZmoSHC1_F486Y AacSHC_Y420C AacSHC 
squalene 0.8 ± 0.1 (2.6)a 0.8 ± 0.2 (3.1)a 6.3 ± 0.5 (5.1)a 97.3 ± 2.9 (6.3)a 
homofarnesol 34.8 ± 1.4 23.9 ± 0.1 n.d. 4.4 ± 0.5 
homofarnesoic acid 7.7 ± 0.22 10.2 ± 1.5 1.0 ± 0.3 2.3 ± 0.3 
nerolidol 0.5 ± 0.0 (3.4)b 1.3 ± 0.0 (2.1)b n.d. 1.4 ± 0.8 (1.8)b 
geranylacetone 1.7 ± 0.1 7.5 ± 0.2 n.d. 1.1 ± 0.1 
farnesylacetone 0.2 ± 0.0 0.3 ± 0.2 < 0.1 0.7 ± 0.1 
     
     
5.4.2 Creation and screening of the loop deletion mutant 
The ZmoSHC1_Loop mutant was expressed and partially purified (for details see 9.6). The 
substrates which had shown activity with the wildtype ZmoSHC1 were screened. The loop 
deletion mutant was expressed in active form, as the conversion of all of the substrates was 
detected. The results are shown in Table 5.13. 
Table 5.13: Conversion of the different substrates after 20 h using 0.35 mg/mL partially purified 
SHCs, shown as percentage of the concentrations of both substrates and products calculated with 
ISTD1 calibration; aratio hopene:hopanol; bratio (-)-caparrapioxide:(-)-8-epi-caparrapioxide. 
substrate ZmoSHC1 ZmoSHC1_Loop AacSHC 
squalene 0.8 ± 0.1 (2.6)a 0.3± 0.0 (1.9)a 97.3 ± 2.9 (6.3)a 
homofarnesol 34.8 ± 1.4 13.0 ± 1.0 4.4 ± 0.5 
homofarnesoic acid 7.7 ± 0.2 12.5 ± 1.0 2.3 ± 0.3 
nerolidol 0.5 ± 0.0 (3.4)b 0.2 ± 0.0 (1.9)b 1.4 ± 0.8 (1.8)b 
geranylacetone 1.7 ± 0.08 0.7 ± 0.1 1.1 ± 0.1 
farnesylacetone 0.2 ± 0.0 1.6 ± 0.1 0.7 ± 0.1 
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6 Discussion 
6.1 Squalene-hopene cyclases: cloning, expression, enzyme 
preparation and biotransformations 
The cloning of the SHCs into the expression strain and the functional expression of the 
enzymes could be confirmed by biotransformation experiments with whole cells. First 
conversion experiments were carried out with three model substrates containing different 
carbon chain lengths and functional groups: squalene, homofarnesol and (S)-citronellal. 
6.1.1 Biotransformations with whole cells 
Using a low cell density of OD600 = 10 and a long incubation time of 20 h (shown in Fig. 6.1 A), 
almost full conversion of squalene was obtained with AacSHC, while both ZmoSHC1 and 
ZmoSHC2 catalyzed the cyclization of the natural substrate squalene in much lower rates. In 
contrast to this, with an 8-fold higher cell density of OD600 = 80 and a 4-fold shorter 
incubation time of 5 h (Fig. 6.1 B) there was almost no squalene conversion detected with all 
of the three enzymes. This presents a confirmation for works previously reporting that 
AacSHC expressed in E. coli showed activity towards squalene using the membrane fraction 
of the cells but not applied as whole cell biocatalysts. As E. coli does not synthesize squalene 
it was assumed that the membranes are not permeable for this substrate.60,89 
A completely different observation was made for the biotransformations with the smallest 
substrate, (S)-citronellal. This substrate was accepted by ZmoSHC1 and AacSHC, but the rates 
differed depending on the setup. In contrast to squalene, a much better citronellal 
conversion was observed using a higher cell density of OD600 = 80 and a shorter incubation 
time of 5 h. 
Remarkably, high homofarnesol conversions of were obtained using cells expressing 
ZmoSHC1 in both setups, showing that ZmoSHC1 is much more capable to convert the C16 
alcohol homofarnesol than the natural substrate squalene, yielding in much higher 
biotransformation rates. In addition to this, the activity towards citronellal was shown to be 
considerably higher than towards squalene in both systems. 
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Fig. 6.1: Biotransformations with cells expressing ZmoSHC1, ZmoSHC2 and AacSHC. The 
biotransformations were carried out A) for 20 h using a cell density of OD600 = 10 and B) for 5 h 
using a cell density of OD600 = 80. The results are given as percentage of the product peaks in 
relation to the total GC peak areas. Conversions of (S)-citronellal are shown as orange, 
homofarnesol as green and squalene as blue bars, respectively. 
The results obtained from these whole cell experiments demonstrated the ability of the 
SHCs to catalyze the cyclization of unnatural substrates. The use of whole cells as 
biocatalysts provides several advantages, especially the easy and fast handling makes this 
procedure very attractive, and the experiments are useful for a fast estimation of the SHCs’ 
capabilities to catalyze the cyclization of different substrates. However, there were also 
several drawbacks using this system. As shown in Fig. 5.2, the expressions between different 
SHCs varied regarding their content of enzyme and, thus, the biotransformations did not 
result in reproducible biotransformation data, even for different expressions of the same 
enzyme. 
In addition to this, the different properties of the substrates in these systems have to be 
considered. The permeability of the E. coli cell membranes differs between the substrates. 
The E. coli cells are not permeable for squalene and conversion was only observed after long 
incubation times when cell lysis and the resulting access of the substrate to the membrane-
bound enzymes is possible. However, it is difficult to estimate when the cell lysis starts 
during the incubation, since there are several influencing parameters, such as (i) the cell 
density, (ii) the treatment of the cells during preparation like freezing and thawing, or (iii) 
the type and concentration of detergent added to the system. Especially (iii) is expected to 
have a strong influence. The present detergent can affect the cell lysis and the solubilization 
of the SHCs from the membranes. It can also have a strong effect on the access of the 
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substrates to the enzyme since the emulsification of the different substrates depends on the 
present surfactant. 
In contrast to the observations made with squalene, the smaller substrates, such as 
citronellal, can pass E. coli cell membranes and obtain a better access to the enzyme 
resulting in higher conversion rates. Thus, the biotransformation rates obtained from these 
experiments represent the biocatalytic activities of the different SHCs but are strongly 
influenced by other parameters, such as expression, enzyme content and accessibility of the 
substrates to the enzyme. 
A reproducible system was generated enabling the comparison of both the conversion of 
different substrates with the same enzyme and the different enzymes’ activities towards the 
same substrate. 
6.1.2 Biotransformations with partially purified SHCs 
Considering the results obtained from biotransformation experiments using whole cells 
expressing SHCs as biocatalysts, a protocol for biotransformations with partially purified 
SHCs was elaborated. The obtained fractions of partially purified SHCs had constant protein 
concentrations of 3.5 to 6.0 mg/mL and a SHC content of 90-95 % of the total protein. 
As shown in Fig. 6.6, the experiments with the three model substrates, using 0.1 mg/mL 
SHCs, led to similar patterns as seen for whole cell biotransformations using the setup A 
(OD600 = 10, 20 h, Fig. 6.1 A). This coincides with the observations made before: ZmoSHC1 
typically prefers other substrates rather than its natural substrate squalene. As also already 
seen before, again ZmoSHC2 is simply converting squalene at a low rate. 
The advantage of using partially purified SHCs for biotransformations in comparison to 
whole cell biocatalysis is the comparability of both different enzymes and substrates. As the 
cyclases are solubilized from the membranes, the differences in permeability for the 
substrates cannot influence the conversion rates any longer. Thus, the results obtained from 
these experiments enabled a better comparison of the substrate activities. In addition, the 
rates obtained from these biotransformations with the three model substrates were 
reproducible. 
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Fig. 6.2: Biotransformations of 10 mM of substrate with 0.1 mg/mL partially purified ZmoSHC1, 
ZmoSHC2 and AacSHC carried out for 20 h. The results are given as percentage of the product 
peaks in relation to the total GC peak areas. Conversions of (S)-citronellal are shown as yellow, 
homofarnesol as green and squalene as blue bars, respectively. 
Unfortunately, a loss of enzyme during partial purification has been determined (Fig. 5.3, Fig. 
5.4). Another drawback is the permanent incorporation of detergent in the enzyme solution, 
as it had been shown that detergents influence the enzymatic activity of the biocatalyst 
towards different substrates.147,148 It also has to be considered that the interactions of 
detergent molecules and substrates of varying hydrophobicity are different and the 
emulsions of the hydrophobic substrates in the aqueous system are unequal. Thus, the 
accessibilities of the substrates to the enzymes’ active sites are influenced. 
6.1.3 Stability experiments 
Experiments regarding the biocatalytic stability revealed that ZmoSHC1, used as whole cell 
biocatalyst, exhibit a good stability at 30°C incubation temperature over four days (Fig. 5.6). 
Higher temperatures caused a loss of activity. The activity of partially purified ZmoSHC1 
showed highest activity combined with good stability at 30°C and 37°C (Fig. 5.7). Whereas 
the whole cell system was not active at all at 42°C, the partially purified ZmoSHC1 displayed 
a good activity in the first 24 h of the experiment. However, the activity decreased 
significantly with longer pre-incubation at 42°C. For this reasoning, biotransformations were 
performed at 30°C using ZmoSHC1 as biocatalyst either in a whole cell system or as partially 
purified cyclase. 
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Additional experiments carried out at 30°C with partially purified ZmoSHC1 and with cells 
expressing ZmoSHC1 demonstrated activity towards homofarnesol conversion over 96 h. 
However, low activity was observed in the first 12 h of the experiments. 
The low conversion without pre-incubation using partially purified ZmoSHC1 could be due to 
the hydrophobicity of homofarnesol. The required emulgation in the aqueous system could 
be improved with increased pre-incubation time of the enzyme and the detergent at 30°C 
and, thus, the substrate’s access to the enzyme is improved. Here it has to be considered, if 
different conditions could improve the conversion rates right from the beginning of the 
experiments. The selection of an appropriate detergent of the right concentration could be 
crucial to enhance the formation of the desired product. Thus, the careful selection of the 
surfactant should be studied in more detail. 
In addition to these discussed explanations, the reason for the low activity of the whole cell 
biotransformation setup without any or just 12 h of pre-incubation could be traced to the 
permeability of the E. coli cell membrane. As already mentioned in the previous chapters, 
the E. coli cell membrane is not permeable for squalene, and thus, the biotransformation of 
squalene with cells expressing AacSHC could only be observed after several hours of 
incubation, due to the cell lysis leading to access for squalene to the enzyme. Using 
homofarnesol as a substrate in the whole cell biotransformations, conversion was observed 
after shorter time periods and it was assumed that homofarnesol was able to pass the cell 
membrane. However, in direct comparison, this conclusion has to be corrected, as the 
results shown in Fig. 5.8 exhibit an enhanced homofarnesol conversion after a longer pre-
incubation time and expected cell lysis. Thus, it is assumed that homofarnesol can pass the 
cell membrane but its access to the active site and the conversion is facilitated when cell 
lysis has started. 
In another experiment, different densities of cells expressing ZmoSHC1 were used and the 
conversion of homofarnesol during a period of one to five days was determined. The highest 
activity was observed after 24 h. With longer incubation time, the activity decreased. 
However, here it has to be considered that after a certain time the substrate concentration 
was lower than in the beginning of the experiment and, thus, the conversion rates can 
decrease. One should also take into account the fact that the product ambroxan could have 
inhibiting effects on the cyclase. The analysis of this possible inhibition was carried out and 
the discussion will follow in the next chapters. 
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6.1.4 Substrate and product inhibition 
The biotransformation rates when both squalene and homofarnesol were added to cells 
expressing ZmoSHC1 and AacSHC or partially purified SHCs were tested, showing that the 
activity of ZmoSHC1 towards squalene was increased when homofarnesol was added to the 
system (Fig. 6.3). An explanation for these enhanced squalene conversions could be due to 
the amphiphilic properties of homofarnesol. As it contains both a non-polar carbon chain 
and a polar hydroxyl-group, homofarnesol could act as co-surfactant and improve the 
emulsification of the hydrophobic squalene. Regarding the two setups using cells of a 
different density, it was remarkable that the conversion of squalene was enhanced with cells 
of lower cell density (Fig. 5.10). This can be explained by differences in cell lysis enabling the 
access of squalene to the active site of ZmoSHC1 as previously discussed. Ambroxan addition 
did not affect the activity of ZmoSHC1 towards squalene. 
 
Fig. 6.3: Conversion of squalene using 0.1 mg/mL of partially purified ZmoSHC1 / AacSHC and the 
following substrates: S: 2 mM squalene, SH: 2 mM squalene + 2 mM homofarnesol, SA: 2 mM 
squalene + 2 mM ambroxan, SHA: 2 mM squalene + 2 mM homofarnesol + 2 mM ambroxan; the 
results are shown as percentage of product GC peak area of the sum of GC peak areas of both 
substrates and products. 
The activity of ZmoSHC1 towards homofarnesol was decreased when squalene or especially 
ambroxan were present in the system (Fig. 6.4). 
Therefore, the inhibiting effect of the product ambroxan formed from homofarnesol was 
investigated in more detail. Different homofarnesol concentrations were incubated with 
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0.1 mg/mL partially purified ZmoSHC1 and the conversions were determined. Low 
concentrations of homofarnesol (0.1-1 mM) were converted almost completely (Fig. 5.11 A). 
However, when ambroxan reached a certain concentration, no more product was formed 
(Fig. 5.11 B). That means that increasing substrate concentrations yielded in lower 
conversion rates. The results accompany the observations made before: Ambroxan is 
inhibiting the activity of ZmoSHC1 when it reaches a certain product concentration. 
Taking these results into account, the biotransformation protocol was changed to an 
increased enzyme concentration of 0.35 mg/mL instead of 0.1 mg/mL for later experiments 
(see 5.3 and 5.4). Using this enhanced ratio of enzyme to substrate, the inhibiting 
concentration of ambroxan was not reached during the biotransformation time and, 
importantly, there was still conversion detected with the less active enzyme-substrate 
combinations. Using this enzyme concentration, comparable conversion rates for all of the 
tested substrates were generated. 
 
Fig. 6.4: Conversion of homofarnesol using 0.1 mg/mL of partially purified ZmoSHC1 / AacSHC and 
the following substrates: H: 2 mM homofarnesol, HS: 2 mM squalene + 2 mM homofarnesol, HA: 
2 mM homofarnesol + 2 mM ambroxan, HSA: 2 mM squalene + 2 mM homofarnesol + 2 mM 
ambroxan; the results are shown as percentage of product GC peak area of the sum of GC peak 
areas of both substrates and products. For approaches with ambroxan addition, the concentration 
of the additional ambroxan was substracted. n.d.: no conversion detected. 
Different results were obtained from biotransformations carried out with AacSHC as 
biocatalyst. The activity of AacSHC towards squalene was strongly decreased when 
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homofarnesol was added to the system (Fig. 6.3). Addition of ambroxan did not influence 
squalene conversion catalyzed by AacSHC. 
While the addition of squalene had no influence on homofarnesol conversion, the activity of 
AacSHC towards homofarnesol was completely lost when ambroxan was added to the 
system (Fig. 6.4). This result goes along with observations made by Neumann et al. in 1986, 
in which they already reported that ambroxan showed inhibitory effects on the 
homofarnesol cyclization catalyzed by AacSHC.16 
However, there are certain facts that have to be discussed in the context with these 
observations, revealing that not only the presence of additional products or substrates 
influences the activity of an enzyme. The solubility and emulsion of the substrates is 
different and has to be considered, as the experiments were carried out in aqueous 
environment. As already mentioned above, the reason for enhanced squalene conversions 
under presence of homofarnesol could be the improved emulsion of squalene providing an 
enhanced access of the non-polar substrate to the enzyme in the aqueous environment. In 
addition to this, also the other components could influence micelle formation, emulsification 
and therefore access and conversion. It also has to be considered, that the detergent 
present in the reaction mixture could affect the conversions. In the discussed experiments, 
0.2 % of Triton X-100 was present in all samples. Both the concentration of the surfactant 
and the detergent itself can be beneficial or not for the different reactions. Consequently, 
additional experiments have to be carried out in the future in order to obtain a better 
understanding of the surfactant’s effects on the different biotransformations and to 
generate optimal conditions for each substrate. 
6.1.5 Internal standard experiments 
It was shown that the addition of 1-decanol prior to biotransformation affects the 
conversion rates significantly and cannot be used in this way. Adding 1-decanol to 
homofarnesol conversion assays using partially purified ZmoSHC1 as biocatalyst caused a 
decrease of conversion from 15.9 % to 8.0 % and squalene conversion catalyzed by partially 
purified AacSHC was reduced freum 97.8 % to 31.8 %. Based on these results it was assumed 
that 1-decanol shows remarkable inhibiting effects on both ZmoSHC1 and AacSHC. 
Consequently, it was decided to use the internal standard just as an extraction standard by 
adding a certain amount of 1-decanol to the samples after incubation but prior to extraction 
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and analysis. Using the internal standard in this way, quantification of substrates and 
products was possible. 
6.1.6 pH Studies 
Testing the activity of partially purified ZmoSHC1, ZmoSHC2 and AacSHC towards the three 
model substrates squalene, homofarnesol and (S)-citronellal at pH 4.5, 5.0 and 6.0, the best 
conversion of homofarnesol and squalene was observed at pH 6.0 (Table 5.6). Strongly 
reduced conversion could be detected at pH 4.5. In contrast to this, the conversion of (S)-
citronellal, which was only observed using partially purified ZmoSHC1 under the given 
conditions, was comparably low with all of the three pH values. However, at pH 5.0 and 6.0, 
reduction of (S)-citronellal to citronellol was observed (Fig. 5.14). It is suggested that alcohol 
dehydrogenases from the E. coli expression strain are active at higher pH values, thus 
reducing the aldehyde to the alcohol product. 
Taking these results into account, the subsequent reactions were carried out at pH 6.0. 
However, citronellal biotransformations were performed at pH 4.5 due to the increased 
reduction rate of citronellal to citronellol at higher pH values. 
6.2 Substrate specificity of SHCs 
Previous studies indicated that the SHCs bear the potential to convert various truncated 
squalene analogs to cyclic products. This high catalytic flexibility was furthermore 
emphasized by conversion of homofarnesol with AacSHC, where the ene-functionality 
relevant for termination of the cyclization reaction was replaced by a hydroxy-group forming 
a cyclic ether as product.. Therefore, , it was decided to explore this diversity by testing new 
substrates which contain different carbon chain lengths and provide different functional 
groups serving as new nucleophiles (Fig. 6.5). Other decisive arguments that were taken into 
account were the possible applications of the generated products and the availability of the 
substrates. 
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Fig. 6.5: Functional groups selected for replacement of the ene-functionality of the substrates 
taking part in the termination step of the cyclization reactions. 
Outgoing from the results obtained by Neumann et al., where homofarnesol cyclization to 
ambroxan was performed with AacSHC, the substrates were expected to be cyclized 
analogously. The suggested mechanism includes protonation of a C=C double bond by the 
catalytic aspartate in the active site, stereospecific cyclization forming a final carbocation 
and a termination step integrating an oxygen containing group in the last cycle of the formed 
product. This mechanism is displayed in Fig. 6.6. 
 
Fig. 6.6: Suggested mechanism for the cyclizations of homofarnesol and homofarnesoic acid to 
ambroxan and sclareolide using SHCs. After initial protonation of the C=C-double bond, the 
stereospecific cyclization of the linear substrates occurs forming a final carbocation. The positive 
charge is quenched by intramolecular nucleophilic attack of the alcohol- / carboxy-group. 
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Taking these considerations into account, several substrates were selected, tested and the 
activities of ZmoSHC1, ZmoSHC2 and AacSHC towards them were compared to the activities 
of these enzymes towards their natural substrate squalene. Terpenoids containing 10 to 18 
carbon atoms and different functional groups such as hydroxy-, carboxy-, keto- and 
carbonyl-groups were selected as new substrates, since they were promising precursors for 
formation of cyclic products with new properties.  
6.3 Comparison of the substrate specificity of ZmoSHC1, 
ZmoSHC2 and AacSHC 
Under the given conditions, both partially purified ZmoSHC1 and AacSHC exhibited activity 
towards all of the mentioned substrates, namely geranylacetone, nerolidol, 
homofarnesoic acid, homofarnesol and farnesylacetone as well as towards the natural 
substrate squalene (Fig. 5.22, Table 5.8). In contrast to this, ZmoSHC2 showed activity just 
towards squalene and very low activity towards farnesylacetone. 
Regarding the conversion rates obtained for ZmoSHC1 and AacSHC, there are remarkable 
differences to be discussed in detail. While AacSHC showed the highest activity towards the 
natural substrate squalene, which was converted almost completely under the given 
reaction conditions, much lower rates were detected for all of the other substrates, which 
were converted in rates of less than 5 %. This behavior was expected, as the cyclization of 
squalene is the natural reaction catalyzed by the SHCs and catalysis of all of the other 
substrates can be traced to the enzyme’s flexibility towards other substrates. In contrast to 
this, ZmoSHC1 exhibited a completely different activity pattern. While conversion of 
squalene was determined as 0.8 %, the C16 alcohol homofarnesol was converted best with 
34.8 %, which is more than 40-fold higher than the conversion of squalene. Also the 
corresponding homofarnesoic acid was converted much better than squalene, exhibiting an 
almost 10-fold higher conversion rate of 7.7 %. Geranylacetone was converted about twice 
as well as squalene. Just the tertiary alcohol nerolidol and the C18 ketone farnesylacetone 
were converted in lower rates of less than 1 %, respectively. 
These results are visualized in Fig. 5.22, showing the “activity patterns” of the SHCs towards 
the different substrates. Comparing the relative biotransformation rates, the difference 
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between ZmoSHC1, ZmoSHC2 and AacSHC substrate specificity is even more obvious, as 
shown in Fig. 6.7. 
 
Fig. 6.7: Conversion rates in relation to the preferred substrate (homofarnesol for ZmoSHC1 and 
squalene for ZmoSHC2 and AacSHC). 
From these results the question arises, why ZmoSHC1 exhibits such a different substrate 
activity pattern compared to the other SHCs and why the activity of this enzyme towards its 
natural substrate squalene is so low. As Zymomonas mobilis is known to be one of the best 
hopanoid producing bacteria found in nature, we have to reflect how these hopanoids are 
generated and if ZmoSHC1 is involved in the hopanoid biosynthesis or if this enzyme is 
responsible for the catalysis of other reactions. It also has to be considered which reactions 
could be catalyzed in nature by this enzyme as well as if there are other substrates towards 
which ZmoSHC1 shows an even higher activity than towards homofarnesol. 
One explanation for differences in the activity towards different substrates can be found 
looking at the genetic surroundings of ZmoSHC1 and ZmoSHC2 genes which are completely 
different (Fig. 6.8).270 While the gene encoding for ZmoSHC2 shows several genes with 
connection to the hopanoid biosynthesis in its proximity, the ZmoSHC1 gene does not have 
any neighboring genes related to the squalene metabolism. The genetic surrounding of 
AacSHC is similar to that from ZmoSHC2 as there are various genes encoding for enzymes 
connected to the hopanoid metabolism. 
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Fig. 6.8: Genomic regions surrounding of ZmoSHC1 (A) and ZmoSHC2 (B) (blue): genes associated 
to the hopene metabolism are coloured in green, genes not associated to the hopene metabolism in 
yellow. 
These observations shown in Fig. 6.8 emphasize the hypothesis that ZmoSHC1 is most 
probably not a squalene-hopene cyclase, rather an enzyme catalyzing the cyclization of 
other terpenoids. However, in comparison to AacSHC, ZmoSHC2 exhibited a very low activity 
towards squalene. This is surprising, since ZmoSHC2 in difference to ZmoSHC1 was almost 
exclusively showing conversion with squalene besides a low conversion with 
farnesylacetone. Also the genetic surrounding of this enzyme unveils a hopanoid-
biosynthesis connected genetic neighborhood, similar to the gene encoding for AacSHC. The 
low activity can probably be explained as the conditions for expression, partial purification 
and substrate conversion were optimized for ZmoSHC1 and AacSHC but not for ZmoSHC2, 
where the standard conditions of ZmoSHC1 handling were assumed. In conclusion, the 
genetic surrounding of ZmoSHC1 indicates that it might be not a real squalene-hopene 
cyclase and it could be assumed that ZmoSHC1 belongs to another group of isoprenoid 
cyclases. 
Besides the different genetic surroundings of ZmoSHC1 and the other two SHCs there is 
another evident difference to mention regarding the hydrophobicity of the accepted 
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substrates. The highest activity of AacSHC and ZmoSHC2 was shown with squalene, the most 
hydrophobic substrate. In contrast to this, ZmoSHC1 displayed higher activity towards the 
conversion of other, less hydrophobic substrates. Thus, another approach to explain the 
differences between ZmoSHC1 and AacSHC could be found by considering the differences in 
polarity of the substrates. The partition coefficients (log P) were determined (9.10.5) and 
give comparable information about the hydrophobicities of the substrates (Table 6.1).271–273 
Table 6.1: Overview of the substrates used for biotransformations, the corresponding log P values, 
the number of carbon atoms of the substrates and the conversion rates with ZmoSHC1 and AacSHC. 
The values given for conversions are shown as percentage of the product concentration in respect 
to the total concentration of both substrates and products calculated with ISTD1 calibration. 
substrate log P 
carbon chain 
lentgh 
conversion [%] with 
ZmoSHC1 AacSHC 
squalene 10.60 ± 2.34 30 0.8 ± 0.1 97.3 ± 2.9 
farnesylacetone 5.58 ± 1.04 18 0.2 ± 0.0 0.7 ± 0.1 
homofarnesol 5.01 ± 1.02 16 34.8 ± 1.4 4.4 ± 0.5 
homofarnesoic acid 4.91 ± 1.02 16 7.7 ± 0.2 2.3 ± 0.3 
nerolidol 4.67 ± 0.57 15 0.5 ± 0.0 1.4 ± 0.1 
geranylacetone 4.00 ± 0.53 13 1.7 ± 0.1 1.1 ± 0.1 
         
In previous works dealing with the crystal structure of AacSHC and the positions of crucial 
amino acids in the active site it was confirmed that the entrance to active cavity is 
hydrophobic.58 Thus, it is not surprising that the most hydrophobic substrate, squalene, is 
the one which is converted best by AacSHC. The log P values displayed in Table 6.1 show that 
the gap between the polarities of the most hydrophobic substrate, squalene, and the less 
hydrophobic one, geranylacetone, is large and the log P values correlate with the conversion 
rates determined for AacSHC. This is visualized in Fig. 6.9 (red areas). That means that the 
more polar the substrate the less conversion with AacSHC could be observed. One exception 
constitutes farnesylacetone which was converted much worse than homofarnesol. ZmoSHC1 
however exhibits a different behavior (Fig. 6.9, blue areas). With ZmoSHC1 as biocatalyst, no 
correlation between partition coefficients and activities can be found. This significant 
difference again indicates that ZmoSHC1 could constitute an enzyme catalyzing a different 
reaction in nature and that it is not in charge of the biosynthesis of the hydrophobic 
membrane constituents hopene and hopanol but for something else in its original host. 
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Fig. 6.9: Comparison of the enzymatic activities of ZmoSHC1 and AacSHC towards the different 
substrates arranged by substrate carbon chain lengths. The blue curve represents the conversion 
with ZmoSHC1, the red curve the conversion with AacSHC as enzyme. The areas refer to the left y-
axis, showing conversion rates. The gray line, referring to the right y-axis, is showing the log P 
values for the different substrates. 
As already mentioned, in the active site of AacSHC there were 36 amino acids defined as 
being in direct contact with the substrate analog.10 In order to find another explanation for 
the discussed differences in substrate activity, the corresponding amino acids in ZmoSHC1 
and ZmoSHC2 were defined by multisequence alignment, as highlighted in Fig. 3.22. The 
amino acids are listed in Table 6.2. Comparing these residues in ZmoSHC1 and AacSHC, 30 of 
the 36 discussed positions hold the same amino acids, while just six positions show 
differences. In contrast, comparison of ZmoSHC1 with ZmoSHC2 and AacSHC with ZmoSHC2 
reveals 23 corresponding amino acids besides 13 non-matching residues. However, it is 
difficult to explain the different substrate activities of ZmoSHC1 and AacSHC observing the 
high correspondence of the crucial amino acids. Three of the six differing amino acids are 
quite similar regarding their polarities (ZmoSHC1_V88 vs AacSHC_L36, ZmoSHC1_M227 vs 
AacSHC_V174, ZmoSHC1_T369 vs AacSHC_S307). Subsequently, there are just three amino 
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acid residues in the active sites of ZmoSHC1 and AacSHC which could offer an explanation, 
namely the residues E429, F486 and S506 (for ZmoSHC1; corresponding Q366, Y420 and 
V440 for AacSHC numbering). In order to explore the influence of at least one of these 
positions, the couple ZmoSHC1_F486 vs AacSHC_Y420 was selected for mutational analysis 
(see 5.4.1). 
Table 6.2: Amino acid residues in the active sites of ZmoSHC1, ZmoSHC2 and AacSHC; the amino 
acids of AacSHC have shown to be in direct interaction with the substrate analog azasqualene in 
the crystallized enzyme; the corresponding amino acids of ZmoSHC1 and ZmoSHC2 were 
associated by sequence alignment. Very hydrophobic amino acids are marked in blue, hydrophobic 
amino acids in green, neutral amino acids in orange and hydrophilic amino acids in red.10,274 
ZmoSHC1 ZmoSHC2 AacSHC 
 
ZmoSHC1 ZmoSHC2 AacSHC 
aa pos aa pos aa pos 
 
aa pos aa pos aa pos 
V 88 L 43 L 36 
 
D 439 D 392 D 376 
M 94 I 49 M 42 
 
D 440 D 393 D 377 
R 180 N 135 R 127 
 
A 485 A 437 A 419 
F 182 F 137 F 129 
 
F 486 F 438 Y 420 
W 222 W 177 W 169 
 
F 500 F 452 F 434 
A 223 A 178 A 170 
 
C 501 A 453 C 435 
T 226 V 181 T 173 
 
F 503 H 455 F 437 
M 227 L 182 V 174 
 
E 505 A 457 E 439 
G 319 G 268 G 259 
 
S 506 L 458 V 440 
I 321 I 270 I 261 
 
V 514 V 466 V 448 
Q 322 Y 271 Q 262 
 
W 555 W 507 W 489 
P 323 P 272 P 263 
 
Y 561 Y 513 Y 495 
A 368 P 321 A 306 
 
G 667 G 619 G 600 
T 369 C 322 S 307 
 
F 668 F 620 F 601 
W 374 W 327 W 312 
 
F 698 F 624 F 605 
F 428 F 381 F 365 
 
L 700 L 626 L 607 
E 429 Q 382 Q 366 
 
Y 702 Y 628 Y 609 
D 437 D 390 D 374 
 
Y 705 Y 631 Y 612 
             Concerning the distribution of hydrophobic and hydrophilic amino acids among the 36 
relevant positions in the active sites of the three SHCs there is no significant difference. The 
polarity tendencies of the amino acids was classified into the four groups very hydrophobic, 
hydrophobic, neutral and hydrophilic according to literature data and highlighted in different 
colors in Table 6.2.274 However, also the overall differences in the polarities of the amino 
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acids in the relevant positions are too small to generate a theory which explains the different 
properties of the SHCs. 
It is surprising that the 36 amino acids which were defined to be very important for the 
catalysis of the squalene cyclization show so few differences between AacSHC and ZmoSHC1. 
However, it has to be considered, that these amino acids in ZmoSHC1 were just defined by 
multisequence alignment. Since the crystal structure of ZmoSHC1 remains unknown, it is also 
possible that the mentioned relevant residues are positioned in a different manner than in 
AacSHC. Thus, the active cavity of ZmoSHC1 could exhibit a completely different surrounding 
for the substrate. In conclusion, without knowledge of the three-dimensional structure of 
ZmoSHC1 it is very difficult to explain its remarkable shift in substrate specificity towards the 
unnatural substrate homofarnesol. 
6.3.1 Enhanced conversions 
Homofarnesol was converted to ambroxan, and this reaction is interesting as the product 
ambroxan is a valuable flavor compound. Furthermore, the cyclization of citronellal to 
isopulegol is remarkable, as this product can be reduced to the smelling compound menthol. 
In order to increase the conversion rates forming these products, the density of cells 
expressing ZmoSHC1 was increased. The rates could be enhanced up to 16.4 % for isopulegol 
formation from (S)-citronellal and 50.3 % for the conversion of homofarnesol to the 
corresponding cyclic product ambroxan. However, squalene conversion remained low under 
these conditions, displaying the low activity of ZmoSHC1 again. Another important fact for 
the low activity is the supposed low access of squalene to the active cavity of ZmoSHC1, as 
this substrate cannot pass the E. coli cell membrane. 
Furthermore, also the novel reactions shown in the expanded substrate spectrum catalyzed 
by the SHCs are of economic interest. The products sclareolide, sclareoloxide, 
hexahydrochromene and caparrapioxide are important intermediates in synthesis of 
fragrances or other valuable compounds. 
Using a higher concentration of partially purified ZmoSHC1 of 4 mg/mL instead of 
0.35 mg/mL exhibited higher conversion rates with all of the substrates. However, it has to 
be taken into account that the increase of conversion differed between the substrates (Fig. 
5.23). Highest increase of conversion was shown for geranylacetone, which was increased 
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14-fold. In contrast to this, the lowest enhancement (2-fold) was shown for the conversion 
of nerolidol. 
These differences can be traced back to different detergent concentrations used in these 
experiments. The biotransformations with 0.35 mg/mL of enzyme were carried out under 
presence of 0.2 % of Triton X-100, since the solutions of partially purified SHCs were diluted 
prior to application. In contrast to this, the partially purified ZmoSHC1 used for the enhanced 
conversion was not diluted and contained 1 % Triton X-100. It is supposed that different 
amounts of tensides could influence the conversions, as the emulsion of enzyme and 
substrates are influenced and, thus, the access of the substrates to the active site of the 
enzyme can differ. 
In conclusion, ZmoSHC1 is a not efficient catalyst for the cyclization of squalene to hopene 
and hopanol, but a much more effective catalyst for ambroxan formation from 
homofarnesol. 
6.3.2 Limits of substrate specificity 
Several substrates were expected to be cyclized by the SHCs but did not show any 
biotransformation product under the applied reaction conditions (Table 5.7). Remarkably, 
substrates of shorter chain lengths were not converted, like linalool, geraniol or geranic acid, 
while larger homologs were accepted as substrates. These observations go along with the 
assumption made by Hoshino and coworkers, who reported that substrates of short C-chain 
lengths cannot be accepted as substrates by the triterpene cyclases.17 The SHCs’ missing 
abilities to catalyze the cyclizations of these C10 substrates can have the following reasons: (i) 
The substrates are more hydrophilic than the substrates which were shown to be accepted 
and, thus, it is possible that they cannot enter the hydrophobic active cavity. (ii) They might 
enter the channel to the active site but get bound to another position and do not reach the 
catalytic Brønsted acid. (iii) It is possible that the substrates reach the catalytic aspartate but 
cannot be stabilized in a conformation enabling the cyclization reaction due to their small 
size. Modeling experiments with AacSHC and selection of positions for directed mutagenesis 
could enable the conversion of small substrates. However, this remains difficult for 
ZmoSHC1, as the crystal structure is unknown and definition of amino acid residues for 
mutagenesis is not possible. 
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Another observation was the inacitivity of the SHCs towards cyclization of pseudoionone or 
citral, while the substrates geranylacetone and citronellal, which just differ by the absence of 
a C=C-double bond, were accepted. The explanation for this could be found right in the 
presence of this additional C=C-double bond which prevents an active conformation of the 
substrate and, thus, biotransformation is not possible (Fig. 6.10). 
 
Fig. 6.10: Suggested mechanism for geranylacetone cyclization. Pseudoionone cannot adopt a 
conformation enabling the cyclization. 
Citronellal represents the only monoterpenoid which was accepted and cyclized. However, 
this substrate differs from the other mentioned substrates by the presence of an aldehyde 
group replacing the ene-functionality at the initiation site of the substrate. A reason for 
catalysis of this reaction can be the fact that protonation of the C=O double is facilitated in 
comparison to C=C protonation. It is also possible that citronellal is activated by water 
addition and cyclization is facilitated, as shown in Fig. 6.11. 
 
Fig. 6.11: Supposed cyclization of citronellal after water addition. 
6.4 Directed mutagenesis 
6.4.1 Selection of spots for single mutants and screening 
Mutations of single amino acids can be crucial for changing the properties of an enzyme, its 
substrate acceptance and activity. Several positions were expected to have an influence on 
the substrate specificity of the SHCs. In scope of the present work, mutational analysis was 
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performed for position F486 (referring to the numbering for ZmoSHC1), which was shown to 
be a highly conserved residue.10,275 In 96 % of 325 aligned SHC sequences phenylalanine was 
conserved. In contrast to this, AacSHC represents one of the SHCs not harboring 
phenylalanine but tyrosine at this position (Y420). In order to investigate the influence of this 
position on the specificity and activity of the cyclases, two mutants were tested. For 
ZmoSHC1, the phenylalanine residue was changed to tyrosine, expecting to increase the 
conversion of squalene. For AacSHC, the corresponding tyrosine was replaced by a cysteine 
residue, as previous works by Siedenburg et al. had indicated that a cysteine residue at this 
position could shift the substrate activity towards shorter chain substrates.275,276 
In comparison to the wildtype, the single mutant of ZmoSHC1, ZmoSHC1_F486Y, showed 
several differences regarding its activity towards the different substrates. It was expected 
that the conversion rates would match the rates observed for AacSHC, as the amino acid 
F486 has been replaced for a tyrosine, which corresponds to the amino acid at this position 
in AacSHC (Y420). Regarding the biotransformation of squalene, where an increase was 
expected, no difference in comparison to ZmoSHC1 wildtype could be observed for the 
mutant. The conversions of homofarnesoic acid and geranylacetone were increased. For 
farnesylacetone a slight enhancement of activity was detected for the mutant in comparison 
to the wildtype. Homofarnesol and nerolidol conversion showed the expected behavior: The 
rate for homofarnesol biotransformation diminished about 1.5-fold from 34.8 % (wildtype 
ZmoSHC1) to 23.9 % (mutant ZmoSHC1_F486Y), and the nerolidol conversion was increased 
about 3-fold (Table 5.12, Fig. 6.12). 
For the mutation Y420C in AacSHC, it was presumed that the enzymatic activity towards the 
larger substrates would decrease and the activity towards smaller substrates would rise. 
Testing the mutant under the same conditions as the wildtype and comparing the activities 
with each other, the following observations were made: The activities towards squalene, 
farnesylacetone and homofarnesoic acid were reduced with the mutation. The other 
substrates, homofarnesol, nerolidol and geranylacetone, did not show conversion with the 
mutant at all. From these results it can be concluded that the position Y420 of AacSHC is 
very important for the catalysis of squalene cyclization. Also for all of the other substrates, a 
lower conversion was observed with the AacSHC_Y420C mutant in comparison to the 
wildtype. Y420 is crucial for the activity of AacSHC towards all of the substrates. 
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Fig. 6.12: Conversion rates of geranylacetone (orange), nerolidol (yellow), homofarnesoic acid 
(red), homofarnesol (green), farnesylacetone (purple) and squalene (blue), using partially 
purified ZmoSHC1, ZmoSHC1_F486Y, AacSHC_Y420C and AacSHC. The values are shown as 
percentage of the concentrations of both substrates and products calculated with ISTD1 
calibration. 
In contrast to this, mutations of the corresponding F486 of ZmoSHC1 did not exhibit such a 
strong impact on the activity of this SHC. The mutations lead to differences in substrate 
activities compared to the wildtype SHC but did not change the activities in such a high rate 
as observed for Y420 in AacSHC. Remarkably, the conversion of two of the substrates, 
geranylacetone and homofarnesoic acid, were significantly increased with ZmoSHC1_F486Y. 
This observation indicates that with few mutations the activity pattern of ZmoSHC1 can be 
shifted. Thus, the potential for usage of ZmoSHC1 for catalysis of complex reactions and 
formation of attractive products could be enlarged by usage of appropriate mutants. 
6.4.2 Creation and screening of the loop deletion mutant 
A sequence alignment of ZmoSHC1, ZmoSHC2 and AacSHC has shown that there is one 
significant difference (Fig. 3.22). In contrast to AacSHC and ZmoSHC2, the amino acid 
sequence of ZmoSHC1 shows an insertion at the C-terminal end of the sequence. This 
insertion (“loop”) contains 26 amino acids. Modeling of the crystal structure of ZmoSHC1 
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(Fig. 3.23, done by A. Steudle and B. Juhl, bioinformatics group, ITB) revealed that this 
insertion possibly could be positioned right at the entrance of the substrate channel. As it 
was already discussed that ZmoSHC1 and AacSHC show a high similarity regarding the amino 
acids in the active site, these results triggered the question if the insertion could be the 
reason for the decreased activity of ZmoSHC1 towards squalene, as it is possible that the 
bulkier substrate is just hindered in its access to the active site. In order to test this 
hypothesis, a loop deletion mutant of ZmoSHC1, ZmoSHC1_Loop, was created and tested. 
The conversion rates of the loop deletion mutant in comparison to the wildtype SHCs are 
displayed in Fig. 6.13. 
 
Fig. 6.13: Conversion rates of geranylacetone (orange), nerolidol (yellow), homofarnesoic acid 
(red), homofarnesol (green), farnesylacetone (purple) and squalene (blue), using partially 
purified ZmoSHC1, ZmoSHC1_Loop and AacSHC. The values are shown as percentage of the 
concentrations of both substrates and products calculated with ISTD1 calibration. 
The activity towards squalene was decreased with deletion of the loop. This indicates that 
the loop does not hinder access of squalene to the active site and that there must be some 
other reasons for the low activity of ZmoSHC1 towards squalene cyclization. For 
homofarnesol, nerolidol and geranylacetone, a decrease of activity was observed. 
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Interestingly, the conversion rates of farnesylacetone and homofarnesoic acid were 
significantly increased for the loop deletion mutant in comparison to the wildtype enzyme. 
Considering these observations, it is clear that the loop indeed has an influence on the 
substrate specificity of ZmoSHC1 and that a deletion of the loop causes shifts regarding the 
substrate activities. 
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7 Conclusion 
The aim of the present work was the investigation of SHCs which catalyze cyclization 
reactions of new, unnatural substrates. The studied substrates provide different carbon 
chain lengths and functional groups which are the decisive molecular parameters for the 
final nucleophilic attack terminating the cyclization procedure. The novel squalene-hopene 
cyclase ZmoSHC1 was characterized and found to be a promising biocatalyst for the 
cyclization of varying substrates and the stereospecific formation of bi- and triheterocyclic 
products was observed. All of the products exhibit beneficial properties, as being fragrances 
or intermediates in the synthesis of pharmaceuticals for example. 
ZmoSHC1’s activity towards these novel substrates was determined and compared to the 
well investigated AacSHC and ZmoSHC2, revealing a completely different activity pattern. 
While AacSHC and ZmoSHC2 showed highest conversion of the natural substrate squalene, 
ZmoSHC1 was found to be much more active towards the cyclization of the C16 alcohol 
homofarnesol to the flavor compound ambroxan. Besides formation of this valuable tricyclic 
ether which is used in the perfume industry, the cyclic lactone sclareolide was formed from 
homofarnesoic acid as well as two enol ethers from the ketones geranylacetone and 
farnesylacetone and the ether caparrapioxide from nerolidol. 
In addition to the description and discussion of these findings, approaches for an explanation 
of the substrate specificity and the differences between these enzymes were made. The 
biocatalytic potential of SHCs general and ZmoSHC1 in particular was clarified leading to new 
ideas for their application as well as for the understanding of this attractive class of 
triterpene cyclases. 
  Outlook 
 - 106 -  
8 Outlook 
The characterization of the SHCs revealed a flexible substrate spectrum and special 
biocatalytic properties of ZmoSHC1, as this enzyme was shown to be much more potent to 
catalyze the cyclization of other substrates than squalene. 
It has to be questioned whether the function of if ZmoSHC1 function in nature is the catalysis 
of hopene and hopanol formation from squalene, or if this enzyme catalyzes another 
reaction. One approach to discover the natural reaction is to screen further substrates of 
varying carbon chain lengths containing not yet investigated functional groups. As new 
nucleophiles, nitrogen- or sulfur-containing functional groups could be studied. By 
enhancement of the substrate spectrum, more information about the promiscuity of the 
SHCs and the possible catalysis of completely different reaction types can be gained. 
Further mutational analysis could elucidate the functionality of the “loop”. Interestingly, the 
deletion mutant showed differences regarding the activities towards the different substrates 
compared to the wildtype and, thus, the mutant could serve for catalysis of other cyclization 
reactions. Another interesting mutant could be created with the insertion of the loop into 
AacSHC or ZmoSHC2, or with the deletion of the N-terminal residue of ZmoSHC1 or by 
exchange of other positions discussed as crucial for squalene conversion. Moreover, it could 
be helpful to screen other SHCs. The loop-containing SHCs from strains with two SHCs are 
promising examples for further investigations. 
The conversion rates for some of the new substrates were low. An enhancement of these 
rates could be achieved by optimization of the biotransformation conditions. One very 
important fact is the selection of a suitable surfactant. Possibly, for each substrate another 
surfactant of a distinct concentration can provide the optimal conditions for a good 
conversion. 
Several substrates were not accepted by the SHCs. Random and site-directed mutagenesis 
could change the structure of the active cavity and enable the conversion of these 
substrates. The mutants could be selected by bioinformatic methods like docking 
experiments. The solving of the crystal structure of ZmoSHC1 is indispensable for a entire 
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understanding of the reaction mechanisms and the selection of important amino acid 
residues for mutagenesis. 
In summary, there remains plenty of work to do on the understanding of the SHCs. In my 
opinion, it is worth investigating on these fascinating enzymes that could one day be applied 
as versatile biocatalysts for highly complex reactions. 
  Materials and methods 
 - 108 -  
9 Materials and methods 
9.1 Instruments 
agarose gel   Mini Sub Cell GT (Bio Rad) 
bioreactor   42 L bioreactor, (Bioengineering AG, Wald, Switzerland) 
cell homogenisator  APV 1000 (APV GmbH, Unna, Germany) 
centrifuges centrifuge RC 6 Plus / 5C Plus, Sorvall, Thermo Scientific, 
Langenselbold, Germany; Rotors: SLA-3000 (Sorvall), SS-34 
(Sorvall), Fiberlite F21-8x50y (Piramoon) 
centrifuge 5418 R (Eppendorf) 
centrifuge 5810 R (Eppendorf); Rotor: A-4-62. 
GC columns   5 % phenyl / 95 % dimethypolysiloxane phase columns 
DB-5 / DB-5 MS (30 m, 0.25 mM, 0.25 μm, agilent technologies) 
FS-Supreme 5 / FS-Supreme 5 HT (30 m, 0.25 mM, 0.25 μm, CS-
Chromatographie) 
GC-FID    GC-2010 Plus (Shimadzu), AOC-20i auto injector (Shimadzu) 
GC-MS GCMS-QP 2010 (Shimadzu), AOC-5000 auto injector (CTC 
Analytics) 
HPLC    Knauer HPLC coupled with RI detector K2400 (Knauer) 
HPLC column preparative normal-phase silica column, Eurospher 100 Si 
(100 Å pore size, 350 m2 / g surface area, Vertex) 
HREIMS   MAT 95 (Finnigan) 
IR spectra   Vector 22 FT-IR spektrometer in ATR modus (Bruker) 
NMR    Avance 500 spectrometer (Bruker) 
photo station   Quantum ST4 (Vilber Loumat) 
power supply    Power Pac 300 (Bio Rad) 
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rotary evaporator  Laborota 400 efficient (Heidolph) 
SDS-PAGE   SE 250 (Hoefer) 
shaking incubator  Multitron HT (Infors AG, Bottmanningen, Switzerland) 
thermomixer   Thermomixer comfort (Eppendorf) 
ultrasonifier   Sonifier 250, duty cycle 35 %, output control 4 (Branson) 
9.2 Software 
alignment Multisequence Alignments: MAFFT, version 6, CLUSTAL format 
alignment by MAFFT, version v6.935b (CBRC – Computational 
Biology Research Centre; AIST – Advanced Industrial Science 
and Technology, Japan)277–281 
For the calculation of global sequence identities: LALIGN-
software; BLOSUM 50, penalty settings of 14 for opening and 4 
for extending a gap (EMBnet)153,282 
Chemdraw   ChemDraw Ultra, version 11.0.1 (Cambridge Soft) 
Clonemanager  Clone Manager 7, version 7.03 (Si Ed Central) 
densitometric analysis ImageJ software, version 1.44p (Wayne Rasband) 
GC-FID    LabSolutions, GCsolution, version 2.30.00 (Shimadzu) 
GC-MS    LabSolutions, GCMSsolution, version 2.50 (Shimadzu) 
HPLC    EUROCHROM 2000 for Windows, version 3.05 (Knauer) 
literature   Mendeley Desktop, version 1.6 (Mendeley Ltd)  
MS Office Microsoft Office Professional Plus 2010, version 14.0.6123.5001 
(Microsoft) 
NMR Evalutaion  TOPSPIN, version 3.0 pl 2 (Bruker BioSpin GmbH) 
photo station   Quantum ST4, version 15.12 (Vilber Lourmat) 
phylogenetic tree  Dendroscope, version 3.3.2 (Daniel H. Huson) 
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Pymol The PyMOL Molecular Graphics System, version 1.2r1 (DeLano 
Scientific LLC) 
9.3 Consumables 
Eppendorf tubes  0.5 / 1.5 / 2.0 mL (Eppendorf) 
GC consumables  glass vials (1.7 mL), caps and inserts (300 µL) (WICOM) 
Greiner tubes   15 / 50 mL (Greiner) 
Microtiter plates  96-well DeepWellTM plates (nunc) 
9.4 Chemicals 
The chemicals and solvents were purchased from Sigma-Aldrich. Homofarnesol and 
homofarnesoic acid were provided by BASF SE. Bishomofarnesol, bishomofarnesoic acid and 
bishomofarnesal were provided by Michael Pohl (ITB, 2012).238 All products were identified 
with GC-MS or GC-FID analysis by using reference material. The systematic nomenclature of 
the substrates, products and other compounds relevant in this work is shown in Table 9.1. 
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Table 9.1: Systematic nomenclature of substrates, products and other compounds used in this 
work. 
compound systematic nomenclature 
(±)-ambraoxide 
(4αR,6αS,10αS,10ßR)-4α,7,7,10α-tetramethyldodecahydro-1H-
benzo[f]chromene 
(±)-epi-ambraoxide 
(4αR,6αS,10αR,10ßR)-4α,7,7,10α-tetramethyldodecahydro-1H-
benzo[f]chromene 
(±)-9-epi-ambraoxide 
(4αR,6αS,10αS,10ßS)-4α,7,7,10α-tetramethyldodecahydro-1H-
benzo[f]chromene 
(±)-ambreinolide 
(4αR,6αS,10αS,10ßR)-4α,7,7,10α-tetramethyldecahydro-1H-
benzo[f]chromen-3(2H)-one 
(±)-9-epi-ambreinolide 
(4αR,6αS,10αS,10ßS)-4α,7,7,10α-tetramethyldecahydro-1H-
benzo[f]chromen-3(2H)-one 
(±)-10-epi-ambreinolide 
(4αR,6αS,10αR,10ßR)-4α,7,7,10α-tetramethyldecahydro-1H-
benzo[f]chromen-3(2H)-one 
ambroxan (3αR,5αS,9αS,9ßR)-3α,6,6,9α-tetramethyl-dodecahydronaphto[2,1-ß]furan 
(-)-8-epi-caparrapioxide (2R,8αS)-2,5,5,8α-tetramethyl-2-vinyloctahydro-2H-chromene 
(-)-caparrapioxide (2S,8αS)-2,5,5,8α-tetramethyl-2-vinyloctahydro-2H-chromene 
cis-citral (Z)-3,7-dimethylocta-3,6-dienal 
farnesylacetone  (5E,9E)-6,10,14-trimethylpentadeca-5,9,13-trien-2-one 
geranic acid (E)-3,7-dimethylocta-2,6-dienoic acid 
geraniol (E)-3,7-dimethylocta-2,6-dien-1-ol 
geranylacetone (E)-6,10-dimethylundeca-5,9-dien-2-one 
hexahydrochromene 2,5,5,8α-tetramethyl-4α,5,6,7,8,8α-hexahydro-4H-chromene 
homofarnesoic acid (3E,7E)-4,8,12-trimethyltrideca-3,7,11-trienoic acid 
homofarnesol (3E,7E)-4,8,12-trimethyltrideca-3,7,11-trien-1-ol, > 90 % E,E-homofarnesol  
hopanol hopan-22-ol 
hopene hop-22(29)-ene 
linalool 3,7-dimethylocta-1,6-dien-3-ol 
nerolidol (E)-3,7,11-trimethyldodeca-1,6,10-trien-3-ol 
pseudoionone (3E,5E)-6,10-dimethylundeca-3,5,9-trien-2-one 
sclareolide 
(3αR,9ßS)-3α,6,6,9α-tetramethyldecahydronaphtho[2,1-ß]furan-2(3αH)-
one 
sclareoloxide  
3,4α,7,7,10α-pentamethyl-4a,5,6,6a,7,8,9,10,10a,10b-decahydro-1H-
benzo[f]chromene 
squalene 
(6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-
hexaene 
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9.5 Media, buffers and Kits  
Media 
LB agar: 10 g tryptone, 5 g yeast extract, 5 g NaCl, 16 g agar-agar, ad 1000 mL (dH2O). 
LB medium: 10 g tryptone, 5 g yeast extract, 5 g NaCl, ad 1000 mL (dH2O). 
TB medium: 10 g tryptone, 24 g yeast extract, 4 mL glycerol, ad 900 mL (dH2O); addition of 
100 mL 10 × TB phosphate buffer after autoclaving. 
Buffers 
cell disruption buffer 1: 0.2 M sodium citrate, 0.1 M EDTA, pH 6.0 (dH2O). 
cell disruption buffer 2: 0.2 M Tris/HCl, 0.5 M EDTA, pH 8.0 (dH2O). 
cell washing buffer: 0.1 M sodium phosphate, pH 7. 
DNA—sample buffer: 2 g sucrose, 10 mg Orange G, ad 5 mL (ddH2O). 
SDS—sample buffer: 2 mL 1 M Tris/HCl (pH 6.8), 405.7 mg MgCl2*6 H2O, 1 mL glycerol, 0.8 g 
SDS, 2 mg bromphenolblue, 30.85 mg dithiothreitol, ad 20 mL (ddH2O). 
solubilization buffer 1: 0.05 M sodium citrate, 0.01 M MgCl2, 1 % Triton X-100, pH 6.0 (dH2O). 
solubilization buffer 2: 0.05 M Tris/HCl, 0.01 M MgCl2, 1 % Triton X-100, pH 8.0 (dH2O). 
10 × TB phosphate buffer: 0.17 M KH2PO4, 0.72 M K2HPO4, pH = 7.0. 
Kits 
Bradford: Bradford Ultra® (Expedeon, UK-Harston). 
gel extraction: QlAquick® Gel Extraction Kit (Qiagen). 
plasmide isolation: ZyppyTM Plasmid Miniprep Kit (Zymo-Research). 
Others 
agarose gel staining: GelRedTM (Biotium). 
DNA marker: 1 kb DNA Ladder (Fermentas). 
IPTG stock solution (1 M): 476,6 mg isopropyl-β-ᴅ-thiogalactopyranoside, ad 2 mL (ddH2O). 
PMSF-solution (0.1 M): 17.42 mg in isopropanol, ad 1 mL (ddH2O). 
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protein marker: PageRulerTM Unstained Protein Ladder (Fermentas). 
9.6 Molecular biological devices 
Organisms and plasmids 
expression plasmid: pET22-b(+) (Novagen). 
strain for enzyme expression: Escherichia coli (E. coli) BL21(DE3) (Novagen). 
strain for plasmid amplification: Escherichia coli (E. coli) DH5α (Clontech). 
Wildtype enzymes 
AacSHC: Squalene-hopene cyclase from Alicyclobacillus acidocaldarius (P33247.4) was 
derived from S. Hammer (ITB, Uni Stuttgart) as E. coli BL21(DE3)_pET22b(+)_AacSHC. 
ZmoSHC1: Squalene-hopene cyclase 1 from Zymomonas mobilis (YP_163283.1) was derived 
from M. Breuer (BASF SE) as E. coli LU15568_pDHE_ZmoSHC1 and could be amplified and 
subcloned into the expression vector pET-22b(+) from Novagen by using the restriction sites 
BamHI and NdeI (Fermentas; Buffer: 10 × Tango buffer).283 
ZmoSHC2: Squalene-hopene cyclase 2 from Zymomonas mobilis (AAF12829.1) was derived 
from G. Siedenburg (IMB, Uni Stuttgart) as E. coli BL21(DE3)_pET16b_ZmoSHC2 and could be 
amplified and subcloned into the expression vector pET-22b(+) from Novagen by using the 
restriction sites BamHI and NdeI (Fermentas; Buffer: 10 × Tango buffer).283 
All genes were confirmed by sequencing (GATC-Biotech AG, Konstanz). 
Mutant enzymes 
ZmoSHC1_Loop: The loop deletion mutant was created using the QuikChange® protocol 
from the PfuUltra II Fusion HS DNA Polymerase Kit (Stratagene, Agilent Technologies). The 
primer were chosen as follows: 
#1  5’ – CGG CAC CGG ATT CCC CCG GGC GTT TAT GCT GC – 3’ 
#2  3’ – GCA GCA TAA ACG CCC GGG GGA ATC CGG TGC CG – 5’ 
ZmoSHC1_F486Y: The mutant was derived from S. Racolta (ITB, Uni Stuttgart) as E. coli 
BL21(DE3)_pET22b(+)_ZmoSHC1_F486Y. 
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AacSHC_Y420C: The mutant was derived from S. Hammer (ITB, Uni Stuttgart) as E. coli 
BL21(DE3)_pET22b(+)_ZmoSHC1_F486Y. 
All genes were confirmed by sequencing (GATC-Biotech AG, Konstanz). 
Other enzymes 
restriction enzymes: BamHI, NdeI (Fermentas), used with Tango-Buffer (Fermentas). 
9.7 Cell culture and enzyme expression 
For plasmid maintenance, protein expression and biotransformations with cells, the E. coli 
strain BL21(DE3) was used and 100 µg/mL ampicillin was added to all growth media. 
a) Enzyme expression 
Precultures of the strains were grown overnight in 5 mL LB medium at 37°C with shaking at 
180 rpm. These precultures were used to inoculate three independent 200 mL TB cultures in 
2 L Erlenmeyer flasks (without baffles) with an optical density of OD600 = 0.05 and the 
cultures were incubated as described above. When an OD600 = 0.5 was reached, SHC 
expression was induced by the addition of IPTG in a final concentration of 0.2 mM. 4 h after 
induction, the three cultures were mixed, the cells were harvested by centrifugation at 
13,670 × g for 20 min at 4°C, pooled and washed twice with cell ashing buffer (9.5). After the 
final washing step the cells were aliquoted and stored at -20°C until further usage for 
biotransformations (see 9.9.1) or partial purification (see 9.8.1). For controlling of successful 
expressions of the enzymes, aliquots were routinely analyzed by SDS-PAGE using standard 
protocols.284 
b) Fermentation 
Precultures of the strains were grown overnight in 5 mL LB medium at 37°C with shaking at 
180 rpm. These precultures were used to inoculate three 400 mL TB cultures in 2 L 
Erlenmeyer flasks (without baffles) with an optical density of OD600 = 0.05 and the cultures 
were incubated as described above. When an OD600 = 0.7 was reached, the cultures were 
subsequently used to seed a 42 L bioreactor containing 25 L buffered complex medium (25 L 
containing 550 g tryptone, 275 g yeast extract, 125 g NaCl, 1.875 g CaCl2*2 H2O, 500 g 
glycerol (87 %), 354 g Na2HPO4, 83 g KH2PO4, 200 g (NH4)2SO4, 41 g NH4Cl, 50 g 
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MgSO4*7 H2O, 15 mL Antifoam 204 (Sigma, Taufkirchen, Germany). The fermentation 
temperature was 30°C, the pH was maintained at 7 using NH4OH (28 %) and H2PO4 (10 %). 
The airflow was kept at 15 L/min and the stirrer speed was adjusted to 550 rpm. 8 h after 
inoculation, the glycerol feeding (1500 g glycerol + 100 g (NH4)2HPO4 in 200 mL water) was 
started. Cyclase expression was induced 16 h after inoculation with IPTG (final concentration 
0.1 mM) when cell density reached OD600 = 38.6. The expression was maintained for at least 
4 h. Subsequently, the cells were harvested by centrifugation at 13,500 × g for 20 min at 4°C. 
The obtained wet cell weight was 1.4 kg. The cells were stored overnight at 4°C. The 
following procedures are described in 9.8.1 b). 
9.8 Protein biochemical methods 
9.8.1 Partial purification of the membrane bound protein fraction 
a) Standard protocol for partial purification 
For the partial purification of the SHCs, thawed cells (OD600 = 100) were resuspended in cell 
disruption buffer 1 (9.5). The cells were disrupted by ultrasonic treatment for six times one 
minute on ice, with cooling on ice for at least one minute in between the sonification steps. 
The cell debris was collected by centrifugation at 38,000 × g for 60 min at 4°C; the 
supernatant was discarded. The cell debris was resuspended in 1/5 of the volume used for 
cell disrupture in solubilization buffer 1 (9.5) and incubated for 1 h gently mixing at 4°C, in 
order to solubilize the membrane-bound proteins from the membranes with the detergent 
(1 % Triton X-100). Afterwards, the mixture was centrifuged (conditions see above) and the 
supernatant was used for the biotransformations (partially purified enzyme). 
b) Protocol for partial purification after fermentation 
The obtained wet cell weight of total 1.4 kg was resuspended in 3.6 L cell disruption buffer 2 
(9.5) and after addition of 32 mL PMSF solution, cells were disrupted by homogenization at 
900 bar. The cell debris was collected by centrifugation at 13,500 × g for 60 min and 
resuspended in 3 L solubilization buffer 2. After a final centrifugation step at 13,500 × g for 
60 min, the cell debris was discarded and the supernatant was stored at -18°C. 
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9.8.2 Protein determination 
The protein expression was confirmed by standard SDS-PAGE methods using a 12.5 % 
polyacrylamide SDS-Gel.284 The total protein concentration was determined using the 
Bradford Ultra assay. The quantification was performed in two different dilutions in triplicate 
using bovine serum albumin containing 0.1 % Triton X-100 as a standard. The percentage of 
SHC within the total protein mixture was determined densitometrically from SDS-gels. The 
optical measurements were performed by a digital photo station and densitometric analysis 
of the gels was performed using the ImageJ software. 
9.9 Biotransformations 
All experiments were performed technical triplicates. As negative control, cells / membrane 
protein fraction of E. coli BL21(DE3) carrying the empty pET-22b(+) vector were used. If not 
further mentioned, the final biotransformation conditions were: 10 mM substrate, 0.05 M 
sodium citrate, 0.002 M MgCl2, 0.2 % Triton X-100, pH 6.0; for biotransformations of (S)-
citronellal pH 4.5. The substrates were added as 100 mM emulsion in solubilzation buffer 
after mixing thoroughly. The biotransformations were carried out at 30°C for conversions 
with ZmoSHC1 and ZmoSHC2 and at 60°C for conversions with AacSHC, respectively, with 
shaking at 1,200 rpm in an Eppendorf Thermomixer. The reactions were carried out in 2 mL 
Eppendorf reaction tubes. 
9.9.1 Biotransformations with whole cells 
a) Standard protocol for biotransformations with whole cells 
Cells expressing ZmoSHC1, ZmoSHC2 and AacSHC (9.7 a) were resuspended and diluted to 
OD600 = 10 / 80 and the final conditions as described above. The biotransformations were 
carried out for 5 or 20 h. The biotransformations were carried out for 5 or 20 h. 
b) Protocol for stability experiments with whole cells at different temperatures 
Cells expressing ZmoSHC1 (9.7 a) were resuspended and diluted to OD600 = 5 and the 
following final conditions: 10 mM substrate, 0.05 M Tris/HCl, 0.1 M sodium citrate, 0.01 M 
MgCl2, 1 % Triton X-100, pH 4.5. The biotransformations were carried out for 12 / 24 / 48 / 
72 / 96 / 120 h at 30 / 37 / 42°C with shaking at 180 rpm in a shaking incubator. 
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c) Protocol for stability experiments with whole cells at 30 C 
Cells expressing ZmoSHC1 (9.7 a) were resuspended and diluted to OD600 = 80 and the final 
conditions mentioned above but without addition of the substrate. After 0 / 12 / 24 / 48 / 
72 / 96 / 120 h of pre-incubation at 30°C with shaking at 1,200 rpm in an Eppendorf 
Thermomixer, the substrate homofarnesol was added to a final concentration of 10 mM and 
incubated further for 5 h under the same conditions. 
d) Protocol for stability experiments with whole cells of different cell densities 
Cells expressing ZmoSHC1 (9.7 a) were resuspended and diluted to OD600 = 30 / 20 / 10 / 5 / 
1 and the final conditions mentioned above. The biotransformations were carried out for 
24 / 48 / 72 / 96 / 120 h. 
e) Protocol for inhibition experiments with whole cells 
Cells expressing ZmoSHC1 and AacSHC (9.7 a) were resuspended and diluted to 
OD600 = 10 / 80 and the final conditions mentioned above but with both 5 mM of squalene 
and 5 mM homofarnesol as substrates. The biotransformations were carried out for 20 h. 
9.9.2 Biotransformations with partially purified SHC 
a) Protocol for biotransformations with partially purified SHC 
Partially purified SHCs (9.8.1 a) were diluted to a protein concentration of 0.1 / 0.35 mg/mL 
and the final conditions mentioned above. The biotransformations were carried out for 20 h  
b) Protocol for stability experiments with partially purified ZmoSHC1 at different 
temperatures 
Partially purified ZmoSHC1 (9.8.1 b) was diluted to a protein concentration of >1 mg/mL and 
the following final conditions: 0.05 M Tris/HCl, 0.1 M sodium citrate, 0.01 M MgCl2, 1 % 
Triton X-100, pH 4.5. After 0 / 12 / 24 / 48 / 72 / 96 / 120 h of pre-incubation at 30°C with 
shaking at 1,200 rpm in an Eppendorf Thermomixer, the substrate homofarnesol was added 
to a final concentration of 10 mM and incubated further for 5 h under the same conditions. 
As negative control, solubilization buffer 2 instead of partially purified enzyme was used. 
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c) Protocol for stability experiments with partially purified ZmoSHC1 at 30°C 
Partially purified ZmoSHC1 (9.8.1 a) was diluted to a protein concentration of 0.1 mg/mL and 
the final conditions mentioned above but without addition of the substrate. After 0 / 12 / 
24 / 48 / 72 / 96 / 120 h of pre-incubation at 30°C with shaking at 1,200 rpm in an Eppendorf 
Thermomixer, the substrate homofarnesol was added to a final concentration of 10 mM and 
incubated further for 5 h under the same conditions. 
d) Protocol for inhibition experiments with partially purified SHCs 
Partially purified SHCs (9.8.1 a) were diluted to a protein concentration of 0.1 mg/mL and 
the final conditions mentioned above but with (i) 5 mM of squalene and 5 mM of 
homofarnesol or with (ii) 20 mM of squalene  /homofarnesol / ambroxan or (iii) 0.1 / 0.05 / 
1 / 2 / 4 / 6 / 8 / 10m M of homofarnesol as substrates. The biotransformations were carried 
out for 20 h. 
e) Protocol internal standard experiments with partially purified SHCs 
Partially purified SHCs (9.8.1 a) were diluted to a protein concentration of 0.1 mg/mL and 
the final conditions mentioned above but with 5 mM of squalene /homofarnesol and 5 mM 
of 1-decanol as substrates. The biotransformations were carried out for 20 h. 
f) Protocol pH experiments with partially purified SHCs 
Partially purified SHCs (9.8.1 a) were diluted to a protein concentration of 0.1 mg/mL and 
the final conditions mentioned above but with pH 6.0 / 5.0 / 4.5. The biotransformations 
were carried out for 20 h. 
g) Protocol enhanced conversions with partially purified SHCs 
900 µL of partially purified ZmoSHC1 (9.8.1 a), containing a final protein concentration of 
4.4 mg/mL was mixed with 100 µL substrate emulsion (100 mM in solubilization buffer 1) 
(final conditions: protein concentration 4 mg/mL, 1 % Triton X-100, 10 mM substrate). The 
biotransformations were carried out for 20 h. 
9.9.3 Sample preparation 
After incubation, 20 µL of internal standard 1 (1 M 1-decanol in solubilization buffer 2, 
ISTD1) was added to the samples and mixed thoroughly. Subsequently, 750 µL of n-heptane 
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was added. After mixing and centrifugation at 20,800 × g for 60 min at room temperature 
(Eppendorf, Centrifuge 5417R), the organic phases were transferred into glass GC-Vials. The 
extraction procedure was performed two times leading to a final volume of 1.5 mL. The 
analysis was performed by gas chromatography coupled with a flame ionization detector 
(GC-FID). 
9.9.4 Preparative biotransformations and product isolation 
To obtain the products hopene, hopanol, sclareolide, sclareoloxide, (-)-caparrapioxide, (-)-8-
epi-caparrapioxide and hexahydrochromene, a large scale incubation was conducted by 
using 100 mg – 1 g of the corresponding substrates squalene, homofarnesoic acid, 
farnesylacetone, nerolidol and geranylacetone, upscaling the total reaction and extraction 
volume as used for standard biotransformations. The biotransformations were performed 
with partially purified ZmoSHC1 (derived as described in 9.8.1 b) at 30°C, 180 rpm for 70-
144 h. 
Biotransformation of squalene to hopene and hopanol 
biotransformation: 1 g of substrate, 70 h, conversion: 97.8 % (88.9 % hopene, 8.9 % 
hopanol); 
extraction: 2*100 mL n-heptane; 
purification: column chromatography, silica gel, petrolether:ethylacetate (10:1); 
product: due to losses during isolation approx. 150 mg product hopene (white solid, 99 %) 
and 50 mg product hopanol (colourless oil); 
TLC: silica gel: cyclohexane:ethylacetate (5:1), Rf(squalene) = 1.0, Rf(hopene) = 0.9, 
Rf(hopanol) = 0.5, stained with vanillin/sulfuric acid. 
Biotransformation of homofarnesoic acid to sclareolide 
biotransformation: 0.5 g of substrate, 120 h, conversion: 55 %; 
extraction: 500 mL cyclohexane / ethylacetate; 
purification: column chromatography, silica gel, cyclohexane: ethylacetate (20:1, 10:1, 
0:100); 
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product: due to losses during isolation approx. 100 mg product sclareolide (white solid, 
99 %); 
TLC: silica gel: cyclohexane:ethylacetate (5:1), Rf(homofarnesoic acid) = 0.2, 
Rf(sclareolide) = 0.4, stained with vanillin/sulfuric acid. 
Biotransformation of farnesylacetone to sclareoloxide 
biotransformation: 2 g of substrate, 144 h, conversion 0.7 %; 
extraction: 2*100 mL n-heptane, 2*100 mL ethylacetate; 
purification: column chromatography, silica gel, cyclohexane:ethylacetate (20:1); 
product: due to losses during isolation approx. 10 mg product sclareoloxide (yellow oil, 
91 %); 
TLC: silica gel: cyclohexane:ethylacetate (5:1), Rf(farnesylacetone) = 0,5, 
Rf(sclareoloxide) = 2,8, Stained with vanillin/sulfuric acid 
Biotransformation of nerolidol to (-)-caparrapioxide and (-)-8-epi-caparrapioxide 
biotransformation: 3 g of substrate, 144 h, conversion 2.5 % (1.9 % (-)-caparrapioxide / 0.6 % 
(-)-8-epi-caparrapioxide); 
extraction: 2*100 mL n-heptane, 2*100 mL ethylacetate; 
purification: column chromatography, silica gel, cyclohexane:ethylacetate (30:1); 
product: due to losses during isolation approx. 30 mg products (pale yellow oil, 95 %, 73 % 
(-)-caparrapioxide / 22 % (-)-8-epi-caparrapioxide); 
separation of the products: separation of (-)-caparrapioxide and (-)-8-epi-caparrapioxide: the 
products were separated with HPLC (Kramer HPLC with RI-detector K2400), column: Vertex 
Eurospher 100 Si (normal phase), 7 mL/min, petrolether:ethylacetate (30:1), fraction 1: 
9.10 min-10.00 min ((-)-caparrapioxide, 91 %, approx. 10 mg), fraction 2: 10.00-10.50 min 
((-)-8-epi-caparrapioxide, 87 %, approx. 8 mg); 
TLC: silica gel: cyclohexane:ethylacetate (5:1), Rf(nerolidol) = 0.42, Rf(caparrapioxide) = 0.77, 
stained with vanillin/sulfuric acid, the products (-)-caparrapioxide and (-)-8-epi-
caparrapioxide could not be separated using TLC. 
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Biotransformation of geranylacetone to hexahydrochromene 
biotransformation: 1 g of substrate, 70 h, conversion 70 %; 
extraction: 500 mL cyclohexane/ethylacetate, 2*100 mL ethylacetate; 
purification: column chromatography: cyclohexane:ethylacetate (50:1, 20:1, 0:100); 
product: due to losses during isolation approx. 20 mg product (yellow brown oil, 97 %); 
TLC: silica gel: cyclohexane:ethylacetate (10:1), Rf(substrate) = 0.37, Rf(product) = 0.74, 
stained with vanillin/sulfuric acid. 
9.10 Analysis and evaluation 
9.10.1 GC-FID 
GC-FID analyses were performed using H2 as a carrier gas (linear velocity 30 cm/sec). The 
injection temperature was set as 250°C and the detector temperature was set as 330°C. The 
temperature programs were as follows: 
Table 9.2: GC-FID parameters for squalene conversions showing the temperature program and the 
retention times of the different analysts. 
rate [°C/min] final temp. [°C] holding time [min] 
- 120 3 
60 310 16 
retention times: ISTD1: 4.79 min, squalene: 9.57 min, hopene: 14.23 min, hopanol: 17.26 min 
 
Table 9.3: GC-FID parameters for homofarnesol conversions showing the temperature program 
and the retention times of the different analysts. 
rate [°C/min] final temp. [°C] holding time [min] 
- 120 2 
4 200 0 
60 300 3 
retention times: ISTD1: 6.46 min, ambroxan: 18.72 min, cis-homofarnesol: 19.13 min, trans-homofarnesol: 
19.42 min 
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Table 9.4: GC-FID parameters for conversions of homofarnesol and squalene showing the 
temperature program and the retention times of the different analysts. 
rate [°C/min] final temp. [°C] holding time [min] 
- 120 2 
4 200 0 
60 320 14 
retention times: ISTD1: 6.44 min, ambroxan: 18.56 min, cis-homofarnesol: 19.00 min, trans-homofarnesol: 
19.26 min, squalene: 26.66 min, hopene: 30.36 min, hopanol: 32.44 min 
 
Table 9.5: GC-FID parameters for geranylacetone conversions showing the temperature program 
and the retention times of the different analysts. 
rate [°C/min] final temp. [°C] holding time [min] 
- 120 0 
5 200 0 
50 300 5 
retention times: ISTD1: 5.36 min, hexahydrochromene: 6.71 min, geranylacetone: 8.40 min 
 
Table 9.6: GC-FID parameters for farnesylacetone conversions showing the temperature program 
and the retention times of the different analysts. 
rate [°C/min] final temp. [°C] holding time [min] 
- 200 0 
10 220 0 
5 250 0 
50 300 3 
retention times: ISTD1: 2.28 min, farnesylacetone: 4.42 / 4.61 / 4.80 min, sclareoloxide: 4.97 min 
 
Table 9.7: GC-FID parameters for nerolidol conversions showing the temperature program and the 
retention times of the different analysts. 
rate [°C/min] final temp. [°C] holding time [min] 
- 100 2 
10 300 2 
retention times: ISTD1: 7.34 min, (-)-caparrapioxide: 10.03 min, (-)-8-epi-caparrapioxide: 10.20 min, cis-
nerolidol: 10.85 min, trans-nerolidol: 11.22 min 
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Table 9.8: GC-FID parameters for conversions of homofarnesoic acid, bishomofarnesol, 
bishomofarnesoic acid, bishomofarnesal, geraniol, geranic acid, farnesene, pseudoionone, beta-
ionone and linalool showing the temperature program and the retention times of the different 
analysts. 
rate [°C/min] final temp. [°C] holding time [min] 
- 100 0 
15 300 5 
retention times: ISTD1: 4.89 min, homofarnesoic acid: 9.46 min, sclareolide: 11.27 min, bishomofarnesol: 
9.78 min, bishomofarnesol conversion product: 9.94 (major product) / 10.35 min, bishomofarnesoic acid: 
10.01 min, bishomofarnesoic acid conversion product: 10.76 / 12.50 (major product) min, 
bishomofarnesal: 9.37 min, bishomofarnesal conversion product: 11.20 min, geraniol: 4.77 min, geranic 
acid: 4.83 / 4.89 / 4.99 / 5.11 / 5.33 (major product) min, farnesene: 6.43 (major product) / 7.18 min, 
pseudoionone: 6.85 / 7.07 / 7.48 (major product) min, beta-ionone: 6.78 min, linalool: 3.64 min 
 
For GC-FID chromatograms see supporting information on CD-ROM. 
9.10.2 GC-MS 
GC-MS analyses were performed using He as a carrier gas (linear velocity 30 cm/sec). The 
injection temperature was set as 250°C and the detector temperature was set as 280°C. The 
MS detector was operating with 70 eV (EI ionisation) in full scan mode ranging from 40 m/z 
to 250 -420 m/z (depending on the molecular weight of the analysts). The temperature 
programs were as follows: 
Table 9.9: GC-MS parameters for squalene conversions showing the temperature program and the 
retention times of the different analysts. 
rate [°C/min] final temp. [°C] holding time [min] 
- 120 0 
20 320 20 
retention times: squalene: 11.51 min, hopene: 15.87 min, hopanol: 18.36 min 
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Table 9.10: GC-MS parameters for homofarnesol conversions showing the temperature program 
and the retention times of the different analysts. 
rate [°C/min] final temp. [°C] holding time [min] 
- 120 3 
20 205 0 
3 225 0 
15 320 8 
retention times: cis-homofarnesol: 9.44 min, trans-homofarnesol: 9.56 min, ambroxan: 9.61 min 
 
Table 9.11: GC-MS parameters for homofarnesoic acid conversions showing the temperature 
program and the retention times of the different analysts. 
rate [°C/min] final temp. [°C] holding time [min] 
- 100 2 
10 300 2 
retention times: homofarnesoic acid: 13.01 min, sclareolide: 15.70 min 
 
Table 9.12: GC-MS parameters for geranylacetone conversions showing the temperature program 
and the retention times of the different analysts. 
rate [°C/min] final temp. [°C] holding time [min] 
- 100 2 
10 300 2 
retention times: hexahydrochromene: 9.07 min, geranylacetone: 10.29 min 
 
Table 9.13: GC-MS parameters for nerolidol conversions showing the temperature program and 
the retention times of the different analysts. 
rate [°C/min] final temp. [°C] holding time [min] 
- 100 2 
10 300 2 
retention times: (-)-caparrapi oxide: 8.56 min, (-)-8-epi-caparrapi oxide: 8.90 min, cis-nerolidol: 9.91 min, 
trans-nerolidol: 10.29 min 
 
For GC-MS chromatograms and spectra see supporting information on CD-ROM. 
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9.10.3 New products – characterization with NMR 
The cyclic products of the conversions were characterized by comparison with authentical 
standards and standard nuclear magnetic resonance (NMR) methods after large scale 
conversion and isolation of the product using silica gel chromatography (9.9.4). The 1H and 
13C NMR spectra were recorded on a Bruker Avance 500 spectrometer operating at 
500.15 MHz. All spectra were recorded at room temperature in CDCl3. Chemical shifts are 
expressed in parts per million (ppm, δ) and referenced to tetramethylsilane (TMS, 
δ = 0 ppm). The correct assignment of the chemical shifts was confirmed by application of 
two-dimensional correlation measurements, including correlation spectroscopy (COSY), 
heteronuclear single quantum coherence (HSQC), heteronuclear multiple bond coherence 
(HMBC), and nuclear Overhauser enhancement spectroscopy (NOESY). The numbering of the 
C-atoms is shown in Fig. 9.1. The product was characterized by 1H, 13C, COSY, HSQC, HMBC 
and NOESY NMR. The H-atoms and C-atoms could be assigned by comparison with literature 
data.108 The chemical shifts of 1H and 13C spectra are shown in Table 9.14, Table 9.15 and 
Table 9.16. The new bonds formed could be confirmed by HMBC signals. The three 
dimensional structures were confirmed with NOESY (Fig. 9.2 and Fig. 9.3). 
For 2D and 3D NMR spectra see supporting information on CD-ROM. 
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Fig. 9.1: Products characterized showing the numbering of the C-atoms. 
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Table 9.14: Chemical shifts for 13C NMR expressed in parts per million (ppm, δ) and referenced to 
tetramethylsilane (TMS, δ = 0 ppm). The atom numbers are shown in Fig. 9.1. 
C-# hopene hopanol 
scla-
reolide 
sclareol-
oxide 
(-)-
caparrapi-
oxide 
(-)-8-epi-
caparrapi-
oxide 
hexa-
hydro-
chromene 
C-1 40.31 40.29 38.70 39.31 41.6* 41.7* 40.00 
C-2 18.70 18.68 18.08 18.58 20.1 16.9 19.83 
C-3 42.10 42.09 42.16 41.93 41.9* 41.5* 41.66 
C-4 33.24 33.24 33.11 33.17 33.6 33.4 33.26 
C-5 56.10 56.08 56.64 56.19 51.6 54.4 48.38 
C-6 18.70 18.68 20.55 19.76 16.2 20.2 19.22 
C-7 33.24 33.22 39.49 41.15 51.6 35.1 94.99 
C-8 41.89 41.83 86.39 76.24 73.4 73.5 148.00 
C-9 50.37 50.33 59.10 52.46 - - - 
C-10 37.39 37.38 36.04 36.70 75.2 76.2 76.49 
C-11 20.91 20.89 28.71 18.28 32.0 32.5 32.25 
C-12 23.98 24.13 176.90 94.61 20.7 20.9 20.78 
C-13 49.42 49.83 21.56 147.86 24.3 22.7 19.07 
C-14 42.06 41.90 33.16 21.58 28.7 32.8 20.51 
C-15 33.62 34.36 20.92 33.45 148.0 147.8 
 
C-16 21.66 21.95 15.06 15.03 110.2 109.5 
 
C-17 54.88 53.91 
 
20.10 
   
C-18 44.78 44.08 
 
20.47 
   
C-19 41.89 41.23 
     
C-20 27.38 26.60 
     
C-21 46.48 51.11 
     
C-22 148.76 73.94 
     
C-23 33.41 33.41 
     
C-24 21.59 21.59 
     
C-25 15.84 15.82 
     
C-26 16.69 17.02* 
     
C-27 16.75 16.71* 
     
C-28 16.07 16.14 
     
C-29 110.07 28.73 
     
C-30 25.02 30.85 
     
* might be reversed 
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Table 9.15: Chemical shifts for hopene and hopanol 1H NMR expressed in parts per million (ppm, 
δ) and referenced to tetramethylsilane (TMS, δ = 0 ppm). The atom numbers are shown in Fig. 9.1. 
H-# hopene hopanol 
H-1 1.65, 0.77 1.65, 0.74 
H-2 1.54, 1.35 1.60, 1.41 
H-3 1.33, 1.12 1.33, 1.12 
H-4 - - 
H-5 0.69 0.72 
H-6 1.49, 1.37 1.46, 1.33 
H-7 1.48, 1.19 1.48, 1.23 
H-8 - - 
H-9 1.25 1.25 
H-10 - - 
H-11 1.54, 1.30 1.51, 1.30 
H-12 1.46, 1.40 (e) 1.54, 1.38 
H-13 1.33 1.38 
H-14 - - 
H-15 1.38, 1.22 1.43, 1.22 
H-16 1.62, 1.43 1.93, 1.57 
H-17 1.35 1.35 
H-18 - - 
H-19 1.60, 1.03 1.51, 0.93 
H-20 1.84, 1.80 1.74, 1.47 
H-21 2.67 2.22 
H-22 - - 
H-23 0.84 (3H, s) 0.84 (3H, s) 
H-24 0.79 (3H, s) 0.76 (3H, s) 
H-25 0.81 (3H, s) 0.81 (3H, s) 
H-26 0.96 (3H, s) 0.95 (6H, s)* 
H-27 0.94 (3H, s) 0.95 (6H, s)* 
H-28 0.72 (3H, s) 0.76 (3H, s) 
H-29 4.78 (2H, s) 1.18 (3H, s) 
H-30 1.75 (3H, s) 1.21 (3H, s) 
*methyl groups at C-26 and C-27 one signal 
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Table 9.16: Chemical shifts for sclareolide, sclareoloxide, (-)-caparrapioxide, (-)-8-epi-
caparrapioxide and hexahydrochromene 1H NMR expressed in parts per million (ppm, δ) and 
referenced to tetramethylsilane (TMS, δ = 0 ppm). The atom numbers are shown in Fig. 9.1. 
H-# sclareoloxide sclareolide 
(-)-caparrapi-
oxide 
(-)-8-epi-
caparrapioxide 
hexahydro-
chromene 
H-1 1.62* 
1.43, 
1.08 
1.22 (a)** 
1.65 (e), 
1.30 (a) 
1,82 (e), 1.46 (a) 
H-2 
1.78 (e), 
1.42 (a) 
1.64 (a), 
1.48 (e) 
1.52 (m, 2H) 
1.55 (e), 
1.44 (a) 
1.58, 1.49 
H-3 
1.37 (a), 
1.13 (e) 
1.45 (e), 
1.20 (a) 
1.70 (a)***, 1.38 
(e)*** 
1.36 (e) , 1.23 (a) 1.40 (e), 1.26 (a) 
H-5 0.97 1.05 1.36 1.25 1.44 
H-6 1.70 (e), 1.29 (a) 1.88, 1.38 1.58 (e), 1.50 (a) 1.5 (m, 2H) 1.92 (e), 1.75 (a) 
H-7 1.93 (e), 1.52 (a) 2.08 (e), 1.73 (a) 1.78 (e) 2.22 (a), 1.5 (e) 4.46 
H-9 1.39 1.97 
   
H-11 1.82 (a), 1.58 (e) 2.41 (a), 2.23 (e) 0.86 (3H, s) 0.89 (3H, s) 0.91 (3H, s) 
H-12 4.43 - 0.79 (3H, s) 0.73 (3H, s) 0.82 (3H, s) 
H-13  0.84 (3H, s) 1.30 (3H, s) 1.22 (3H, s) 1.17 (3H, s) 
H-14 0.81 (3H, s) 0.89 (3H, s) 1.28 (3H, s) 1.14 (3H, s) 1.69 (3H, s) 
H-15 0.88 (3H, s) 0.91 (3H, s) 
5.89 (dd, 
J = 17.23, 
J' = 10.49) 
6.01 (dd, 
J = 17.71, 
J' = 10.73)  
H-16 0.81 (3H, s) 1.34 (3H, s) 
5.15 (Z, d, 
J = 17.55), 4.92 
(E, d, J = 10.83) 
4.98 (Z, d, 
J = 18.16), 4.92 
(E, d, J = 10.77)  
H-17 1.15 (3H, s) 
    
H-18 1.68 (3H, s) 
    
*no HSQC for the second H-1 could be seen 
**H-1(e) below one of these 
*** might be reversed 
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Fig. 9.2: Products hopene and hopanol in chair conformation showing the HMBC signals as dashed 
and the NOESY signals as black arrows. The new formed carbon-carbon bonds are marked in red. 
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Fig. 9.3: New products sclareolide, sclareoloxide, hexahydrochromene, (-)-caparrapioxide and (-)-
8-epi-caparrapioxide in chair conformation showing the HMBC signals as dashed and the NOESY 
signals as black arrows. The new formed carbon-carbon bonds are marked in red. 
9.10.4 IR and HREIMS analyses 
IR spectra were measured on a Bruker Vector 22 FT-IR spectrometer in an ATR mode. Mass 
spectra were measured using electron impact ionization on a Finnigan MAT 95. The values 
for HREIMS are as follows: 
hopene: predicted as 410.3913 and determined as 410.3916.107 Full MS spectrum: m/z (rel. 
int.) 410 [M] (75), 395 (14), 367 (5), 342 (9), 299 (13), 218 (19), 204 (18). 191 (100), 189 (78), 
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177 (10), 161 (14), 150 (13), 138 (17), 121 (19), 109 (27), 95 (34), 81 (29), 69 (26), 55 (16). 41 
(10). 
hopanol: predicted as 428.4018 and determined as 428.4016. 285 Full MS spectrum: m/z (rel. 
int.): 428 [M] (32), 410 (16), 395 (9), 370 (15), 355 (6), 231 (6), 207 (38), 191 (100), 177 (8), 
163 (15), 149 (58), 137 (16), 113 (16), 109 (18), 95 (39), 81 (22), 69 (21), 59 (30), 43 (9). 
sclareoloxide: predicted as 262.2297 and determined as 262.2297. Full MS spectrum: m/z 
(rel. int.): 262 [M] (3), 247 (1), 212 (3), 197 (3), 183 (7), 169 (10), 155 (10), 141 (8), 113 (14), 
99 (17), 85 (52), 71 (69), 57 (100), 43 (49). 
(-)-caparrapioxide: predicted as 222.1984 and determined as 222.1981.219 Full MS spectrum: 
m/z (rel. int.): 222 [M] (4), 207 (100), 189 (25), 177 (7), 152 (7), 137 (13), 124 (33), 109 (47), 
95 (16), 81 (35), 69 (21), 55 (17), 43 (21). 
(-)-8-epi-caparrapioxide: predicted as 222.1984 and determined as 222.1982.219 Full MS 
spectrum: m/z (rel. int.): 222 [M] (3), 207 (100), 189 (21), 177 (7), 152 (8), 137 (13), 124 (32), 
109 (46), 95 (16), 81 (34), 69 (21), 55 (18), 43 (24). 
sclareolide: predicted as 250.3807 and determined as 250.1930.286 Full MS spectrum: m/z 
(rel. int.): 250 [M] (5), 235 (82), 206 (54), 191 (18). 177 (14), 163 (8), 150 (25), 137 (45), 136 
(42), 123 (100), 109 (58), 95 (67), 82 (65), 81 (52), 69 (54), 67 (35), 55 (41), 43 (64) 
hexahydrochromene:
 predicted as 194.1671 and determined as 194.1668. Full MS spectrum: 
m/z (rel. int.): 194 [M] (52), 179 (19), 161 (21), 151 (12), 136 (20), 123 (34), 109 (100), 95 
(23), 81 (26), 71 (24), 55 (17), 43 (38). 
For IR and HREIMS spectra see supporting information on CD-ROM. 
9.10.5 Determination of log P values 
The log P values of the substrates and products were determined using the online tool on 
the vcclab (virtual computational chemistry laboratory) homepage using the ALOGPS 2.1 
program (Table 9.17).271–273 
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Table 9.17: Log P values of the substrates and products determined with ALOGP 2.1. 
  log P 
squalene 10.60 ± 2.34 
hopene 9.21 ± 1.88 
hopanol 8.18 ± 1.67 
farnesylacetone 5.58 ± 1.04 
sclareoloxide 5.26 ± 0.90 
homofarnesol 5.01 ± 1.02 
ambroxan 4.43 ± 0.75 
homofarnesosoic acid 4.91 ± 1.02 
sclareolide 4.05 ± 0.79 
nerolidol 4.67 ± 0.57 
caparrapioxide 4.24 ± 0.60 
geranylacetone 4.00 ± 0.53 
hexahydrochromene 3.85 ± 0.68 
  
9.10.6 Quantification 
The concentrations of the internal standards in the samples were determined with an 
external calibration curve. Using effective carbon number (ECN) values, the concentrations 
all of the substrates and products could be determined in reference to the internal 
standards. ISTD1 was used for correction of the loss of the analysts during extraction. 
The concentrations of the internal standards in the samples were determined with an 
external calibration curve. Using an internal standard (1-decanol) and external calibration of 
this, the substrates and products were quantified by using relative response factors (RF). 
These RF values are calculated from the ECNs of the different compounds (ECNx) in relation 
to ECN of the internal standard (ECNISTD) using the following equation (1).
287 ܴܨ ൌ  ா஼ேೣா஼ே಺ೄ೅ವ   (1) 
The concentration of the internal standard (CISTD) was determined by external calibration and 
the concentrations of the analysts (cx) could be determined from the GC peak areas (areaISTD, 
areax) using the following equation (2). ܿ௫ ൌ  ௖಺ೄ೅ವோி ൈ ௔௥௘௔ೣ௔௥௘௔಺ೄ೅ವ  (2) 
The ECNs and RF values of the different compounds are given in Table 9.18. 
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Table 9.18: Calculated effective carbon numbers (ECN) of the substrates and products and the 
relative response factors (RF) in relation to the internal standard 1-decanol. 
compound ECN RF 
1-decanol 9.50 1.00 
squalene 29.40 3.09 
hopene 29.90 3.15 
hopanol 29.75 3.13 
homofarnesol 14.45 1.52 
ambrox 15.00 1.58 
homofarnesoic acid 14.70 1.55 
homofarnesoic acid derivate TMSH 17.70 1.86 
sclareolide 15.00 1.58 
linalool 9.30 0.98 
nerolidol 14.20 1.49 
(-)-caparrapioxide 13.90 1.46 
(-)-8-epi-caparrapioxide 13.90 1.46 
geranylacetone 11.80 1.24 
hexahydrochromene 11.90 1.25 
pseudoionone 11.70 1.23 
farnesylacetone 16.70 1.76 
sclaroeloxide  16.90 1.78 
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11 Supplementary data 
11.1 Abbrevations 
× g    gravitational acceleration 
°C    degree celsius 
µL    microliter 
µm    micrometer 
13C NMR  Carbon-13 NMR 
1H NMR  Proton-NMR 
aa    amino acid 
AaciSHC  Alicyclobacillus acidoterrestris squalene-hopene cyclase 
AacSHC  Alicyclobacillus acidocaldarius squalene-hopene cyclase 
AceSHC  Acidothermus cellolyticus squalene-hopene cyclase 
ApaSHC1  Acetobacter pasteurianus squalene-hopene cyclase 1 
ApaSHC2  Acetobacter pasteurianus squalene-hopene cyclase 2 
approx.  approximately 
BamHI restriction enzyme from Bacillus amyloliquefaciens, recognition site 
(G'GATCC) 
BINOL    binaphtol 
bp    base pair 
BSA    bovine serum albumin 
CacSHC  Catenulispora acidiphila squalene-hopene cyclase 
CDCl3    deuterated chloroform 
CHAPS   3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate hydrate 
cm/sec   centimeters per second 
cmc    critical micelle concentration 
COSY    1H-1H correlated spectroscopy 
ddH2O    double demineralized water 
dH2O    demineralized water 
DMAPP  dimethylallyl diphosphate 
DNA    deoxyribonucleic acid  
DxDD    conserved motif in SHCs 
E. coli    Escherichia coli 
ECN    effective carbon number 
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EDTA    ethylenediaminetetraacetic acid 
eV    electron volt 
FID    flame ionization detector  
final temp.  final temperature 
FPP    farnesyl diphosphate 
g    gram 
GC    gas chromatography 
GC-FID   gas chromatography coupled with flame ionization detector 
GC-MS    gas chromatography coupled with mass spectrometry 
GFPP    geranylfarnesyl diphosphate 
GGPP    geranylgeranyl diphosphate 
GPP    geranyl diphosphate 
GthSHC  Geobacillus thermodentrificans squalene-hopene cyclase 
h    hour 
H2    hydrogen 
HCl*aq   hydrochloric acid 
HMBC    heteronuclear multiple bond coherence 
HREIMS  high resolution electron impact mass spectrometry 
HsaOSC  human lanosterol synthase 
HSQC    heteronuclear single quantum coherence  
IPP    isopentenyl diphosphate 
IPTG    isopropyl-β-ᴅ-thiogalactopyranoside 
ISTD    internal standard 
kb    kilo-base pair 
kDa    kilo Dalton 
LB    lysogeny broth 
LBA    Lewis acid-assisted chiral Brønsted acid 
MAD route   mevalonate-dependent route 
MAI    mevalonate independent 
McaSHC  Methylococcus capsulatus squalene-hopene cyclase 
MeOH    methanol 
mg    milligram 
MgCl2    magnesium chloride 
MHz    Megahertz 
min    minute 
mL    milliliter 
mM    millimolar 
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MS    mass spectrometry 
NaCl    sodium chloride  
NaOH    sodium hydroxide 
NdeI restriction enzyme from Neisseria denitrificans, recognition site 
(CA’TATG) 
NMR    nuclear magnetic resonance 
no.    number 
NOESY   nuclear Overhauser effect spectroscopy 
OD600    optical density measured at 600 nm 
OSC    oxidosqualene cyclase 
part. purified  partially purified 
PcaSHC1  Pelobacter carbinolicus squalene-hopene cyclase 1 
PcaSHC2  Pelobacter carbinolicus squalene-hopene cyclase 2 
PMSF    phenylmethanesulfonyl fluoride 
RF    relative response factors 
Rf    retention factor 
RpaSHC1  Rhodopseudomonas palustris squalene-hopene cyclase 1 
RpaSHC2  Rhodopseudomonas palustris squalene-hopene cyclase 2 
rpm    rounds per minute 
RT    room temperature  
ScoSHC  Streptomyces coelicolor SHC squalene-hopene cyclase 
SDS    sodium dodecyl sulfate 
SDS-PAGE  sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SfuSHC1  Syntrophobacter fumaroxidans squalene-hopene cyclase 1 
SfuSHC2  Syntrophobacter fumaroxidans squalene-hopene cyclase 2 
SHC    squalene-hopene cyclase 
SscSHC   Streptomyces scabiei squalene-hopene cyclase 
SsvSHC   Streptomyces sviceus squalene-hopene cyclase 
SthSHC   Spherobacter thermophilus squalene-hopene cyclase 
SviSHC   Saccharomonospora viridis squalene-hopene cyclase 
TB    terrific broth  
TelSHC   Thermosynechococcus elongatus squalene-hopene cyclase 
TLC    thin layer chromatography 
Tris    Tris(hydroxymethyl)-aminomethane 
TSMSH   trimethylsulfonium hydroxide 
TtuSHC  Teredinibacter turnerae squalene-hopene cyclase 
WT    wildtype 
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xxDC    conserved motif in OSCs 
ZmoSHC1  Zymomonas mobilis squalene-hopene cyclase 1 
ZmoSHC2  Zymomonas mobilis squalene-hopene cyclase 2 
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11.2 Sequences and other informations about the SHCs 
Table 11.1: Overview of the SHCs discussed and characterized in the present work. 
name original host information 
available at 
ITB? 
ITB no. 
AaciSHC Alicyclobacillus acidoterrestris 
GI: 927384; 
CAA61950.1 
yes ITB286 
AacSHC 
Alicyclobacillus 
acidocaldarius 
GI: 2851526; 
P33247.4 
yes ITB285 
AceSHC Acidothermus cellolyticus 
GI: 117928904; 
YP_873455.1 
yes ITB287 
ApaSHC1 Acetobacter pasteurianus 
GI: 258541105; 
YP_003187836.1 
yes ITB312 
ApaSHC2 Acetobacter pasteurianus 
GI: 258541296; 
YP_003186729.1 
no - 
CacSHC Catenulispora acidiphila 
GI: 256395787; 
YP_003117351.1 
yes ITB288 
GthSHC 
Geobacillus 
thermodentrificans 
GI: 138895534; 
YP_001125987.1 
yes ITB162 
McaSHC Methylococcus capsulatus 
GI: 53804820; 
YP_113312.1 
yes ITB164 
PcaSHC1 Pelobacter carbinolicus 
GI: 77544139; 
ABA87701.1 
no - 
PcaSHC2 Pelobacter carbinolicus 
GI: 77544053; 
ABA87615.1 
yes ITB313 
RpaSHC1 Rhodopseudomonas palustris 
GI: 115526460; 
YP_783371.1 
yes ITB314 
RpaSHC2 Rhodopseudomonas palustris 
GI: 90421528; 
YP_531598.1 
no - 
ScoSHC Streptomyces coelicolor 
GI: 21225057; 
NP_630836.1 
yes ITB315 
SfuSHC1 
Syntrophobacter 
fumaroxidans 
GI: 116698484; 
ABK17672.1 
yes ITB316 
SfuSHC2 
Syntrophobacter 
fumaroxidans 
GI: 116699226; 
ABK18414.1 
no - 
SscSHC Streptomyces scabiei 
GI: 260645368; 
CBG68454.1 
yes ITB289 
SsvSHC Streptomyces sviceus 
GI: 197784692; 
YP_002207454.1 
yes ITB290 
SthSHC Spherobacter thermophilus 
GI: 269838031; 
YP_003320259.1 
yes ITB291 
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SviSHC Saccharomonospora viridis 
GI: 257056311; 
YP_003134143.1 
yes ITB292 
TelSHC 
Thermosynechococcus 
elongatus 
GI: 22299852; 
P_683099.1 
yes ITB171 
TtuSHC Teredinibacter turnerae 
GI: 254787171; 
YP_003074600.1 
yes ITB320 
ZmoSHC1 Zymomonas mobilis 
GI: 56552444; 
YP_163283.1 
yes ITB104 
ZmoSHC2 Zymomonas mobilis 
GI: 6466213; 
AAF12829.1 
yes ITB283 
ZmoSHC1_F486Y - - yes ITB294 
AacSHC_Y420C - - yes ITB304 
ZmoSHC1_Loop - - yes ITB322 
11.2.1 Wildtype SHCs 
The amino acid sequences of the SHCs characterized in the present work are shown in this 
paragraph. For the DNA sequence and further information, see supporting information on 
the CD-ROM. 
ZmoSHC1 
MGIDRMNSLSRLLMKKIFGAEKTSYKPASDTIIGTDTLKRPNRRPEPTAKVDKTIFKTMGNS
LNNTLVSACDWLIGQQKPDGHWVGAVESNASMEAEWCLALWFLGLEDHPLRPRLGNALLEMQ
REDGSWGVYFGAGNGDINATVEAYAALRSLGYSADNPVLKKAAAWIAEKGGLKNIRVFTRYW
LALIGEWPWEKTPNLPPEIIWFPDNFVFSIYNFAQWARATMVPIAILSARRPSRPLRPQDRL
DELFPEGRARFDYELPKKEGIDLWSQFFRTTDRGLHWVQSNLLKRNSLREAAIRHVLEWIIR
HQDADGGWGGIQPPWVYGLMALHGEGYQLYHPVMAKALSALDDPGWRHDRGESSWIQATNSP
VWDTMLALMALKDAKAEDRFTPEMDKAADWLLARQVKVKGDWSIKLPDVEPGGWAFEYANDR
YPDTDDTAVALIALSSYRDKEEWQKKGVEDAITRGVNWLIAMQSECGGWGAFDKDNNRSILS
KIPFCDFGESIDPPSVDVTAHVLEAFGTLGLSRDMPVIQKAIDYVRSEQEAEGAWFGRWGVN
YIYGTGAVLPALAAIGEDMTQPYITKACDWLVAHQQEDGGWGESCSSYMEIDSIGKGPTTPS
QTAWALMGLIAANRPEDYEAIAKGCHYLIDRQEQDGSWKEEEFTGTGFPGYGVGQTIKLDDP
ALSKRLLQGAELSRAFMLRYDFYRQFFPIMALSRAERLIDLNN 
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ZmoSHC2 
MTVSTSSAFHHSPLSDDVEPIIQKATRALLEKQQQDGHWVFELEADATIPAEYILLKHYLGE
PEDLEIEAKIGRYLRRIQGEHGGWSLFYGGDLDLSATVKAYFALKMIGDSPDAPHMLRARNE
ILARGGAMRANVFTRIQLALFGAMSWEHVPQMPVELMLMPEWFPVHINKMAYWARTVLVPLL
VLQALKPVARNRRGILVDELFVPDVLPTLQESGDPIWRRFFSALDKVLHKVEPYWPKNMRAK
AIHSCVHFVTERLNGEDGLGAIYPAIANSVMMYDALGYPENHPERAIARRAVEKLMVLDGTE
DQGDKEVYCQPCLSPIWDTALVAHAMLEVGGDEAEKSAISALSWLKPQQILDVKGDWAWRRP
DLRPGGWAFQYRNDYYPDVDDTAVVTMAMDRAAKLSDLHDDFEESKARAMEWTIGMQSDNGG
WGAFDANNSYTYLNNIPFADHGALLDPPTVDVSARCVSMMAQAGISITDPKMKAAVDYLLKE
QEEDGSWFGRWGVNYIYGTWSALCALNVAALPHDHLAVQKAVAWLKTIQNEDGGWGENCDSY
ALDYSGYEPMDSTASQTAWALLGLMAVGEANSEAVTKGINWLAQNQDEEGLWKEDYYSGGGF
PRVFYLRYHGYSKYFPLWALARYRNLKKANQPIVHYGM 
AacSHC 
MAEQLVEAPAYARTLDRAVEYLLSCQKDEGYWWGPLLSNVTMEAEYVLLCHILDRVDRDRME
KIRRYLLHEQREDGTWALYPGGPPDLDTTIEAYVALKYIGMSRDEEPMQKALRFIQSQGGIE
SSRVFTRMWLALVGEYPWEKVPMVPPEIMFLGKRMPLNIYEFGSWARATVVALSIVMSRQPV
FPLPERARVPELYETDVPPRRRGAKGGGGWIFDALDRALHGYQKLSVHPFRRAAEIRALDWL
LERQAGDGSWGGIQPPWFYALIALKILDMTQHPAFIKGWEGLELYGVELDYGGWMFQASISP
VWDTGLAVLALRAAGLPADHDRLVKAGEWLLDRQITVPGDWAVKRPNLKPGGFAFQFDNVYY
PDVDDTAVVVWALNTLRLPDERRRRDAMTKGFRWIVGMQSSNGGWGAYDVDNTSDLPNHIPF
CDFGEVTDPPSEDVTAHVLECFGSFGYDDAWKVIRRAVEYLKREQKPDGSWFGRWGVNYLYG
TGAVVSALKAVGIDTREPYIQKALDWVEQHQNPDGGWGEDCRSYEDPAYAGKGASTPSQTAW
ALMALIAGGRAESEAARRGVQYLVETQRPDGGWDEPYYTGTGFPGDFYLGYTMYRHVFPTLA
LGRYKQAIERR 
11.2.2 Mutants 
The amino acid sequences of the SHC mutants characterized in the present work are shown 
in this paragraph. For the DNA sequence and further information, see supporting 
information on the CD-ROM. 
ZmoSHC1_F486Y 
MGIDRMNSLSRLLMKKIFGAEKTSYKPASDTIIGTDTLKRPNRRPEPTAKVDKTIFKTMGNS
LNNTLVSACDWLIGQQKPDGHWVGAVESNASMEAEWCLALWFLGLEDHPLRPRLGNALLEMQ
REDGSWGVYFGAGNGDINATVEAYAALRSLGYSADNPVLKKAAAWIAEKGGLKNIRVFTRYW
LALIGEWPWEKTPNLPPEIIWFPDNFVFSIYNFAQWARATMVPIAILSARRPSRPLRPQDRL
DELFPEGRARFDYELPKKEGIDLWSQFFRTTDRGLHWVQSNLLKRNSLREAAIRHVLEWIIR
HQDADGGWGGIQPPWVYGLMALHGEGYQLYHPVMAKALSALDDPGWRHDRGESSWIQATNSP
VWDTMLALMALKDAKAEDRFTPEMDKAADWLLARQVKVKGDWSIKLPDVEPGGWAFEYANDR
YPDTDDTAVALIALSSYRDKEEWQKKGVEDAITRGVNWLIAMQSECGGWGAYDKDNNRSILS
KIPFCDFGESIDPPSVDVTAHVLEAFGTLGLSRDMPVIQKAIDYVRSEQEAEGAWFGRWGVN
YIYGTGAVLPALAAIGEDMTQPYITKACDWLVAHQQEDGGWGESCSSYMEIDSIGKGPTTPS
QTAWALMGLIAANRPEDYEAIAKGCHYLIDRQEQDGSWKEEEFTGTGFPGYGVGQTIKLDDP
ALSKRLLQGAELSRAFMLRYDFYRQFFPIMALSRAERLIDLNN 
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AacSHC_Y420C 
MAEQLVEAPAYARTLDRAVEYLLSCQKDEGYWWGPLLSNVTMEAEYVLLCHILDRVDRDRME
KIRRYLLHEQREDGTWALYPGGPPDLDTTIEAYVALKYIGMSRDEEPMQKALRFIQSQGGIE
SSRVFTRMWLALVGEYPWEKVPMVPPEIMFLGKRMPLNIYEFGSWARATVVALSIVMSRQPV
FPLPERARVPELYETDVPPRRRGAKGGGGWIFDALDRALHGYQKLSVHPFRRAAEIRALDWL
LERQAGDGSWGGIQPPWFYALIALKILDMTQHPAFIKGWEGLELYGVELDYGGWMFQASISP
VWDTGLAVLALRAAGLPADHDRLVKAGEWLLDRQITVPGDWAVKRPNLKPGGFAFQFDNVYY
PDVDDTAVVVWALNTLRLPDERRRRDAMTKGFRWIVGMQSSNGGWGACDVDNTSDLPNHIPF
CDFGEVTDPPSEDVTAHVLECFGSFGYDDAWKVIRRAVEYLKREQKPDGSWFGRWGVNYLYG
TGAVVSALKAVGIDTREPYIQKALDWVEQHQNPDGGWGEDCRSYEDPAYAGKGASTPSQTAW
ALMALIAGGRAESEAARRGVQYLVETQRPDGGWDEPYYTGTGFPGDFYLGYTMYRHVFPTLA
LGRYKQAIERR 
ZmoSHC1_Loop 
MGIDRMNSLSRLLMKKIFGAEKTSYKPASDTIIGTDTLKRPNRRPEPTAKVDKTIFKTMGNS
LNNTLVSACDWLIGQQKPDGHWVGAVESNASMEAEWCLALWFLGLEDHPLRPRLGNALLEMQ
REDGSWGVYFGAGNGDINATVEAYAALRSLGYSADNPVLKKAAAWIAEKGGLKNIRVFTRYW
LALIGEWPWEKTPNLPPEIIWFPDNFVFSIYNFAQWARATMVPIAILSARRPSRPLRPQDRL
DELFPEGRARFDYELPKKEGIDLWSQFFRTTDRGLHWVQSNLLKRNSLREAAIRHVLEWIIR
HQDADGGWGGIQPPWVYGLMALHGEGYQLYHPVMAKALSALDDPGWRHDRGESSWIQATNSP
VWDTMLALMALKDAKAEDRFTPEMDKAADWLLARQVKVKGDWSIKLPDVEPGGWAFEYANDR
YPDTDDTAVALIALSSYRDKEEWQKKGVEDAITRGVNWLIAMQSECGGWGAFDKDNNRSILS
KIPFCDFGESIDPPSVDVTAHVLEAFGTLGLSRDMPVIQKAIDYVRSEQEAEGAWFGRWGVN
YIYGTGAVLPALAAIGEDMTQPYITKACDWLVAHQQEDGGWGESCSSYMEIDSIGKGPTTPS
QTAWALMGLIAANRPEDYEAIAKGCHYLIDRQEQDGSWKEEEFTGTGFPRAFMLRYDFYRQF
FPIMALSRAERLIDLNN 
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11.3 Multiple sequence alignments 
11.3.1 SHCs from strains containing two SHCs 
a) Zymomonas mobilis SHCs: ZmoSHC1 and ZmoSHC2 
 
Fig. 11.1: Sequence alignment of ZmoSHC1 and ZmoSHC2. The aspartate residues in the active site 
(DxDD motif) are underlined and highlighted in grey, the loop in ZmoSHC1 is marked in grey and 
underlined with a wavy line, the long N-terminal residue of ZmoSHC1 is marked in grey. 
b) Acetobacter pasteurianus SHCs: ApaSHC1 and ApaSHC2 
 
Fig. 11.2: Sequence alignment of ApaSHC1 and ApaSHC2. The aspartate residues in the active site 
(DxDD motif) are underlined and highlighted in grey, the loop in ApaSHC1 is marked in grey and 
underlined with a wavy line, the long N-terminal residue of ApaSHC1 is marked in grey. 
ZmoSHC1         MGIDRMNSLSRLLMKKIFGAEKTSYKPASDTIIGTDTLKRPNRRPEPTAKVDKTIFKTMGNSLNNTLVSACDWLIGQQKPDGHWVGAVESNASMEAEWCLALWFLG-LEDHPLRPRLGNA 
ZmoSHC2         MTVSTSSAF--------------HHSP-------------------------------LSDDVEPIIQKATRALLEKQQQDGHWVFELEADATIPAEYILLKHYLGEPEDLEIEAKIGRY 
                * :.  .::               :.*                               :.:.::  : .*   *: :*: *****  :*::*:: **: *   :**  **  :..::*.  
 
ZmoSHC1         LLEMQREDGSWGVYFGAGNGDINATVEAYAALRSLGYSADNPVLKKAAAWIAEKGGLKNIRVFTRYWLALIGEWPWEKTPNLPPEIIWFPDNFVFSIYNFAQWARATMVPIAILSARRPS 
ZmoSHC2         LRRIQGEHGGWSLFYG-GDLDLSATVKAYFALKMIGDSPDAPHMLRARNEILARGGAMRANVFTRIQLALFGAMSWEHVPQMPVELMLMPEWFPVHINKMAYWARTVLVPLLVLQALKPV 
                * .:* *.*.*.:::* *: *:.***:** **: :* *.* * : :*   *  :**  . .****  ***:*  .**:.*::* *:: :*: * . * ::* ***:.:**: :*.* :*  
 
ZmoSHC1         RPLRPQDRLDELF-PEGRARFDYELPKKEGIDLWSQFFRTTDRGLHWVQSNLLKRNSLREAAIRHVLEWIIRHQDADGGWGGIQPPWVYGLMALHGEGYQLYHPVMAKALSALDD----P 
ZmoSHC2         ARNRRGILVDELFVPDVLPTL-----QESGDPIWRRFFSALDKVLHKVEPYWPK--NMRAKAIHSCVHFVTERLNGEDGLGAIYPAIANSVMMYDALGYPENHPERAIARRAVEKLMVLD 
                   *    :**** *:  . :     ::.*  :* :** : *: ** *:.   *  .:*  **:  :.:: .: :.:.* *.* *. . .:*  .. **   **  * *  *::.      
 
ZmoSHC1         GWRHDRGESSWIQATNSPVWDTMLALMALKDAKAEDRFTPEMDKAADWLLARQV-KVKGDWSIKLPDVEPGGWAFEYANDRYPDTDDTAVALIALSSYRDKEEWQKKGVEDAITRGVNWL 
ZmoSHC2         GTEDQGDKEVYCQPCLSPIWDTALVAHAMLEVGG-DEAEKSAISALSWLKPQQILDVKGDWAWRRPDLRPGGWAFQYRNDYYPDVDDTAVVTMAMDRAAKLSDLHDD-FEESKARAMEWT 
                * ..: .:. : *.  **:*** *.  *: :. . *.   .  .* .** .:*: .*****: : **:.******:* ** ***.*****. :*:.   . .: :.. .*:: :*.::*  
 
ZmoSHC1         IAMQSECGGWGAFDKDNNRSILSKIPFCDFGESIDPPSVDVTAHVLEAFGTLGLSRDMPVIQKAIDYVRSEQEAEGAWFGRWGVNYIYGTGAVLPALAAIGEDMTQPYITKACDWLVAHQ 
ZmoSHC2         IGMQSDNGGWGAFDANNSYTYLNNIPFADHGALLDPPTVDVSARCVSMMAQAGISITDPKMKAAVDYLLKEQEEDGSWFGRWGVNYIYGTWSALCALNVAALPHDHLAVQKAVAWLKTIQ 
                *.***: ******* :*. : *.:***.*.*  :***:***:*: :. :.  *:*   * :: *:**: .*** :*:************* :.* ** . .    :  : **  ** : * 
 
ZmoSHC1         QEDGGWGESCSSYMEIDSIGKGP--TTPSQTAWALMGLIAANRPEDYEAIAKGCHYLIDRQEQDGSWKEEEFTGTGFPGYGVGQTIKLDDPALSKRLLQGAELSRAFMLRYDFYRQFFPI 
ZmoSHC2         NEDGGWGENCDSY-ALDYSGYEPMDSTASQTAWALLGLMAVGEANS-EAVTKGINWLAQNQDEEGLWKEDYYSGGGFP--------------------------RVFYLRYHGYSKYFPL 
                :*******.*.**  :*  *  *  :*.*******:**:*....:. **::** ::* :.*:::* ***: ::* ***                          *.* ***. * ::**: 
 
ZmoSHC1         MALSRAERLIDLNN------- 
ZmoSHC2         WALARYRNLKKANQPIVHYGM 
                 **:* ..* . *:        
ApaSHC1         MNMASRFSLKKILRSGSDTQGTNVNTLIQSGTSDIVRQKPAPQEPADLSAL---KAMGNSLTHTLSSACEWLMKQQKPDGHWVGSVGSNASMEAEWCLALWFLGLEDHPLRPRLGKALLE 
ApaSHC2         M-------------------------------------------AADGSALSESRLSSEALDRAVLSAHTALSQAQQDDGHWVYELEADATIPAEYILLEHFMDRIDDALEQKIAIYLRR 
                *                                           .** ***   :  .::* ::: **   * : *: ***** .: ::*:: **: *   *:.  *..*. ::.  * . 
 
ApaSHC1         MQRPD-GSWGTYYGAGSGDINATVESYAALRSLGYAEDDPAVSKAAAWIISKGGLKNVRVFTRYWLALIGEWPWEKTPNLPPEIIWFPDNFVFSIYNFAQWARATMMPLAILSARRPSRP 
ApaSHC2         IQSEEHGGWPLYHN-GKFDLSATVKAYFALKAVGDDINAPHMQRAREAILDHGGAERSNVFTRSQLALFGEVPWRATPVMPVELMLLPAKAFFSVWNMSYWSRTVIAPLLVLAALRPVAA 
                :*  : *.*  *:. *. *:.***::* **:::*   : * :.:*   *:.:** :. .****  ***:** **. ** :* *:: :* : .**::*:: *:*:.: ** :*:* **  . 
 
ApaSHC1         LRPQDRLDALFPGGRANFDYELPTKEGRDVIADFFRLA----DKGLHWLQSSFLKRAPSR--EAAIKYVLEWIIWHQDADGGWGGIQPPWVYGLMALHGEGYQFHHPVMAKALDALNDPG 
ApaSHC2         NPRQVHVRELF---------VTPPEKVQDWIRGPYRSAWGYVFKGLDSVLRPVVPFIPEKTHKKAIQAALDFIEPRLNGKDGLGAIYPAMANVVMMYRAMGVPDEDPRAKTAWEAVQ--A 
                   * ::  **           *.:: :* * . :* *     ***. :  ..:   *.:  : **: .*::*  : :...* *.* *. .  :*  :. *   ..*   .* :*::  . 
 
ApaSHC1         WRHDKGDASWIQATNSPVWDTMLSLMALHDAN------AEERFTPEMDKALDWLLSRQV-RVKGDWSVKLPNTEPGGWAFEYANDRYPDTDDTAVALIAIASCRNRPEWQAKGVEEAIGR 
ApaSHC2         LIVEKDDEAYCQPCVSPIWDTGLSGHAMIEAASGPNGIAPEKTVAELKKASAWLRSKQILNVKGDWAVRNPNLAPGGWAFQYGNDYYPDVDDTAVVGMLLHREGDPTN------AEAIER 
                   :*.* :: *.  **:*** **  *: :*       * *: ..*:.**  ** *:*: .*****:*: **  ******:*.** ***.*****. : :    : .:       *** * 
 
ApaSHC1         GVRWLVAMQSSCGGWGAFDKDNNKSILAKIPFCDFGEALDPPSVDVTAHVLEAFGLLGLPRDLPCIQRGLAYIRKEQDPTGPWFGRWGVNYLYGTGAVLPALAALGEDMTQPYISKACDW 
ApaSHC2         ARTWIVGMQSTDGGWGAFDIDNNKDVLNHIPFADHGALLDPPTADVTARCISFLAQLRNPEDEPVIQRGLEYLRKEQEKDGSWFGRWGTNYIYGTWSALCALNAAGVSHDDPAVVKAVEW 
                .  *:*.***: ******* ****.:* :***.*.*  ****:.****: :. :. *  *.* * ***** *:****:  *.******.**:*** :.* ** * * .  :* : ** :* 
 
ApaSHC1         LINCQQENGGWGESCASYMEVSSIGHGATTPSQTAWALMGLIAANRPQDYEAIAKGCRYLIDLQEEDGSWNEEEFTGTGFPGYGVGQTIKLDDPAISKRLMQGAELSRAFMLRYDLYRQL 
ApaSHC2         LRSVQRADGGWGEGCESYEGGPHGTYGESLPSQTAWAVLGLMAAGRRDD-PAVTRGIAWLADQQDANGEWHEDPYNAVGFP--------------------------KVFYLRYHGYKQF 
                * . *: :*****.* **   .   :* : *******::**:**.* :*  *:::*  :* * *: :*.*:*: :...***                          :.* ***. *:*: 
 
ApaSHC1         FPIIALSRASRL-------IKLGN 
ApaSHC2         FPLMALARYRNLESSNTRRVSFGF 
                **::**:*  .*       :.:*  
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c) Rhodopseudomonas palustris SHCs: RpaSHC1 and RpaSHC2 
 
Fig. 11.3: Sequence alignment of RpaSHC1 and RpaSHC2. The aspartate residues in the active site 
(DxDD motif) are underlined and highlighted in grey, the loop in RpaSHC1 is marked in grey and 
underlined with a wavy line. 
d) Syntrophobacter fumaroxidans SHCs: SfuSHC1 and SfuSHC2 
 
Fig. 11.4: Sequence alignment of SfuSHC1 and SfuSHC2. The aspartate residues in the active site 
(DxDD motif) are underlined and highlighted in grey, the loop in SfuSHC1 is marked in grey and 
underlined with a wavy line. 
RpaSHC1         MDSILAPRADAPRNIDGALRESVQQAADWLVANQKPDGHWVGRAETNATMEAQWCLALWFLGLE-DHPLRVRLGRALLDTQRPDGAWHVFYGAPNGDINATVEAYAALRSLGHRDDEEPL 
RpaSHC2         MES---GNNKQPAAAIGALDASIESATNALLGYRQPDGHWVFELEADCTIPAEYVLLRHYLGEPVDAALEAKIANYLRRVQGAHGGWPLVHDG-GFDMSASVKGYFALKMIGDDIDAPHM 
                *:*    . . *    ***  *::.*:: *:. ::****** . *::.*: *:: *   :**   * .*..::.. *  .* ..*.* :.:.. . *:.*:*:.* **: :*.  *   : 
 
RpaSHC1         RKARDWILSKGGLANIRVFTRYWLALIGEWPWEKTPNILPEVIWLPTWFPFSIYNFAQWARATLMPIAVLSAHRPSRPLAPQDRLDALFPQGRDSFNYDLPARLGAGVWDV--IFRKIDT 
RpaSHC2         AKAREAIRSRGGAIHSNVFTRFLLSMFGITTWRSVPVLPVEIMLLPMWSPFHLNKISYWARTTIVPLMVLAALKPRAVNRLDIGLDELFLQ--DPKSIKMPAKAPHQSWALFKLFAGIDA 
                 ***: * *:**  : .****: *:::*  .*...* :  *:: ** * ** : ::: ***:*::*: **:* :*      :  ** ** *  *. . .:**:     * :  :*  **: 
 
RpaSHC1         ILHRLQDWGARRGPHGIMRRGAIDHVLQWIIRHQDYDGSWGGIQPPWIYGLMALHTEGYAMTHP---VMAKALDALNEPGWRIDIGDATFIQATNSPVWDTMLSLLAFDDAGLGERYPEQ 
RpaSHC2         VLRTIEPLFPKR-----LRDHAIKLAVDFVEERLNGEDGLGAIYPPMANTVMMYKVLGFPEDHPPRAITRRGIDKLLVIG-----EDEAYCQPCVSPVWDTALTCHALLEVG-GEAAVPP 
                :*: ::   .:*     :*  **. .:::: .: : :.. *.* **    :*  :. *:.  **   :  :.:* *   *      * :: *.  ****** *:  *: :.* **      
 
RpaSHC1         VERAVRWVLKRQVL-VPGDWSVKLPDVKPGGWAFEYANNFYPDTDDTSVALMALAPFRHDPKWQAEG---IEDAIQRGIDWLVAMQCKEGGWGAFDKDNDKKILAKIPFCDFGEALDPPS 
RpaSHC2         AKRGMDWLLPKQVLDLKGDWAVKRPNLRPGGWAFQYNNAHYPDLDDTAVVVMAM-----DRSRRATGSREYDEAIARAREWIEGMQSDDGGWAAFDVNNLEYYLNNIPFSDHGAMLDPPT 
                .:*.: *:* :*** : ***:** *:::******:* * .*** ***:*.:**:     * . :* *    ::** *. :*: .**..:***.*** :* :  * :***.*.*  ****: 
 
RpaSHC1         ADVTAHIIEAFAKVG-LDRNHPSIVRALDYLKREQEPEGPWFGRWGVNYVYGTGAVLPALAAIGEDMRQPYIARACDWLIARQQANGGWGESCVSY-MDAKQAGEGTATASQTAWALMAL 
RpaSHC2         EDVTARCVSMLSQLGETAASSKAVADGVEYLRRTQLPDGSWYGRWGLNYIYGTWSVLCALNAAGVDHQDPVIRKAVTWLASVQNPDGGWGEGAESYRLNYTRYEQAPTTASQTSWALLGL 
                 ****: :. ::::*    .  ::. .::**:* * *:*.*:****:**:*** :** ** * * * ::* * :*  ** : *:.:*****.. ** :: .:  :..:*****:***:.* 
 
RpaSHC1         IAADRPQDRDAIERGCLYLTETQR-DGTWQEVHYTGTGFPGYGVGQTIKLNDPLLSKRLMQGPELSRSFMLRYDLYRHYFPMMAIGRVLRQRGDRS-----GH 
RpaSHC2         MAAGE-VDSPVVARGVEYLKSTQTGKGLWDEQRYTATGFP--------------------------RVFYLRYHGYAKFFPLWALARYRNLRSTNSKVVGVGM 
                :**..  *  .: **  **..**  .* *:* :**.****                          * * ***. * ::**: *:.*  . *. .*     *  
SfuSHC1         MRRL--------DTFPPE--------------IPTGSRD------KPPSGEEHSCSTPAEPLRSR------LDEGILRAVDWLVCDQHPDGFWAGMLQSNSCMEAEWVLAMHFLGIDDDP 
SfuSHC2         MNPIRGKRGSAADFLEEEYQWENLADHGESGRTPGGGHPAALKEYEAGSATEHTGHHCVHHLGVRNSWLRKIEKAIDNACGQLFKTQYEDGYWWSELESNVTITSEYIMLLYLLEVSRPE 
                *. :        * :  *               * *.:       :. *. **:    .. *  *      :::.* .* . *.  *: **:* . *:**  : :*::: :::* :.    
 
SfuSHC1         KYDGVIRAILGEQRADGSWGVFHKAPNGDINTTVECYAALRASGLAPESAPLSSAREWILAGGGLANIRNFTKYWLALIGEWPWEGTPTIPPELIFFPPRMPLNIYHFASWARSTIVPLS 
SfuSHC2         QQKSMVKYLLNQQRPDGSWGLYY-GDGGNLSTTIEAYFALKLAGEHCESEPMRRAREFILSKGGIESARVFTKIWLALFSQYDWDKVPSMPVELVLLPSSLYFNIYEFSSWARGTVVPLS 
                : ..::: :*.:**.*****::: . .*::.**:*.* **: :*   ** *:  ***:**: **: . * *** ****:.:: *: .*::* **:::*. : :***.*:****.*:**** 
 
SfuSHC1         ILSARRPVRPLPEDRRLDELFPQGRSAFDFRLPRKDGWLSWEGFFHVCDRILRLYARTRRAPFRETAIRVCLEWIIRRQETDGAWSGIQPPWIYALLALHAEGYGLDHPILRAGLRAFDS 
SfuSHC2         IVMSIRPRCPLPAKCSIKELYVPGSKHKNFA-------SCTHKLFFLFDRIAKAFERRPVPSLRNKAVQAAETWVLDHQEDSGDWGGIQPPMVYSVLALYYLGYPLDHEVIVKGIKALDA 
                *: : **  *** .  :.**:  * .  :*         . . :*.: *** : : *   ..:*:.*::..  *:: :** .* *.***** :*::***:  ** *** ::  *::*:*: 
 
SfuSHC1         HWSYERDGGIYLQASESPVWDTVLSLRALADCGEERKASVSIASALEWLLNRQISVPGDWAVRVPSVPCGGWAFQRANSFYPDVDDTAVAIEVLARLRPFTANQ-SAVDRAIRSARDWVL 
SfuSHC2         -FCMEDEEGTRMQSCVSPVWDTALTVLSMLDAGVAAEHP-GLEKAGRWLLENQVLTGGDWQIKNDSLP-GGWAFEFYNTRYPDVDDSAV---VLSTLNRFNAERVEGLEFAKCRGMEWCL 
                 :. * : *  :*:. ******.*:: :: *.*   : . .: .* .***:.*: . *** ::  *:* *****:  *: ******:**   **: *. *.*:: ..:: *   . :* * 
 
SfuSHC1         AMQCSNGGWAAFDRDNDFKLVTKIPFCDFGELLDPPSVDVTAHVIEALAALGWDMTSREIEAAVSFIRREQEAEGSWFGRWGVNHIYGTATVLPALRAIGEDMSSAYVLRAADWLASRQN 
SfuSHC2         SMQSSNGGWAAFDKDNTLEILNRIPFADQEAMVDYPTADVTGRVLEAMGYLGYDGSHPRARKAIQFLKKRQERDGCWWGRWGVNYIYGTWSVLKGLISIGEDPRAAYIRAAVRWVKDHQN 
                :**.*********:** ::::.:***.*   ::* *:.***.:*:**:. **:* :  . . *:.*:::.** :*.*:******:**** :** .* :****  :**:  *. *: .:** 
 
SfuSHC1         ADGGWGETPASYMDDSLRGVGESTASQTAWAIMGLVAVGSGAHDDTVRRGIDFLLFAQ-HGGTWEEPQYTGTGFPGYSVGERIRLRDMGASLKQGTELQRAFMINYNLYRHYFPLMALGR 
SfuSHC2         SDGGWGETCESYENPELRGQGPSTPSQTAWALMSLIACGE-MKSQEASRGIQYLLRTQKRDGTWEELHFTGTGFP------------------------KHFYIRYHNYRNCFPLMALGQ 
                :*******  ** : .*** * **.******:*.*:* *.  :.: . ***::** :* :.***** ::******                        : * *.*: **: *******: 
 
SfuSHC1         ARYHLQLRRSAREGGNGETTPNGSAL 
SfuSHC2         YLRALER------------------- 
                    *:                     
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e) Pelobacter carbinolicus SHCs: PcaSHC1 and PcaSHC2 
 
Fig. 11.5: Sequence alignment of PcaSHC1 and PcaSHC2. The aspartate residues in the active site 
(DxDD motif) are underlined and highlighted in grey, the loop in PcaSHC2 is marked in grey and 
underlined with a wavy line; the long N-terminal residue of PcaSHC1 is marked in grey. The two 
loops of PcaSHC1 are highlighted in grey with dashed underlining. 
 
PcaSHC1         MDKIKMKNINQPKFRVFRGGQKAATPCPGTTNERRGALDRGRLSASLKHSREWLLSLQADAGNWVFALEADTTIASEYVMLQRFLGRPLAPELQQRLANYLLSRQLPDGGWPLYAEDGFA 
PcaSHC2         MNVIRQLN----------SGVNAAK----------------SLDDGIESAIEWLAENQDKEGFWVGMLESNSCIEAEWILAMHLLGVKDDPK-YDKVVQAILNEQREDGSWAVYYDAPAG 
                *: *:  *          .* :**.                 *. .:: : *** . * . * **  **::: * :*:::  ::**    *:  :::.: :*..*  **.*.:* :   . 
 
PcaSHC1         NISTTVKAYLALKLLGYPTHCDPLVRARQIVLALGGAEKCNVFTRIALALFGQIPWRTTPAMPVEIMLLPRWFYFHLSKISYWARTVVVPLLILYAKRPVCRLEPWEGIPELFVTPPDKL 
PcaSHC2         DINATVEAYAALRTAGFGAGDERLIKARNWIFSHGGLKNVRVFTRYWLALIGEWPWDETPALAPEIIYLPAWCPLNIYDFACWARATLVPLSVLSVRRPVKPLPAESRLDELFPEGRENA 
                :*.:**:** **:  *: :  : *::**: ::: ** :: .****  ***:*: **  ***:. **: ** *  ::: .:: ***:.:*** :* .:***  * . . : ***    ::  
 
PcaSHC1         GYLDVCKPGQWRKNVFIWVDRLTRKMVRCVPRRLHNLALRAAETWTREHMQGAGGIGAIFPAMANAVMALRTLGCSPDDADYQRGLKALDDLLIDRCDVPPREDTPVSPCWCTGTSAAPM 
PcaSHC2         DYSLPESEKGLAERFFLVVDWFLKKYNRLPMQFGREKAIRLCLEWIVRHQDYDGGWGGIQPPLIYSLIALNTEGYGINHPVISKGLDAFN------------------PPWAYEKNGGVY 
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